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Abstract 
The canonical Wnt-/β-catenin pathway plays an important role in regulating central physiological 
processes, such as cell proliferation, cellular metabolism, differentiation and apoptosis. Aberrant 
mutational activation of central players in this signaling pathway is closely linked to the modulation 
of the signaling status of the pathway and disease formation such as carcinogenesis. To functionally 
analyze the signaling state of the Wnt pathway, a focus was put on the detection of protein-protein 
complexes comprising the central regulator β-catenin, since it exerts its regulatory role by forming 
protein complexes. Information on interaction partners of β-catenin in different complexes is 
instrumental to decode observed changes in cellular signaling.  
To isolate these protein complexes consisting of β-catenin and differing interaction partners, classical 
Co-Immunprecipiation (Co-IP) was performed on various cell lines in which cell signaling was 
modulated by compound treatment in this thesis. Thereby, it was possible to characterize the state 
of signal transduction in these cell lines with a focus on the activity of the regulatory Wnt pathway. In 
addition, the approach was extended to allow the use of a recently developed class of intracellular 
binding molecules, called chromobodies. These binders can be expressed inside a cell and enable an 
„intracellular Co-Immunoprecipitation”, which gives insight into in vivo conditions by detecting 
endogenous bound target proteins. 
The protein complexes consisting of β-catenin and various interaction partners (e.g. α-catenin and 
GSK3 β) were precipitated and shown by immunoblotting. To obtain a higher resolution picture of 
the isolated β-catenin complexes, a novel Western blotting approach (DigiWest) could be employed. 
This Western blotting approach uses a bead-based microarray platform and allows probing of a low 
amount of precipitate with hundreds of antibodies and thereby a screening for interacting proteins.  
By using this throughput technique, the efficient characterization of cell lines, e.g. tumor cells, was 
enabled. In addition, the analysis of novel and well-known interaction partners of β-catenin was 
facilitated. 
In summary, a combinatory approach consisting of Co-IP and DigiWest was established. This 
approach is suitable for the detection and a wide ranging analysis of posttranslational protein 
modifications and protein-protein interactions as well as their impact on the surrounding signaling 
cascades. An additional advantage of the combinatory approach is the simplification of visualizing 
alterations between different sample types and drug treatments. It consitutes a versatile tool to 
study endogenous complexes and to identify dynamic protein-protein interactions in signaling 
cascades. This approach can generally be applied to analyze regulating pathways and to decipher 
cellular communication processes by precipitating proteins and their key interactions. 
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Zusammenfassung 
Der kanonische Wnt/β-Catenin Signalweg spielt eine wichtige Rolle in der Regulation zentraler 
physiologischer Prozesse wie beispielsweise Zellproliferation, Zellstoffwechsel, Differenzierung und 
Apoptose. Abnorme Aktivierungen von Schlüsselmolekülen durch Mutationen wirken sich auf den 
Signalzustand dieses Signalweges aus und stehen in engem Zusammenhang mit der Entstehung von 
Krankheiten, beispielsweise Krebs. Um den Signalstatus des Wnt Signalweges funktional zu 
analysieren, wurde der Fokus auf die Detektion unterschiedlicher Proteinkomplexen mit  
β-Catenin gelegt, welches eine zentrale regulatorische Rolle bei der Bildung solcher Komplexe spielt. 
Detaillierte Kenntnisse über verschiedene Interaktionspartner von β-Catenin in unterschiedlichen 
Proteinkomplexen sind notwendig, um mögliche auftretende Veränderungen in der zellulären 
Signalgebung zu entschlüsseln. 
Um diese aus β-Catenin und verschiedenen Interaktionspartnern bestehenden Proteinkomplexe zu 
isolieren, wurde in dieser Arbeit eine klassische Co-Immunopräzipitation (Co-IP) auf verschiedenen 
Zelllinien durchgeführt, deren zelluläre Signalgebung durch Behandlung moduliert wurde. Dadurch 
war es möglich, den Status der Signalübertragung, insbesondere des regulatorischen Wnt 
Signalwegs, in diesen Zelllinien zu charakterisieren. Zusätzlich wurde die Co-IP durch die Verwendung 
von kürzlich entwickelten intrazellulären Bindemolekülen, sogenannten Chromobodies, erweitert. 
Diese können innerhalb der Zelle exprimiert werden und ermöglichen eine „intrazelluläre  
Co-Immunopräzipitation“, welche durch die endogene Bindung an Zielproteine einen Einblick in den 
in vivo Zustand erlaubt. 
Proteinkomplexe, bestehend aus β-Catenin und verschiedenen Interaktionspartnern (z.B. α-Catenin 
und GSK3 β), wurden präzipitiert und mittels Immunoblot detektiert. Um eine höhere Auflösung der 
isolierten β-Catenin-Komplexe zu erhalten, wurde ein neuer Western Blot Ansatz (DigiWest) 
eingesetzt. Dieser Ansatz ist an eine Bead-basierte Mikroarray-Plattform adaptiert, welche es 
ermöglicht, eine geringe Menge an Präzipitat mit hunderten von Antikörpern zu untersuchen und 
dabei nach Interaktionspartner zu suchen.  
Durch die Verwendung dieses Durchsatzverfahrens ist eine effizientere Charakterisierung von 
Zelllinien möglich. Zudem können bekannte und neue Interaktionspartner von β-Catenin analysiert 
werden. 
Zusammenfassend wurde eine kombinatorische Methode, bestehend aus Co-IP und und DigiWest, 
entwickelt, welche sich für die Entdeckung und weitläufige Analyse posttranslationaler 
Proteinmodifikationen und Protein-Protein-Interaktionen sowie deren Auswirkung auf die 
umgebenden Signalkaskaden eignet. Ein großer Vorteil dieser Kombination ist die einfachere 
Möglichkeit Veränderungen zwischen unterschiedlichen Probentypen und Behandlungen 
aufzuzeigen. Es wurde gezeigt, dass die Methode ein vielseitiges Werkzeug darstellt, um endogene 
Zusammenfassung   
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Komplexe zu untersuchen und dynamische Protein-Protein-Interaktionen in Signalwegen zu 
identifizieren. Diese Methode kann darüber hinaus allgemein für die Analyse regulierender 
Signalwege sowie für die Entschlüsselung zellulärer Kommunikationsprozesse durch die Präzipitation 
von Proteinen und ihren Schlüsselinteraktionen angewendet werden. 
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1. Introduction 
1.1 Proteomics and protein-protein interactions 
The concept that protein-protein interactions (PPIs) play a fundamental role in biological processes 
evolved considerably and continuously throughout the past decades [1]. Important insights into the 
complex biological interplay of regulatory and control mechanism of various organisms were gained. 
This correlates with the development of innovative technical approaches and the evolution of a 
broader understanding, which led to today’s systems-wide approaches to analyze PPIs [1]. 
 
 
Figure 1: History of protein-protein interactions. 
A timeline of protein-protein interaction research is shown. In the upper part, conceptual advances and 
discoveries are indicated, while in the lower part technological advances and inventions are indicated (altered 
from [1, 2]). 
 
High throughput content analysis, also called the “omics” disciplines, paved the way to such a deeper 
understanding by providing a high-resolution data on biological processes: The study of the whole 
genome delivering information about gene structure and regulatory regions, developed into a new 
field of study, the genomics [3, 4]; the transcriptomics, creating maps of transcriptional regulation 
networks [5, 6], as well as large-scale protein expression data sets belonging to the proteomics [7]. 
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The term proteome was coined in 1994 by Mark Wilkins [8] and followed by the creation of the term 
proteomics in 1997 [9]. Proteomics aims at achieving large-scale information about the protein 
entity, the proteome. The proteome is the set of proteins expressed by a genome at a certain time 
point and under specified conditions [10]. Compared to the lifelong maintained stability of the 
genome, the proteome is very dynamic and highly reliant on regulatory spatiotemporal processes 
[11], resulting in functional and physiological differences between various cells, which carry the same 
genome. Thus, proteomic studies facilitate a more distinct, but only momentary glance at what is 
actually happening [10]. Accordingly, the protein expression pattern of a defined cell and the 
interaction possibilities between proteins differ significantly depending on the phase of cell cycle and 
other internal and external influences. Therefore, a snapshot of the proteome at a given time and 
distinct location can be obtained at most [10]. 
As proteins are major protagonists in biochemical processes, their interactions play a key role in 
almost every type of biological process and at nearly every kind of cellular functioning [1, 12]. These 
processes and functions include signal reception and transduction, the transport machinery, 
regulation of gene expression, structuring of the cytoskeleton, DNA replication and many more. It 
has become apparent that intricate networks are formed by the interactions of proteins, which result 
in the formation of highly organized, dynamic cellular systems and the mediation of a vast range of 
regulatory functions in essentially every biological process [1, 13]. Due to this critical importance, the 
detection of PPIs is among the most informative ways of gaining information on a given protein. 
Starting in the 1940s, the importance of these interactions became apparent, as more and more PPIs 
were uncovered. By that it was also revealed, that proteins change their functions and effects, 
dependent on their complexation [1]. In various diseases, such as cancer, both alterations in the 
proteome and aberrant PPIs are observable and characteristic [10]. Those alterations modulate 
interactions qualitatively (all or none) and quantitatively (strength of interaction) [1]. To transmit 
signaling via PPIs and to establish complex intracellular signaling networks, individual proteins display 
nodes, which can respond to various input signals and control multiple effector outputs [14]. Due to 
this importance in developmental processes and disease progression, PPIs have been in the focus of 
research for many years and still are. 
Thus, many proteomic projects aim at analyzing the changes in the proteome under different 
conditions and the resulting variations for the interacting networks of proteins [10, 15]. A deeper 
understanding of the interplay between different signaling cascades will make it easier to evaluate 
disease patterns correctly. The modulation of PPIs in order to utilize them as therapeutic targets, for 
example as an anticancer strategy, has become reality [15]. In cancer, PPIs have been shown to be 
involved in provoking tumorigenesis through regulating altered networks and present a working 
surface for the development of anticancer therapeutics [15].  
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Special biological databases, like UniProtKB, record knowledge about protein functions and their 
molecular properties [16]. Other databases collect published PPIs or even predict them, like 
“Biological General Repository for Interaction Datasets” (BioGRID) or the “FpClass” list. They try to 
mirror a complete map of the interactome, which is the entity of protein interactions, that may occur 
in a living organism [16]. These databases are used to verify observed interactions and interpret new 
occurring PPIs. By that, structuring of the large datasets of reported PPIs was possible and these 
databases proved to be indispensable tools in recent years.  
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1.2 Cancer and its association to Wnt signaling 
Cancer is a disease, whose occurrence is increasing, due to factors like aging of the population as well 
as the increasing prevalence of established risk factors, such as smoking. For 2012 about  
14.2 mio new cancer cases and 8.2 mio deaths based on cancer were estimated [17]. By that, cancer 
surpassed other illnesses like stroke in the number of deaths caused [10, 18]. In Germany, cancer is 
among the most frequent diseases with approximately 0.5 mio incidence per year. Additionally, it is 
the second most common cause of death [19]. Thus, cancer has become to a significant medical 
burden globally [10]. 
Many diseases are based on alterations in cellular signaling and deviations in the proteome. In 
cancer, most tumors harbor defined mutational alterations in genes encoding proteins, which act as 
central regulators in important signaling cascades. Ten main traits and enabling characteristics 
orchestrate the transformation from a normal state to malignancy, which were named  
“The Hallmarks of Cancer” [20]. One of these characteristics is the instability of the genome and the 
occurrence of mutational events. Often such mutations result in additional features, acquired by the 
cell, such as the ability to invade other tissues or modulate signaling in an inhibiting or activating 
manner [20-22]. As signaling pathways are not isolated, but interconnected in a complex network, 
already mutational changes in one signaling protein lead to wide ranging consequences. Thus, the 
understanding of the intricacy of signaling networks is crucial for speculating about tumor behavior 
and to achieve effective cancer therapies [14]. 
Known for their critical role in signaling transduction and complex interactions are pathways like 
MAPK (mitogen-activated protein kinase), Wnt (portmanteau of the Drosophila gene Wg (= Wingless) 
and mouse proto-oncogene int1 (= integration 1)) [23, 24], Hedgehog, TGF-β (Transforming growth 
factor beta), STAT (signal transducers and activators of transcription) and many more. They 
participate in the transmission of proliferation, differentiation, migration and survival signals [25-27]. 
Hence, in the development of cancer, a deregulation of these key pathways, caused by a mutational 
change, is frequently found [28, 29]. Such an observed deregulation of the Wnt pathway, for example 
the hyper-activation of Wnt/β-catenin pathway, is associated with many cancer forms [30-33].  
The Wnt signaling pathway is an ancient and evolutionary conserved pathway in metazoan animals 
[34-36]. It is essentially involved in the regulation of cell fate determination, cell migration, cell 
polarity, stem/progenitor cell self-renewal and embryonic organogenesis [35, 37]. So far two main 
signaling branches have been discriminated downstream of the frizzled (FZD) receptor complex: the 
canonical or Wnt/β-catenin-dependent pathway and the noncanonical, β-catenin-independent 
pathway. The second branch can be further divided into Wnt/Ca2+ and Planar Cell Polarity pathways 
[35]. All subgroups of the Wnt pathway family are stimulated by a secreted Wnt glycoprotein, which 
binds extracellular to membrane receptors belonging to the FZD family [38]. For mediating the signal, 
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the assembly of additional co-receptors, such as LRP5/6 (low-densitiy-lipoprotein-related protein 
5/6), is required [35, 38]. The signal is transduced to the cytoplasmic protein dishevelled (DVL) [28]. 
At this point, the three major branches of the Wnt signaling separate, but still require an intact 
function of DVL prior to this [28, 35]. Different Wnts exert reciprocal pathway inhibition by 
competing for FZD binding on the cell surface. Hence, through the specific binding and 
phosphorylation of unrelated co-receptors by different Wnts, distinct signaling pathways are 
activated [37]. In this thesis, the noncanonical Wnt pathways will be put aside, while the focus will be 
on the canonical Wnt/β-catenin signaling, which is also referred to as Wnt signaling from now on.  
The key protein of the canonical Wnt signaling is β-catenin, which is responsible for the transduction 
of the Wnt signals into the nucleus. There β-catenin initiates the transcription of Wnt-specific target 
genes [36]. Generally, Wnt/β-catenin signaling is crucially implicated in tumorigenesis [39]. Besides 
this crucial role of deregulations of the pathway for the development of tumorigenesis, also an 
imbalance in the available amount of its key effector or an alteration of β-catenin, can lead to 
deregulations, which are linked to cancer [36]. 
Without a Wnt signal transduced from the membrane, the level of free, cytosolic β-catenin is kept at 
a low level. β-catenin is either bound to E-Cadherin, where it represents an integral structural 
component of cadherin-based adherens junctions (see Figure 2), or gets phosphorylated and thereby 
marked for its immediate degradation [36]. Responsible for this phosphorylation is a multiprotein 
complex, often called the β-catenin destruction complex [40]. This complex is composed of the 
scaffold proteins APC (Adenoma Polyposis Coli) and Axin, which present β-catenin to different 
kinases (GSK3 (glycogen synthase kinase 3), CK1 (Caseinkinase 1)) and phosphatases (PP2A, which is 
the protein phosphatase 2A). These are in charge of facilitating the phosphorylation at the  
N-terminus of β-catenin [36, 41, 42]. Subsequently to the phosphorylation, β-catenin gets 
ubiquitinated, mediated by β-TrCP (F-box/WD repeat-containing protein 1A) and the proteasomal 
degradation of the ubiquitin-conjugated β-catenin is carried out (see Figure 2) [36, 43-45]. 
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Figure 2: Canonical Wnt signaling. 
The active (ON, upper image) and inactive (OFF, lower image) canonical Wnt pathway is represented. In active 
signaling, the Wnt ligand binds to the transmembrane complex, composed out of FZD and LRP5/6. This complex 
recruits DVL, which in turn recruits Axin. By that, the β-catenin destruction complex dissociates. Thus, the 
degradation of β-catenin is inhibited and the protein can translocate into the nucleus, after accumulating in the 
cytosol. There β-catenin acts as a transcriptional co-activator, binds to transcription factors and facilitates gene 
expression. In the absence of a Wnt ligand, the amount of cytosolic β-catenin is kept low, as it is permanently 
marked for degradation by the destruction complex. The destruction complex, composed of CK1, Axin, GSK3 
and APC adds phosphate residues to the protein, which is followed by β-TrCP-mediated ubiquitination and 
proteasomal degradation of β-catenin (Figure adapted from [34, 36, 42]). 
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In the presence of a Wnt signal the β-catenin destruction complex gets inhibited. Binding of the 
ligand to the membranous FZD-LRP receptor complex induces association of the cytoplasmic protein 
DVL. DVL in turn is phosphorylated and activated [46-49]. By the multimerization of DVL, the 
formation of LRP-associated Wnt signalosomes is induced [50]. DVL subsequently recruits Axin, 
possibly together with associated kinases, like GSK3. Axin is an essential scaffolding structure in the 
destruction complex, thus the complex gets destabilized by its absence [51]. Additionally, the correct 
functioning of the Wnt signalosomes, composed of LRP6, DVL and Axin [37], leads to an inhibition of 
the GSK3 kinase activity [52]. As result of the destabilization of the complex and the inhibition of  
β-catenin phosphorylation, free non-phosphorylated β-catenin escapes the degradational machinery 
and is stabilized in the cytosol [53]. There, the stabilized protein accumulates and translocates into 
the nucleus. Nuclear β-catenin binds directly to transcription factors, most of which are members of 
the TCF/LEF family, and turns them from transcriptional repressors to transcriptional activators. This 
initiates transcription of Wnt-response genes, such as cJUN, TCF1, Axin2 and others (see Figure 2) 
[30, 36, 54, 55]. Within the nucleus the interaction of β-catenin with transcriptional co-activators 
additionally enhances or impairs its transcriptional activity [30]. 
It becomes apparent, that the key protein of the canonical Wnt pathway, β-catenin, forms complexes 
with a wide range of different proteins. This is caused, by its involvement at various subcellular 
locations, like its contribution to the cell-cell contact stabilization, its tightly controlled presence in 
the cytoplasm and its nuclear participation in the transcriptional regulation [56]. These PPIs facilitate 
β-catenin to step into direct crosstalk with other signaling cascades, provide a direct link to various 
transcription factors and by that affect its transcriptional output [36]. 
To gain a more comprehensive view on the Wnt signaling cascade, it is relevant to achieve insights 
not only in which interactions between β-catenin and other proteins occur, but also in how these 
spatially and temporally coordinated PPIs are built and which posttranslational modifications (PTMs) 
control these processes. Thus, the structure of β-catenin plays an important role. 
β-catenin itself is a 781 aa long member of the armadillo protein family, which also comprises  
α-catenin, γ-catenin and δ-catenin [56]. It is composed out of a N-terminal domain (NTD), the 
armadillo domain (ARM), consisting out of 12 armadillo repeats (each approximately 40 aa long), 
followed by a conserved Helix-C and adjacent to that, the C-terminal domain (CTD) [56, 57]  
(see Figure 31). The ARM shows predominately a positive charge, while modifications, such as 
phosphorylation alter the local charge of β-catenin. The local charge of β-catenin is thought to have a 
distinct influence on its binding affinity to specific interaction partners [56]. Hence, its function can 
be regulated by PTMs, which are not always caused by signaling through the Wnt receptor [30, 58].  
PTMs in general have a significant influence on the mediation of critical events involved in cellular 
responses. They affect and control enzymatic activity, protein conformation, occurrence of PPIs and 
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the cellular protein localization. Protein phosphorylation is one important example for such a 
modification, which affects approximately one third of all proteins and is one of the most studied 
PTMs overall [59, 60]. PTMs are mostly placed at so-called modular protein domains.  
These interaction modules mediate PPIs, but also serve to target signaling proteins to  
their substrate or distinct subcellular locations and to link proteins to multiprotein complexes  
and signaling cascades [14, 61]. 
β-catenin has a plethora of target sites for many different PTMs, like phosphorylations (some of them 
exemplary illustrated in Figure 31), but also ubiquitinations, acetylations and glycosylations [36]. 
These modifications modulate the operation mode and the different subcellular localizations of  
β-catenin (some of them exemplary listed in Table 39) [56, 62]. For example a C-terminal 
phosphorylation of β-catenin attenuates its binding to the cadherin-adhesion complex, while  
N-terminal phosphorylations often enhance its proteasomal degradation [56]. Also the association of 
β-catenin with TCF/LEF during transcriptional regulation is controlled by phosphorylation [56, 63]. 
The use of β-catenin as a therapeutic target in cancer seems to be of particular interest due to the 
large number of interaction partners that can prove to be valuable intervention points. But it was 
shown to be a formidable challenge to develop direct inhibitors of oncogenic β-catenin, as it holds an 
extensive main ligand interaction surface, which is shared between both positive and negative 
regulators. In addition, many other hindrances exist, which characterize β-catenin as an unattractive 
drug target, such as its promiscuity, which leads to difficulties in the drug design or the lack of a well-
established enzymatic activator, which can be inhibited. Addressing other components of the  
Wnt/β-catenin pathway as therapeutic targets, could serve as an alternative [64, 65]. Therefore, it is 
important to gain a broader understanding of their molecular and cellular biological functioning as 
well as their interplay with different signaling cascades. High throughput experiments will simplify 
the investigation of the Wnt pathway and can additionally provide a detailed insight about changes, 
caused by stimuli or inhibitors. Thus, they can help to identify inter- and intramolecular interactions, 
which are necessary in order to understand the overall architecture of signaling networks [14]. This 
might lead to a more distinct evaluation and planning of target points for drug development. 
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1.3 Significance of liver and liver cell lines 
The liver is a highly complex organ, whose differentiation and growth processes during development 
are modulated by Wnt/β-catenin signaling [66, 67]. Later in the adult liver, the canonical Wnt 
pathway regulates liver metabolism, regeneration and zonation [68, 69]. One of the most common 
solid tumors is primary liver cancer, predominantly hepatoblastoma (HB) and hepatocellular 
carcinoma (HCC) [70]. Constitutively activated Wnt/β-catenin signaling is observed in one third of 
HCCs, which is the most common form of liver cancer and one of the major causes of death 
worldwide [39, 71, 72]. The canonical Wnt signaling is frequently activated in this form of cancer. 
Already β-catenin itself, as the key player of the canonical Wnt signaling, plays a critical role in liver 
homeostasis and during liver regeneration [73]. It was shown that 50 % of mouse HCCs and 26 % of 
human HCCs have β-catenin-activating mutations [74]. Another form of liver cancer is 
hepatoblastoma (HB), which is the most frequent occurring form during childhood. It shows one of 
the highest known frequencies of mutations of the β-catenin gene, encoding for the key player in 
Wnt signaling [30, 39, 75], whereas for HCC also most commonly activating mutations in  
CTNNB1 [39, 74] were observed. The link between Wnt signaling and carcinogenesis in the liver is 
important to analyze, in order to gain useful knowledge for future therapeutical research [39]. 
Thus, four different liver cell lines, derived from mouse or human were chosen, to get a closer insight 
to the changes in regulating signal transduction cascades: 
 
1.3.1 Mouse hepatoma cell line 55.1c 
The cell line 55.1c is a mouse hepatoma cell line (see Table 12), which was established from a mouse 
liver tumor of a C57BL/6J mouse. Tumor formation was induced by a single intraperitoneal injection 
of N-nitrosodietylamine (NDEA) [76]. After a followed feeding with 0.05 % phenobarbital (PB), this 
leads to a CTNNB1 mutation in 80 % of the generated liver tumors in rodents [77]. Additionally, a 
constitutive, but non-maximum activation of β-catenin signaling is observed, that is due to a 
heterozygous deletion within exon 3 of CTNNB1 [78]. The 55.1c cells seem to have a high protein 
expression in general. 
 
1.3.2 Mouse hepatoma cell line 70.4 
The second chosen mouse hepatoma cell line, 70.4, was established in parallel to the cell line 55.1c, 
out of identically generated mouse liver tumors (see Table 12). In this case, C3H/He mice were 
donors. In contrast to the 55.1c cells, 70.4 cells are wild type according to the expression of  
CTNNB1 [76, 78], but harbor two different, independent p53 mutations.  
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1.3.3 Human hepatocellular carcinoma cell line HepG2 
The cell line HepG2 was derived from liver tumor biopsies of a 15-year-old Caucasian boy. Its 
morphological characteristics and epithelia cell shape are compatible with liver parenchymal cells, 
without the presence of the hepatitis B viral genome [79, 80]. It is one of the most frequently used 
cellular models for in vitro liver cancer and toxicity studies, as it represents a well characterized liver 
cancer cell line [81]. This cell line was initially considered to be a representative of pediatric HCC, but 
is in fact an example of an epithelial hepatoblastoma [82]. Its hepatoblastoma characteristics were 
confirmed by the histopathological background, the original histology and recent molecular analyses 
[83]. Like many epithelial cell lines it shows a heterozygous deletion of exon 3 of the β-catenin gene 
[74, 82, 84, 85], which leads to the strong expression of a truncated β-catenin version (aa 25 – 140) 
and a small pool of wild type β-catenin [74, 85]. This results in a high activation of the canonical Wnt 
pathway. 
 
1.3.4 Human hepatocellular carcinoma cell line HB35 
HB35 is a human hepatocellular carcinoma cell line, which was established out of a liver neoplasm of 
a 4-year old, male donor. This cell line represents the first cell line derived from a pediatric HCC, 
without having a background of viral hepatitis or cirrhosis. It presents histological and biological 
characteristics of an epithelial liver tumor. As it is a rather novel cell line, whose characterization was 
first published in 2012, only little analysis was done so far. Because of the little characterization and 
the many preserved hepatocyte characteristics, HB35 represents an interesting liver cancer cell line. 
The cell line shows a heterozygous deletion of 49 bp in β-catenin exon 3 and the deleted  
area encodes a phosphorylation site of GSK3 β. Thus, β-catenin degradation is prevented  
and its accumulation within the cell is enhanced, whereby excessive Wnt/β-catenin signaling  
is observed [83].  
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1.4 DigiWest as screening tool for protein-protein interactions 
The further evolution of research in life sciences resulted in experimental approaches, which are 
capable of handling and analyzing multiple samples and analytes in parallel. Microarray technology, 
which emerged throughout the past years, represents such a technique. It turned out to be a 
milestone for a plethora of different approaches in research, development and diagnostics [86], as its 
applications cover the area of genomics, transcriptomics and proteomics. It also offers the possibility 
of miniaturizing and parallelization [87], which results in less consumption of material, both of 
sample and reagents, but also in the possibility to achieve a high throughput for samples and 
analytes [88]. 
The commercially available Luminex technology provides such a microarray system, based on 
microspheres (beads). 500 different bead populations, containing three internal fluorescent dyes, are 
available. The addition of different amounts of the three fluorescent dyes is used as a specific color 
code to discriminate the beads and assign them to a distinct population. A flow cytometer is used as 
an readout system. This platform is capable of performing multiplexed immunoassays, which allow a 
the measurement of dozens to hundreds parameters in parallel with high sensitivity and reliability 
[89, 90]. In addition, less sample is consumed and fast assay times are possible, which allows 
automating and enhancing of the approach towards a high throughput technique [86]. 
The DigiWest is an optimization of the hitherto existing Western blot by transferring it to a  
bead-based microarray platform. It uses the advantages of the conventional Western blot protein 
detection method, such as providing a corresponding molecular weight, which allows the 
discrimination between specific and unspecific signals. Additionally, it avoids its main disadvantages: 
the detection of a very limited amount of analytes and the consumption of a proportionally high 
amount of sample volume [89, 91].  
During DigiWest, hundreds of replicas of one Western blot are generated. Thereby, one initial 
Western blot lane results in a bead-mix, which still contains all original Western blot information on 
the protein size and attributes it to different distinct bead populations. Thus, results highly 
comparable to the classical Western blot can be achieved, but one experiment is capable of 
performing hundreds of antibody incubations [89, 91]. Especially in experimental setups with a 
limited amount of available material, the DigiWest provides a solution, which yet allows a broad 
testing of analytes. Co-Immunoprecipitation (Co-IP) samples are among such limited samples. The 
possibility to employ a technique like the DigiWest to screen Co-IP samples and thereby connecting 
these two approaches, offers the ability to screen a huge amount of analytes on a very limited 
amount of sample volume. At the same time, the DigiWest is a valid and less material consuming 
alternative for mass spectrometric approaches (MS), which became the method of choice for 
identifying PPIs lately [92-94]. As Co-IP is the most straightforward method for the detection of PPIs 
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[95], the linkage of Co-IP to DigiWest results in an alternate high throughput tool to screen for PPIs. 
This creates the great opportunity of achieving a higher understanding of the interactions between 
proteins, as well as a further investigation of their dynamics under different conditions [89]. That in 
turn allows the exploration of biological processes, such as interactions between signaling pathways 
or the influences of PTMs on these cascades. 
 
  
  Introduction 
  15 
1.5 From antibodies to nanobodies 
The publication of mouse hybridoma technology in 1975 [96] represents a milestone in the 
development of the antibody technology and initiated the emergence of monoclonal antibodies in 
the therapeutical use [97]. Several monoclonal antibodies were approved or tested for 
biopharmaceuticals in the past years [97-99]. Besides that, antibodies have a high relevance in a wide 
range of biochemical applications, such as the identification and precipitation of proteins [100, 101], 
due to their high specificity and selectivity. This specificity turns them into excellent tools, that allows 
the identification of their addressed targets. They enable to draw conclusions about this molecule 
and its surrounding signaling cascades. 
 
 
Figure 3: Schematic presentation of antibody IgG, heavy-chain camelid antibody, nanobody and 
chromobody. 
A: A conventional heavy-chain antibody is represented. It consists out of two light chains with one variable 
domain (VL, dark blue) and a constant domain (CL, bright blue), as well as two heavy chains, with one variable 
domain (VH, red) followed by the first constant domain (CH1, orange), a hinge region and another two constant 
domains (CH2 and CH3, also orange).  
B: A heavy-chain camelid antibody is shown. It is devoid of light chains as well as the first constant region CH1, 
while the VH domain is modified (now called VHH).  
C: VHH is the smallest available intact antigen-binding fragment, derived of a camelid heavy-chain antibody, 
also called nanobody. This nanobody can be tagged by a GFP and results in a so-called chromobody  
(Figure adapted from [102-105]). 
 
Through the discovery of camelid heavy-chain antibodies at the end of the 1980s [2], a new category 
of antigen-binding molecules was identified, which were characterized by their small, but fully 
functional antigen binding fragment VHH (see Figure 3) [97]. The VHH domain, also called nanobody, 
is of small size (only about 15 kDa, roughly 120 aa), but shows a high affinity and selectivity for the 
addressed target [102, 106-108]. Additionally, nanobodies are of particular interest, as their 
generation is both easy and cheap [102, 105, 109], and they exhibit a high stability even under harsh, 
denaturing conditions [97]. These features enable them to penetrate tissue barriers [97], while 
conventional antibodies are too large to pass the cellular membrane and cannot fold correctly within 
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the reducing intracellular environment [107, 110]. It has been shown recently, that nanobodies can 
be selected as so-called intrabodies [105], which can be functionally expressed in living cells. This 
leads to significant advantages of nanobodies in several biotechnological and medical applications in 
comparison to conventional antibodies. One of these application is the possibility of targeting and 
precipitating proteins intracellularly, which to date is not feasible by using conventional  
antibodies [111].  
Beyond the possibility to perform Co-IPs on cellular lysates, it is of high interest to be able to study 
endogenous protein-complexes and identify dynamic PPIs. By inducing the ectopical expression of 
protein fusion constructs inside a cell the validity of Co-IP approaches is frequently deteriorated [94]. 
As the cellular level and the distribution of many proteins underlie a complicated regulation, 
complexes containing these modified proteins might not describe the realistic characteristics of the 
endogenous protein [94, 112]. The utilization of nanobodies tagged by a fluorescent protein, 
facilitates the visualization of their binding to a specific protein, pointing to its subcellular location, 
but might also allow to modulate the proteins’ target structure and subsequently its function [105, 
108, 112-114]. Nanobodies fused to fluorescent proteins, like GFP, are called chromobodies  
(see Figure 3). They facilitate the endogenous protein detection and enable to trace dynamic  
re-localizations of the protein during fluorescence microscopy [108, 112]. Thus, nanobodies depict an 
useful class of novel molecules for biotechnological approaches and will emerge further. In addition, 
they also combine the beneficial characteristics of conventional antibodies with desirable properties 
of small-molecule drugs. This paved the way for designing nanobody-based therapeutical programs 
[102], where nanobodies can address highly potent therapeutic targets [111]. Their impact as an 
available pharmaceutical in clinics will therefore presumably experience an enormous rise. 
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2. Aim of the thesis 
Quantitative and reliable data sets, which illustrate the momentary intracellular protein entity, the 
present protein-protein interactions and posttranslational modifications of proteins, are essential to 
characterize and decode the complexity of dynamic cellular signaling processes. It was revealed to be 
time and/or material consuming to accomplish a systematic pathway analysis for different cell types 
and under various treatments with conventional methods, like quantitative Western blots, Co-IPs 
and MS. Thus, high throughput methods, that go along with low material consumption, are required 
to simplify the analysis of complex cell signaling processes. 
Co-IP is the most straightforward method for the detection of PPIs and is considered as a gold 
standard for the identification of protein functions and interactions as well as the protein 
complexation. As a subsequent approach to confirm PPIs, frequently traditional Western blots are 
performed, but these allow only limited testing and the verification of known or highly predicted 
interaction partners. On the contrary, subsequent MS-based analyses allow wide ranging, unbiased 
screening and are capable to identify de novo interactors. Thus, this approach is able to reveal 
important information on the cellular crosstalk and became the method of choice for PPI analysis 
lately. Still it shows some majors disadvantages, such as the complexity of the technique, the limited 
throughput and the high material consumption. 
In this thesis, a combinatory approach is developed, which holds the capability of analyzing PPIs and 
unites both the advantages of the hitherto existing Western blot approach with the benefits of a high 
throughput tool. Hence, the recently developed DigiWest is connected to a prior performed Co-IP, 
with its high relevance for illustrating PPIs. As standard Co-IP requires a dissolving of the cellular 
structure, the development of intracellularly performed Co-IPs seems a promising way to gain deeper 
insights into in vivo conditions, as it reflects a system that is much closer to the authentic cellular 
networking. Thus, in a second step the DigiWest is combined with a novel intracellular Co-IP 
approach. 
Via the wide ranging analysis of protein interactions, a new type of functional characterization of 
different cell lines, for example tumor cells, is enabled. The opportunity to characterize cell lines, 
provides novel information not only on the amount of expressed proteins within the cellular context 
and thereby goes well beyond a conventional expression analysis and the enhancement of mere 
knowledge about protein concentration. Analyzing complex formation around central proteins of 
important signaling cascades offers the recognition of new modulation points for aberrant cellular 
communication, which results in disease formation. In this thesis, the key player of the canonical Wnt 
pathway, the proto-oncogen β-catenin, and its PPIs are chosen to be analyzed in hepatoma cell lines 
after drug treatment.  
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Wnt/β-catenin signaling regulates central processes like the modulation of differentiation and 
growth processes during development in the liver. The key player of this pathway, β-catenin, 
participates not only in the canonical Wnt signaling, but also other cellular processes, such as cell-cell 
adhesion complexes. The deregulation of this pathway is crucially implicated in tumorigenesis, but 
also an imbalance or alteration of β-catenin itself is linked to the genesis of many common cancer 
forms, e.g. liver cancer. In addition, the functions of β-catenin as a cell adhesions molecule or as a 
transcriptional co-activator are highly dependent on its concentration, its PTMs and its ability to 
complex with other proteins. Via this complexation β-catenin is able to modulate central regulating 
complexes and provides a link between the canonical Wnt signaling and other important signaling 
cascades, like the MAPK pathway. 
The goal of this thesis is to apply the at first developed combinatory high throughput approach, to 
focus on the various posttranslational modified variants of β-catenin and in parallel to screen for 
novel complex partners on different cell lines. By that, a more detailed understanding of the 
dynamics of β-catenin-mediated signaling and its extensive impact on the cellular crosstalk can be 
gained.  
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3. Materials and methods 
3.1 Materials 
3.1.1 Devices 
Table 1: List of devices 
Usage Product Distributor 
Autoclave Autoclave C Webeco, Selmsdorf, GER 
Burner Gasprofi 1 micro WLD TEC, Göttingen, GER 
Centrifuges 
5415D; 
5417R (cooled); 
5810R (cooled); 
 
Heraeus™ Pico™ 21 
Universal 30F 
 
Eppendorf, Hamburg, GER; 
 
Thermo Fisher Scientific, Waltham, MA, 
USA 
Hettich, Tuttlingen, Germany 
Cutting machine Silhouette SD Digital Craft Cutter Silhouette America, Lehi, UT, USA 
Electronic pipettes Xplorer Eppendorf, Hamburg, GER 
Gel electrophoresis -
System (SDS-PAGE) 
XCell SureLock™ Mini-Cell Life Technologies, Carlsbad, CA, USA 
Ice Flaker Scotman AF40 Frimont S.p.A., Pogliano Milanese, ITA 
Incubator Gas jacketed CO2 incubator, BB 
6220 CU 
Heraeus Instruments, Hanau, GER 
Laminar flow cabinet Sterilbank UVF 6.12 F BDK, Sonnenbühl, GER 
LED Copy Board A4 Amazon.com, Seattle, WA, USA 
Magnet comb 
KingFisher®™ 96  
PCR head 
Thermo Fisher Scientific, Waltham, MA, 
USA 
Magnetic comb 
KingFisher®™ 96  
tip comb 
Thermo Fisher Scientific, Waltham, MA, 
USA 
Magnetic separator DynaMag™ Spin Life Technologies, Carlsbad, CA, USA 
Magnetic stirrer RCT basic IKA®-Werke, Staufen, GER 
Magnetpen PickPen 8-M Bio-Nobile, Turku, FIN 
Micro centrifuge  
Carl Roth, Karlsruhe, GER 
neoLab, Heidelberg, GER 
Microsphere read out 
device 
FLEXMAP 3D Luminex, Austin, TX, USA 
Multichannel pipettes Research plus Eppendorf, Hamburg, GER 
Orbital Shaker DRS-12 neoLab, Heidelberg, GER 
Overhead mixing rotator Rotator 2-1175 neoLab, Heidelberg, GER 
pH meter pH meter 766 Knick, Berlin, DE 
Pipette Controller  PIPETBOY INTEGRA Biosciences, Hudson, NH, USA 
Pipettes 
PIPETMAN Neo; 
Research plus 
Research 
Discovery Comfort 
Gilson, Middleton, WI, USA; 
Eppendorf, Hamburg, GER; Eppendorf, 
Hamburg, GER; 
Starlab, Hamburg, GER 
Pipetting robot  Biomek FX Beckman Coulter, Brea, CA, USA 
Plate shaker Thermomixer comfort Eppendorf, Hamburg, GER 
Plate Shaker (16 plates) TiMix 5 Edmund Bühler, Hechingen, GER 
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Usage Product Distributor 
Platemagnet for 
microspheres 
Magnetic Plate Separator Luminex, Austin, TX, USA 
Platform shaker Polymax 2040 Heidolph, Schwabach, GER 
Power supply unit Power Ease 500 Life Technologies, Carlsbad, CA, USA 
Reaction tube shaker Thermomixer comfort Eppendorf, Hamburg, GER 
Rotating mixer for tubes RM5 Assistent, Sondheim, GER 
Scale Explorer E12140 OHAUS, Pine Brook, NJ, USA 
Scalpel  Martor, Solingen, GER 
Shaker Vortex Genie 2 Scientific Industries, Bohemia, NY, USA 
Sonification bath  
Sonorex RK 31 
Transsonic T780/H 
Bandelin, Berlin, GER; 
Elma, Singen, GER 
Tweezers  Dumoxel® 5 EMS, Hatfield, PA, USA 
Vacuum sealer V.200 Landig + Lava, Bad Saulgau, GER 
Water bath 1083 GFL, Burgwedel, GER 
Water purification 
system 
Milli Q Plus; 
arium® 611VF 
Merck Millipore, Billerica, MA, USA; 
Sartorius Stedim Biotech, Göttingen, GER 
Western Blot 
Documentation system 
ODYSSEY Infrared Imaging System; 
ImageQuant LAS 4000 mini 
LI-COR Biosciences, Lincoln, NE, USA; 
GE Healthcare, Chalfont St Giles, UK 
 
Western Blot-System XCell II Blot Module Life Technologies, Carlsbad, CA, USA 
 
3.1.2 Programs 
Table 2: List of programs 
Product Distributor 
Adobe Illustrator CS5 Adobe Systems, San José, CA, USA 
Adobe Photoshop CS5 Adobe Systems, San José, CA, USA 
DigiWest analysis tool  
(version 3.8.5.2, Excel-based) 
NMI Reutlingen, Reutlingen, DE 
DigiWest Viewer (Excel-based) NMI Reutlingen, Reutlingen, DE 
EndNote X7 Thomson Reuters, New York, NY, USA 
etiLABEL ETISOFT, Delmenhorst, GER 
Image Reader LAS-4000 GE Healthcare, Chalfont St Giles, UK 
Image Studio v4 LI-COR Biosciences, Lincoln, NE, USA 
MeV Version 4.8.1,  
TM4 Microarray Software Suite [115, 116] 
Dana-Farber Cancer Institute, Boston, MA, USA  
MS Office 2010, MS Office 2013 Microsoft, Redmond, WA, USA 
Silhouette Studio® Silhouette America, Lehi, UT, USA 
Windows XP, Windows 7 Microsoft, Redmond, WA, USA 
XLfit 5.3.1.3 IDBS, London, UK 
xPONENT Software Solutions IS 2.2 Luminex, Austin, TX, USA 
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3.1.3 Databases 
Table 3: List of databases 
Product Distributor 
BioGRID  
(Biological General Repository for Interaction 
Datasets) [117] 
BioGRID Team  
FpClass [118] 
Princess Margaret Cancer Center,  
University Health Network, Toronto, ONT, CAN 
IntAct database [119, 120] The Molecular Interactions team, EMBL-EBI, Hinxton, UK 
UniProtKB (UniProt Knowledgebase) [121] UniProt Consortium  
 
3.1.4 Consumables 
Table 4: List of consumables 
Usage Product Distributor 
0.65 ml reaction tubes Mµlti®-safety microcentrifuge tubes Carl Roth, Karlsruhe, GER 
1.5 ml protein  
LoBind tubes 
 Eppendorf, Hamburg, GER 
1.5 ml reaction tubes  Vetter Laborbedarf, Ammerbuch, GER 
10 cm cell culture dish  Falcon 3003 BD, Heidelberg, GER 
15 ml tubes  Greiner Bio-One, Frickenhausen, GER 
2 ml reaction tubes  Vetter Laborbedarf, Ammerbuch, GER 
4 ml tubes  Greiner Bio-One, Frickenhausen, GER 
50 ml tubes  Greiner Bio-One, Frickenhausen, GER 
Calibration and 
Verification of the 
FLEXMAP  
FLEXMAP 3D® Calibration Kit and 
Perfomance Verification Kit 
Luminex, Austin, TX, USA 
Calibration solutions for 
pH meter 
Technical buffer solution pH 4.01, 
7.00 and 9.21 
Mettler-Toledo, Columbus, OH, USA 
Cell scraper Costar Cell Lifter Corning Incorporated, Corning, NY, USA 
Disposable bag  Sarstedt. Nümbrecht, GER 
Filter paper 
Whatman cellulose 
chromatography paper 3 mm 
Sigma-Aldrich, St. Louis, MO, USA 
Glass pasteur pipette  WU Mainz, Mainz, GER 
Glass pipette 5 ml, 10 ml, 20 ml Brand, Wertheim, GER 
Glassware  Schott, Mainz, GER 
Gloves 
Micro Touch Hygrip; 
Safeskin Purple Nitrile; 
Nitrile gloves Rotiprotect-NITRIL 
Rotiprotect-LATEX 
Ansell, Munich, GER; 
Kimberly-Clark, Dallas, TX, USA; 
VWR, Darmstadt, GER; 
Carl Roth, Karlsruhe, GER, 
Carl Roth, Karlsruhe, GER 
Magnetic beads Dynabeads® Protein G Life Technologies, Carlsbad, CA, USA 
Microplate sealing tape  Axygen® AxySeal Corning Incorporated, Corning, NY, USA 
Microplate,  
flat bottom 
655101 – Greiner 
96 well 
Greiner Bio-One, Frickenhausen, GER 
Microplate,  
half area flat bottom, 
non-binding surface 
CLS3642 – Corning 96 well 
(Half Area Platte) 
Corning Incorporated, Corning, NY, USA 
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Usage Product Distributor 
Microspheres MagPlex® Microspheres Luminex, Austin, TX, USA 
Needles Sterican® Gr. 1, Gr. 14 Braun Melsungen, Melsungen, GER 
Parafilm PM-996 Bemis, Oshkosh, WI, USA 
PCR comb 
KingFisher®™ 96  
tip comb 
Thermo Fisher Scientific, Waltham, MA, 
USA 
Pipetting tips 
0.1 – 10 µl 
1 – 200 µl; 
1 – 200 µl  
(capillary tips); 
1 – 300 µl; 
100 – 1000 µl; 
100 – 1200 µl; 
 
100 – 5000 µl 
Mettler-Toledo, Columbus, OH, USA 
Starlab, Hamburg, GER; 
VWR, Darmstadt, GER 
 
Starlab, Hamburg, GER; 
Starlab, Hamburg, GER; 
Biozym Scientific, Hessisch Oldendorf, 
GER 
neoLab, Heidelberg, GER 
Polyacrylamid gels 
NuPAGE Novex 4 – 12 % Bis-Tris 
Gels 1.0 mm 12, 15 and 17 well 
Life Technologies, Carlsbad, CA, USA 
Polyvinylidene difluoride 
membrane 
Immobilon-P PVDF Membrane, 
0.45 µm 
Millipore Corporation, Billerica, MA, USA 
Robot pipetting tips 
4 – 220 µl;  
Biomek AP96 P250 Tips, Non-sterile 
Beckman Coulter, Brea, CA, USA 
Silicone tips for 
Magnetpen 
QuickPick tips Bio-Nobile, Turku, FIN 
Sponge Pad 
NuPage Novex  
Sponge Pad for Blotting 
Life Technologies, Carlsbad, CA, USA 
Sterile filter Steritop 0.22 µm Millipore, Eschborn, GER 
Syringes Injekt™ Syringe 10 ml, 5 ml  Braun Melsungen, Melsungen, GER 
Vacuum bags R-Vac Landig + Lava, Bad Saulgau, GER 
 
3.1.5 Chemicals 
Table 5: List of chemicals 
Product Distributor 
2-Mercaptoethanol Sigma-Aldrich, St. Louis, MO, USA 
2-Propanol 70 % Carl Roth, Karlsruhe, GER 
Bromophenol blue sodium salt Carl Roth, Karlsruhe, GER 
BSA 
Albumin Fraction V (protease-free) 
Carl Roth, Karlsruhe, GER 
CHIR 99021 Tocris Bioscience, Bristol, UK 
DMEM Life Technologies, Carlsbad, CA, USA 
DMEM/F-12 Life Technologies, Carlsbad, CA, USA 
DMSO Sigma-Aldrich, St. Louis, MO, USA 
DNAse I AppliChem, Darmstadt, GER 
DTT Sigma-Aldrich, St. Louis, MO, USA 
EDTA Carl Roth, Karlsruhe, GER 
EtOH 96 % Carl Roth, Karlsruhe, GER 
FCS Life Technologies, Carlsbad, CA, USA 
Glycerol Sigma-Aldrich, St. Louis, MO, USA 
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Product Distributor 
HAc Carl Roth, Karlsruhe, GER 
HCl Carl Roth, Karlsruhe, GER 
Hepes Carl Roth, Karlsruhe, GER 
MeOH Carl Roth, Karlsruhe, GER 
MG132 (Z-Leu-Leu-Leu-al) Sigma-Aldrich, St. Louis, MO, USA 
MgCl2 Sigma-Aldrich, St. Louis, MO, USA 
Milk powder Carl Roth, Karlsruhe, GER 
Na3VO4 Sigma-Aldrich, St. Louis, MO, USA 
NaCl Carl Roth, Karlsruhe, GER 
NaClO solution 12 % Carl Roth, Karlsruhe, GER 
NaF Carl Roth, Karlsruhe, GER 
NaHCO3 Merck, Darmstadt, GER 
NaN3 Merck, Darmstadt, GER 
NaOH Carl Roth, Karlsruhe, GER 
NP-40 Sigma-Aldrich, St. Louis, MO, USA 
Penicillin Biochrom, Berlin, GER 
PMSF AppliChem, Darmstadt, GER 
Ponceau S Carl Roth, Karlsruhe, GER 
Protease Inhibitor (EDTA-free) 
Complete C 
Roche Diagnostics, Mannheim, GER 
Protease Inhibitor Mix M Serva, Heidelberg, GER 
SDS Sigma-Aldrich, St. Louis, MO, USA 
Streptomycin Biochrom, Berlin, GER 
Tris–HCl Carl Roth, Karlsruhe, GER 
Triton X-100 Merck, Darmstadt, GER 
Trypsin-EDTA Biochrom, Berlin, GER 
Tween 20 Merck, Darmstadt, GER 
Urea Sigma-Aldrich, St. Louis, MO, USA 
 
3.1.6 Reagents 
Table 6: List of reagents 
Reagent Product Distributor 
Antioxidant NuPAGE® Antioxidant Life Technologies, Carlsbad, CA, USA 
Biotinylation reagent EZ-Link NHS-PEG12-Biotin 
Thermo Fisher Scientific, Waltham, MA, 
USA 
LDS Sample Buffer NuPAGE® LDS Sample Buffer Life Technologies, Carlsbad, CA, USA 
MEME medium 
Minimum Essential  
Medium Eagle 
Sigma-Aldrich, St. Louis, MO, USA 
MES Running buffer 
NuPAGE® MES SDS Running Buffer 
(20x) 
Life Technologies, Carlsbad, CA, USA 
PBS PBS (10x) 
Thermo Fisher Scientific, Waltham, MA, 
USA 
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Reagent Product Distributor 
Protein standard 
SeeBlue® Plus2 Pre-Stained 
Standard 
Life Technologies, Carlsbad, CA, USA 
Reducing Agent NuPAGE® Sample Reducing Agent  Life Technologies, Carlsbad, CA, USA 
Roche buffer Blocking Reagent for ELISA Roche Diagnostics, Mannheim, GER 
Sheath Fluid LiquiChip System Fluid (10x) Qiagen, Venlo, NLD 
Transfer buffer NuPAGE® Transfer Buffer (20x) Life Technologies, Carlsbad, CA, USA 
 
3.1.7 Buffer  
Table 7: List of buffers 
Buffer Reagents and concentration Distributor 
Assay buffer 
Roche buffer  
with 0.2 % milk powder,  
0.05 % NaN3,  
0.05 % (v/v) Tween 20 
Roche Diagnostics, Mannheim, GER 
and see chemicals 
Dilution–buffer for Co-IP 
of HEK293T cells 
10 mM Tris–HCl pH 7.4 
150 mM NaCl 
0.5 mM EDTA 
2 mM PMSF 
1 x Protease Inhibitor Mix M 
 
DMEM medium 
6 g DMEM 
1.22 g NaHCO3 
Ad 450 ml H2Odd pH 7.2 
 
DMEM/F–12 medium 
6 g DMEM/F–12 
1.22 g NaHCO3 
Ad 450 ml H2Odd pH 7.2 
 
Elution buffer  
DigiWest 
1 % (v/v) Triton X–100,  
8 M Urea 
in 100 mM Tris–HCl pH 9.5  
 
Laemmli buffer (4 x) 
2 % SDS 
10 % Glycerol 
60 mM Tris–HCl 
adjust with HCl to pH 6.8 
add 0.02 % Bromophenol blue 
sodium salt 
bring up to 95 ml with H2Odd 
add 5 ml 2-Mercaptopethanol 
 
Lysis–buffer for  
Co-IP of HEK293T cells 
10 mM Tris–HCl pH 7.4 
0.5 % NP-40 
150 mM NaCl 
0.5 mM EDTA 
2 mM PMSF 
1 x Protease Inhibitor Mix M 
200 µg/ml DNAse I 
 
Lysis–buffer for  
Co-IP of the other  
cell lines 
10 mM Hepes pH 7.6 
0.5 % NP-40 
100 mM NaCl 
1 mM DTT 
1 mM MgCl2 
1 x Protease Inhibitors (EDTA-free) 
Phosphatase Inhibitors  
(50 mM NaF, 1 mM Na3VO4) 
 
PBST 0,1 % (v/v) Tween 20 in PBS  
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Buffer Reagents and concentration Distributor 
Ponceau staining 
solution  
0,1 % (w/v) Ponceau S, 
1 % HAc in H2Odd 
 
TBS 
10 mM Tris–HCl 
150 mM NaCl 
in H2Odd pH 7.4 
 
TBST 0,1 % (v/v) Tween 20 in TBS  
 
If no distributor is denoted, the source of supply for the individual buffer components can be 
obtained in the chemicals chapter (see 3.1.5). 
 
3.1.8 Antibodies 
3.1.8.1 Capturing antibodies for Co-IP 
Table 8: Capturing antibodies for Co-IP 
Analyte Species Binding site Distributor 
Product 
number 
Dilution  
for Co-IP 
β-catenin ms aa 571 – 781 BD Biosciences 610154 500 
IgG1 ms  Sigma M5284 400 
 
All distributors for the capturing antibodies are listed beneath the primary antibody table in the 
appendix (see Suppl. Table A).  
 
3.1.8.2 Nanotraps 
Table 9: Nanotraps for Co-IP 
Analyte Binding site Distributor 
BC1-beads aa 61 – 87 Prof. Dr. Rothbauer [112] 
GFP-Trap®  ChromoTek, Planegg-Martinsried, GER 
 
For generating the BC1-beads, a β-catenin-specific nanobody was immobilized on agarose beads. The 
BC1 nanobody binds β-catenin N-terminal close to the SSTS-motif (aa 61 – 87), presumably on a 
three dimensional epitope [112]. The GFP-Trap® represents a non-related nanobody against GFP, the 
GFP-binding protein (GBP), coupled to agarose beads. Nanobodies fused to fluorescent proteins are 
called chromobodies [108]. 
 
3.1.8.3 Primary antibodies 
A complete list of all primary antibodies used for developing this screening approach can be found in 
the appendix (see Suppl. Table A). All antibodies in this list, which were used for ECIP on different 
liver cell lines are marked with *, while antibodies used for ECIP or ICIP on any kind of HEK293T cells 
are marked with **. For usage as a primary antibody in the conventional Western blot, the dilution 
was carried out as recommended by the manufacturer, with the dilution factor used for DigiWest 
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being five times lower as recommended for normal Western blotting. If different antibodies directed 
towards the same protein were used and had to be differentiated throughout the result and 
discussion chapter, their distinct NMI number was added in brackets to identify them in the antibody 
list. If two molecular weights are assigned to an antibody by the manufacturer, the antibodies were 
separated and examined as two individual analytes. Unless otherwise noted, these two peaks always 
correspond to different isoforms or cleaved versions of the same protein (see Suppl. Table B). 
 
3.1.8.4 Detection antibodies 
Table 10: List of detection antibodies for DigiWest. 
Antigen Conjugation Species Distributor 
gt-IgG (H+L) PE dk Jackson Dianova, Hamburg, GER 
ms-IgG(H+L) PE dk Jackson Dianova, Hamburg, GER 
rb-IgG (H+L) PE dk Jackson Dianova, Hamburg, GER 
rt-IgG (H+L) PE gt Jackson Dianova, Hamburg, GER 
Streptavidin PE dk Jackson Dianova, Hamburg, GER 
 
Table 11: List of detection antibodies for Western blot. 
Antigen Conjugation Species Distributor 
ms-IgG (H+L) IRDye 800CW dk LI-COR Bioscience, Lincoln, NE, USA 
ms-IgG (H+L) IRDye 680RD dk LI-COR Bioscience, Lincoln, NE, USA 
rb-IgG (H+L) IRDye 800CW dk LI-COR Bioscience, Lincoln, NE, USA 
rb-IgG (H+L) IRDye 680RD dk LI-COR Bioscience, Lincoln, NE, USA 
 
All used detection antibodies were diluted according to the manufacturers instruction. 
 
3.1.9 Cell lines 
For the identification of different β-catenin complexes, five different cell lines were used.  
Table 12: Mouse hepatoma cell lines 70.4 and 55.1c. 
Cell line 70.4 55.1c 
Cell type Hepatoma Hepatoma 
Species mouse Mouse 
Source Dr. Kress Dr. Kress 
Culture medium 
DMEM/F–12 
10 % FCS 
1 % P/S  
DMEM/F–12 
10 % FCS 
1 % P/S  
Growth conditions 37°C, 5 % CO2 37°C, 5 % CO2 
Mutation status p53 mutation [76] 
heterozygous β-catenin exon 3 
deletion [78]; B-raf mutation 
 
Both mouse hepatoma cell lines were established out of mice liver, induced by a single 
intraperitoneal injection of N-nitrosodietylamine (NDEA), but harbor different mutations [76, 78]. 
  
  Materials and methods 
  27 
Table 13: Human hepatocellular carcinoma cell lines HB35 and HepG2. 
Cell line HepG2 HC-AFW1 (alternative name HB35) 
Cell type Hepatocellular carcinoma Hepatocellular carcinoma  
Species human Human 
Source 
DSMZ (Leibniz Institute DSMZ-German 
Collection of Microorganisms and Cell 
Cultures)  
University Children’s Hospital 
Tübingen, Pediatric Surgery 
Culture medium 
MEME 
10 % FCS 
1 % P/S 
1 % Glutamine 
DMEM 
10 % FCS 
1 % P/S [122] 
Growth conditions 37°C, 5% CO2 37°C, 5 % CO2 
Mutation status 
heterozygous β-catenin exon 3-4 
deletion [74, 79, 82, 85] 
Heterozygous β-catenin exon 3 
deletion [83] 
 
Both human liver cell lines where generated out of liver tumors from young male donors. Both show 
a mutational deletion of β-catenin exon 3, so that an active Wnt/β-catenin signaling can be observed 
[79, 82-84]. To avoid confusion during the presentation of results, the cell line HC-AFW1 will be 
henceforth referred to as HB35 within this thesis. 
 
Table 14: Human embryonic kidney cell line HEK293T. 
Cell line HEK293T HEK293T_BC1 HEK293T_GFP 
Cell type Embryonic Kidney Embryonic Kidney Embryonic Kidney 
Species human human human 
Source 
ATCC (American Type 
Culture Collection) 
ATCC (American Type 
Culture Collection) 
ATCC (American Type 
Culture Collection) 
Culture medium 
DMEM 
10 % FCS [123] 
1 % P/S 
1 % Glutamine 
DMEM 
10 % FCS [123] 
1 % P/S 
1 % Glutamine 
DMEM 
10 % FCS [123] 
1 % P/S 
1 % Glutamine 
Growth conditions 37°C, 5 % CO2 37°C, 5 % CO2 37°C, 5 % CO2 
Mutation status none 
none,  
stabile transfected with 
the BC1-chromobody 
sequence 
none,  
stabile transfected with 
the GFP plasmid 
 
HEK293T cells was generated out of human embryonic kidney cells and shows an epithelioid 
character. The cell line shows no mutations associated with the Wnt/β-catenin pathway and  
is therefore, a relatively complete system to gain deeper insight in the mechanisms of this  
pathway [124]. 
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3.2 Biomolecular and biochemical methods 
3.2.1 Cell Culture 
3.2.1.1 Growth conditions and general remarks 
All working steps were performed under sterile conditions, in order to avoid contaminations. To 
ensure this, culture media, solutions and consumables were autoclaved at 121°C, 1 bar for 40 min. If 
heat sensitive, they were sterile filtered. Working materials were disinfected with 70 % EtOH before 
entering the sterile area underneath the clean bench and glassware was sterilized at 180°C for 4 h. 
All cell lines were cultivated in 10 cm cell culture dishes in the respective recommended growth 
medium (see Table 12 – Table 14) supplemented with 10 % (v/v) FCS and 1 % penicillin (10,000 U/ml) 
/ streptomycin (10 mg/ml) solution at 37°C and 5 % CO2 with almost saturated humidity. The growth 
medium was changed every second day.  
 
 
Figure 4: Cells at maintenance culture. 
Pictures were received from Eva Zeller, Toxicology department, Eberhard Karls University of Tübingen. 
 
HB35
HepG2
55.1c
70.4
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3.2.1.2 Cell Passaging 
At 90 % confluence cells were subcultured; growth medium was aspirated and cells were washed 
with sterile PBS once. By adding 1 ml of trypsin-EDTA cells were detached from the cell culture dish. 
After incubating for 5 min in the incubator at 37°C, 9 ml of regular growth medium were added to 
stop enzymatic activity. It was required to disperse the cells by pipetting up and down, using a 10 ml 
syringe and an injection needle. To maintain a sustainment culture, a few drops of the cell 
suspension were added to a new cell culture dish, filled with fresh growth medium. 
 
3.2.1.3 Drug treatment 
At a confluence status of 70 - 80 % cells were treated for 24h with 10 ml treatment medium. The 
normal growth medium was supplied with less FCS (1 % (v/v) FCS) and supplemented with 
CHIR 99021 or MG132 at concentrations listed below. Untreated cells were used as a negative 
control (see Table 15). MG132 was solved in DMSO, as it is not soluble in water. Since it is known that 
a DMSO concentration above 1 % (v/v) is toxic [125]. It is recommended to stay below a 
concentration of 0.5 % – 1 % in cell culture in order to avoid cellular effects [126]. The used DMSO 
concentration of 0.0025 % (v/v) for the MG132 treatment is well below this concentration and since 
no cellular alterations were observed, no additional negative control was included.  
 
Table 15: Treatment compounds, their mode of action and their final concentration. 
CHIR 99021 and MG132 were dissolved according to the manufacturer’s instructions. 
Reagent Mode of action Final concentration 
CHIR 99021 Inhibition of GSK3 10 µM 
MG132 Inhibition of proteasome 1 µM  
- Negative control  
 
3.2.1.4 Cell harvesting 
For harvesting, cell cultivation plates were placed on ice, and washed once with ice-cold PBS. 
Washing buffer was discarded, cells scraped off the plate in 1 ml of ice-cold PBS and collected into a 
1.5 ml reaction tube. After centrifugation at 4°C and 600 g for 5 min, the supernatant was discarded 
and the cell pellets quick-frozen in liquid nitrogen. Cells were stored at -80°C. 
 
3.2.2 Cell lysis under non-denaturating conditions 
For cell lysis for ECIP or ICIP (see 3.2.3 and 3.2.4), two different lysis protocols were used. 
Pellets of the cell lines (70.4, 55.1c, HepG2 and HB35), received from the Toxicology department, 
Eberhard Karls University of Tübingen, were homogenized in 200 µl of lysis buffer for Co-IP of other 
cells (10 mM Hepes pH 7.6, 0.5 % NP-40, 100 mM NaCl, 1 mM DTT, 1 mM MgCl2, Protease Inhibitors 
(EDTA-free), Phosphatase Inhibitors (50 mM NaF, 1 mM Na3VO4)). The buffer system was adapted to 
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the protein extraction protocol described by Yakulov et al. [127] and thereby a better extraction of 
nuclear β-catenin was facilitated. This modification ensures compatibility to protein fractionation 
protocols, where nuclear and cytoplasmic fractions are generated. 
The lysis procedure varied slightly for the HEK293T cells. Here the pellets were homogenized in 
200 µl of lysis buffer for Co-IP of HEK293T cells (10 mM Tris-HCl pH 7.4, 0.5 % NP-40, 150 mM NaCl, 
0.5 mM EDTA, 2 mM PMSF, 1 x Protease Inhibitor Mix M, 200 µg/ml DNAse I). For lysis, pellets were 
put on ice for 10 min and pipetted up and down for thirty times afterwards. This was repeated twice, 
before the lysate was centrifuged at 14000 rpm for 10 min at 4°C in a precooled centrifuge [112]. The 
supernatant was transferred into a new reaction tube and the protein solutions were adjusted to a 
total volume of 500 µl with the previously used lysis buffer, in case of the cells from the Toxicology 
department. If working with HEK293T, the volume was adjusted with dilution buffer 
(10 mM Tris/Cl pH 7.4, 150 mM NaCl, 0.5 mM EDTA, 2 mM PMSF, 1 x Protease Inhibitor Mix M) 
instead. This procedure was followed either by conventional Co-IP (see 3.2.3), ECIP (see 3.2.3.2) or 
ICIP (see 3.2.4). 
 
3.2.3 Conventional Co-Immunoprecipitation 
50 µl of lysate were taken and mixed with 4 x Laemmli buffer, to generate the input sample.  
 
3.2.3.1 Co-IP on liver cell lines 
For processing the four cell lines, received from the Toxicology department, either 1 µl of a  
β-catenin-specific antibody (dilution factor 1:500) or 1 µl of an identically concentrated monoclonal 
ms, IgG1-isotype control antibody (dilution factor 1:400), serving as a negative control, were added 
to each sample. Samples were mixed and left on ice for approximately 5 min. Afterwards 50 µl of 
magnetic protein G beads were washed in 50 µl of PBST three times and resuspended in lysis buffer, 
prior to adding to the lysate and incubated at 4°C overnight on an overhead mixing rotator. The used 
amounts of antibody and protein G beads for precipitation were determined according to the 
manufacturers protocol and in dependence on the ECIP and ICIP protocol (see 3.2.3.2 and 3.2.4). 
After incubation, the reaction tubes were put onto a magnetic separator, 50 µl of the supernatant 
was recovered and taken as the non-bound sample before mixing with 4 x Laemmli buffer. The 
remaining supernatant was discarded. The bead-pellet was gently washed with 500 µl of lysis buffer. 
This step was repeated twice. The bead-protein suspension was transferred into a new reaction tube, 
to avoid a carry over of sticky proteins attached to the reaction tube walls. After discarding the 
supernatant once more, the bound sample was generated by dissolving each bead-pellet in 100 µl 
2 x Laemmli buffer. All samples (inputs, non-bounds, bounds) were denatured at 95°C for 10 min and 
300 rpm on a reaction tube shaker. The workflow in detail is described in Figure 5. 
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Figure 5: Workflow of Co-IP on other cell lines. 
Cells were lysed, the input sample was taken (a); β-catenin protein complexes were captured by a  
β-catenin-specific antibody coupled to protein G beads overnight (b). Taking of the non-bound sample and 
washing (c); elution of protein complexes from the protein G beads, generating of the bound sample (d). 
(Figure adapted from ChromoTek, Planegg-Martinsried, GER). 
 
3.2.3.2 ECIP on HEK293T samples 
For processing of the HEK293T samples, 50 µl of BC1-beads or GFP-Trap® were added to each lysate 
and incubated at 4°C overnight on an overhead mixing rotator. GFP-Trap® as a nonrelated nanobody, 
was used as a negative control and the generated samples are referred to as GFP-bound [92]. After 
incubation, reaction tubes were centrifuged at 2500g at RT for 2 min and 50 µl of the supernatant 
was removed (non-bound sample) and mixed with 4 x Laemmli buffer. The remaining supernatant 
was aspirated with a needle and discarded. The bead-pellet was gently washed with 500 µl of 
dilution buffer; this step was repeated twice. Afterwards the bead-protein suspension was 
transferred into a new reaction tube. Another centrifugation step was performed and the 
supernatant discarded. The bound sample was generated by adding 100 µl 2 x Laemmli buffer to 
each bead-pellet. Samples were denatured at 95°C for 10 min and 300 rpm on a reaction tube 
shaker. This workflow in detail is shown in Figure 6. 
 
 
Figure 6: Workflow of ECIP on HEK293T cells. 
Cells were lysed, the input sample was taken (a); β-catenin protein complexes were captured by the  
β-catenin-specific nanobody BC1 coupled to agarose beads overnight (b). Taking of the non-bound sample and 
washing (c); elution of protein complexes from the agarose beads, generating of the bound sample (d). (Figure 
adapted from ChromoTek, Planegg-Martinsried, GER). 
 
protein G beads
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protein complexes
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3.2.4 Intracellular Co-Immunoprecipitation (ICIP) 
Analog to 3.2.3, 50 µl of the 500 µl cell lysate (see 3.2.2) were taken and mixed with 4 x Laemmli 
buffer to receive the input sample. Subsequently 50 µl of GFP-Trap® were added to the stabile 
transfected HEK293T lysates. HEK293T cells stabile transfected with plasmid, carrying GFP, served as 
a negative control and were processed analog. After adding the GFP-Trap®, the lysates were 
incubated at 4°C overnight on an overhead mixing rotator. The ensuing procedure was identically 
performed as described in 3.2.3.2. Figure 7 gives a more detailed overview on the workflow. 
 
 
Figure 7: Workflow of ICIP on stable transfected HEK293T cells. 
Cells were transfected with the chromobody plasmid (a); β-catenin protein complexes were bound by the 
intracellular expressed chromobody. Cells were lysed (b); protein complexes were captured via the fluorescent 
tag using the GFP-Trap® (c). Taking of the non-bound sample and washing (d), elution of protein complexes 
from the GFP-Trap®, generating of the bound sample (e). (Figure adapted from ChromoTek, Planegg-
Martinsried, GER). 
 
3.2.5 Polyacrylamid gel electrophoresis 
The used gel electrophoresis system operates according to the principle of the discontinuous 
denaturing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), described by 
Laemmli [128]. The samples were mixed with 4 x Laemmli and denatured for 10 min at 75°C. 10 µl of 
the input samples (= 1 %), 20 µl of the bound samples (= 20 %) [112, 129] and 5 µl of a pre-stained 
marker, as a reference, were subsequently loaded onto a pre-cast NuPAGE gel. For checking the 
quality of the Co-IP additional 10 µl of the non-bound samples (= 1 %) were added onto the gel. All 
used gels were 4 – 12 % Bis-Tris gels with 12 – 17 wells and 1 mm thick. These gels contain a 
polyacrylamide-gradient from 4 to 12 %. Number of wells varied according to the experimental 
requirements. For DigiWest experiments, only 12 well gels were used. On gels, being destined for the 
DigiWest, additionally the molecular weight marker was applied twice and every second lane in 
between the samples was left empty, which was essential for the later blot cutting (see 3.3.2.1). The 
electrophoresis was run for approximately 1.5 h at 150 V in 800 ml 1 x NuPAGE MES buffer with 
500 µl NuPAGE antioxidant per chamber, until the blue buffer front reached the bottom of the gel. 
For only checking the quality of the Co-IP procedure, gels were run shorter at 200 V. The successful 
performance of Co-IP was checked by proceeding with a conventional Western blot (see 3.2.6), 
before processing the samples in the DigiWest. If the blot was intended for specific immunological 
detection, it was proceeded into the microsphere-based DigiWest. (see 3.3.2). 
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3.2.6 Western blot 
The proteins from the gel matrix were transferred onto a PVDF membrane using NuPAGE  
blotting system [130]. The transfer in transfer buffer with 10 % MeOH was carried out for 75 min at 
30 V, 160 mA and RT.  
 
 
Figure 8: Western blot transfer setup. 
The Western blot transfer setup consists out of three blotting sponges soaked with transfer buffer, two soaked 
Whatman papers, the gel, a PVDF membrane, activated in MeOH and rinsed with transfer buffer, two 
Whatman papers soaked with transfer buffer and again three soaked blotting sponges placed on top of each 
other.  
 
After transferring the proteins, the membrane was washed in PBST for 15 min. 
 
3.2.7 Ponceau S staining 
The transfer efficiency was monitored by reversibly staining of the membranes with Ponceau S 
(10 min on an orbital shaker) to detect immobilized proteins on the membrane. After washing and 
decolorizing the membrane with H2Odd to an extent that protein bands were visible, they were 
detected by the ImageQuant LAS 4000 mini. For blots, which were processed further in the DigiWest, 
the lane positions were labeled with a pencil to guarantee a successful cutting of the membrane later 
on. Subsequently the membrane was completely destained by incubation in TBST or PBST for 30 min 
with exchanging the buffer several times. 
 
3.2.8 Immunodetection 
For blocking of free sites on the PVDF membrane 3 % BSA in TBST were added and incubated for 
60 min on a rotating mixer. Blots were placed in 15 ml or 50 ml tubes and the incubation with 
primary antibodies was carried out in 1 % BSA in TBST overnight at 4°C on a rotating mixer (antibody 
dilutions see 3.1.8.3 and Suppl. Table A) [92]. Depending on the size of the membrane, 2.5 ml or 4 ml 
3x blotting sponges
2x filter papers
1x transfer membrane
1x gel
3x blotting sponges
2x filter papers
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of antibody dilution were used. Subsequently, the antibody solution was discarded and the 
membrane was washed three times for 5 min each with 10 ml of TBST to remove the unbound 
antibody. The species-specific, LI-COR IRDye labeled secondary antibodies diluted in 1 % BSA in TBST 
were applied and the membrane was incubated in the dark for 1 h at RT on a rotating mixer 
(antibody dilutions see Table 11). The earlier described washing was repeated three times and the 
membrane dried afterwards. Signal detection was performed at excitation wavelengths 685 nm and 
785 nm on the ODYSSEY Infrared Imaging System; Images with a resolution between 42 – 337 µm 
were recorded. Via pre-scanning the optimal laser power setting (high intensity, but no saturated 
pixels), for the ensuing a high dynamic range, was determined. The Odyssey CLx was used due to the 
advantage of its multiplex analysis capacity. By selecting appropriate antibodies a simultaneous 
detection of two targets by using two different IR fluorophores is possible [131]. 
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3.3 Microarray methods 
The described microarray-based Western blots were performed on the microsphere-based, Luminex 
technology. The Luminex Flexmap 3D device was used, which is able to distinguish up to  
500 different types of microspheres via their internal color-coding. Here, a 384-plex DigiWest bead 
mix was employed. The coupling conditions for generating such a 384-plex DigiWest bead mix were 
established and described in detail recently [89]; therefore, are only brieftly oulined here.  
 
3.3.1 Preparation of magnetic microspheres 
3.3.1.1 NeutrAvidin coating 
NeutrAvidin coated Luminex MagPlex® beads provide an efficient binding matrix for biotinylated 
proteins. NeutrAvidin is a deglycosylated avidin, which has a strong affinity for biotin (dissociation 
constant ~ 10-14 M) [132]. Therefore, NeutrAvidin was coupled to Luminex MagPlex® beads with a 
KingFisher® 96 automated magnetic particle processor. In preparation of the coupling, the MagPlex® 
beads were vortexed firmly and treated with ultrasound to reduce bead agglomeration. Beads were 
provided in 96 well plates and placed together with the buffer plates into the KingFisher® 96. During 
the coupling process a covalent bond between primary amines and activated carboxyl groups on the 
surface of the Luminex beads is formed. These carboxyl groups can be activated with EDC and form a 
reactive sulfo-NHS-ester intermediate in the presence of sulfo-NHS. Primary amines and the 
intermediate react and form a covalent amide bond, which is later used by biotinylating proteins and 
coupling them to the MagPlex® beads in a second coupling step [133]. The beads covered with 
reactive sulfo-NHS-ester intermediates are washed and transferred into storage tubes. 
 
3.3.1.2 Quality control of NeutrAvidin coupling 
To guarantee a high biotin binding capacity, all bead populations were tested for functionality. In a 
first step a bead count of a mixture of all 400 bead IDs was generated. Eight replicas of 100 µl each 
were pipetted into an assay plate and the number of entities was counted on a Luminex Flexmap 3D. 
To ensure that all beads in a well are counted, the settings on the Luminex device were chosen 
accordingly. The measured number of beads was used for a backwards calculation to determine the 
bead concentration of each bead ID, which allowed the adjustment of each of the 400 bead sets to a 
concentration of 4000 beads/µl. The biotin binding capacity was monitored by incubating the 
generated bead mixture with a biotinylated c-Myc peptide (1 mg/ml concentration). The peptide was 
loaded onto the bead, the mixture was pipetted into 16 wells of a microplate and incubated with a 
dilution series of anti-c-Myc antibody. After washing, the beads were incubated with a PE-tagged, 
species-specific, secondary antibody and the plate was placed in the Luminex Flexmap 3D for 
Materials and methods   
38 
readout. The total intensity of the signal and the CV was measured for every bead ID. Only IDs with a 
CV below 3 % were selected for the later composed 384-plex DigiWest bead-mix. 
 
3.3.1.3 Bead plate composition and preparation 
Out of the 400 coupled bead sets, the best 384 bead IDs were chosen to compose four 96-plex bead 
plates with an ascending sorting of the bead ID. Criteria for exclusion were mainly due to technical 
problems, that prevented the specific classification for several bead IDs. But also a weak 
performance in the biotin binding capacity test or a low count (described in 3.3.1.2) led to an 
exclusion of bead IDs from the 384-plex. To create DigiWest bead plates with a defined number of 
beads per well, master plates with 200 µl/well per bead ID were pipetted in a first step. The master 
plates served as a source for the pipetting robot BioMek FX, which transferred between 20000 and 
80000 beads/well into the correspondent DigiWest plates. For storage the plates were labeled, 
vacuum sealed and kept at 4°C in the dark.  
 
3.3.2 Digitalized Western blot (DigiWest) 
To carry on with the DigiWest procedure, blots were prepared as described above (see 3.2.5, 3.2.6 
and 3.2.7). A summarized overview can be gained in Figure 9. 
 
3.3.2.1 Membrane processing 
The transferred proteins on the PVDF membrane were biotinylated by adding 20 ml of a  
50 µM dilution of NHS-PEG12-Biotin (50 mM, 20 µl in DMSO) in PBST. Membranes were incubated 
for 1 h on an orbital shaker (30 shakes/min, 6° angle), at RT in the dark. Blots were subsequently 
washed in PBST three times and dried between Whatman papers overnight. For transferring the 
proteins onto beads according to their molecular size, the dried membranes were placed onto a 
printed Adobe Illustrator template and fixed with tape. To prevent rupture of the membrane while 
cutting, it was covered by an additional layer of paper. For cutting, the template with the fixed 
membrane was attached to the Silhouette cutting mat and inserted into the Silhouette SD cutting 
plotter. Lanes containing electrophoretically separated proteins, were cut into 96 equally sized, 
horizontal strips (7 mm wide, 0.5 mm high), linear from high to low molecular weight. Thereby a 
molecular range between 12 kDa and approximately 400 kDa was covered (see Figure 9). 
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Figure 9: Schematic representation of the DigiWest assay design. 
Proteins were separated via SDS-Page (a) and transferred onto a PVDF membrane via Western blotting (b). 
Each protein containing lane was cut into 96 strips corresponding to the molecular seize of the protein 
fractions, (c) strips were plucked and sorted into a 96 well microplate. Proteins were eluted from the strips (d). 
The proteins eluted from each strip were assigned to one of 96 specific Luminex MagPlex® bead IDs and 
coupled onto these beads (e). By pooling and mixing the different bead IDs, an original blot lane was 
represented (f). Immunoassays with one individual Western blot antibody per well can be performed (g). 
Subsequently the signal readout was carried out on a Luminex Flexmap 3D (h). The original Western blot was 
reconstituted. On the x-axis the 96 different bead IDs were arranged, while the y-axis represents the median of 
the median fluorescence intensity obtained for the species-specific, fluorescent, secondary antibody  
(Figure adapted from [89]). 
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3.3.2.2 Protein elution 
These strips were plucked and sorted ascending into a 96 well microplate according to the molecular 
seize of the contained, immobilized protein fraction. Each lane was assigned to an individual 
microplate. 10 µl/well of elution buffer were added and it was insured that every strip was 
completely covered by buffer. Plates were sealed with plate sealing tape and incubated for  
1.5 h at 1200 rpm on a plate shaker at RT to solubilize the bound proteins from the membrane  
again (see Figure 9). 
 
3.3.2.3 Protein coupling to microspheres 
After elution, 90 µl of 5 % BSA in PBST were added to each well. This led to a dilution of the 
denaturing elution buffer and facilitated the later immobilization of the eluted proteins onto the 
surface of the NeutrAvidin coated beads. Plates were placed on a shaker to mix the buffers briefly. 
Stored DigiWest plates (see 3.3.1.3) were unwrapped and beads were transferred manually from the 
prepared DigiWest plates into the elution plates by using a KingFisher® 96 PCR magnet head mantled 
with a KingFisher® 96 tip comb. For coupling, the plates were sealed after the bead transfer with 
plate sealing tape and incubated for 18 h at 750 rpm and RT on a plate shaker. After coupling, the 
remaining biotin binding sites on the Luminex MagPlex® were blocked by adding 5 µl of deactivated 
NHS-PEG12-Biotin to each well and incubating for 1 h at 750 rpm and RT on a plate shaker. For 
generating the deactivated biotin reagent, NHS-PEG12-Biotin (50 mM, 20 µl in DMSO) was diluted in 
6 ml TBST and left overnight at RT. Adding an excess of biotin to the wells, also leads to the 
prevention of bead aggregation.  
As different Luminex MagPlex® microspheres can be distinguished by their various embedded color 
codes, it is possible to assign one distinct bead ID to a specified protein fraction of a distinct 
molecular weight range. By pooling the coupled beads from each 96 well plate, the bead collection 
leads to a bead mix, out of which an aliqot corresponds to the prior, original Western blot lane. 
Due to the usage of a 384-plex, four different 96 well plates containing proteins coupled to beads 
presented four different Western blot lanes. These were pooled, mixed and could still be 
discriminated during the subsequent assay readout. For pooling, a KingFisher® 96 PCR magnet head 
manually mantled with a KingFisher® 96 tip comb was used to transfer the beads from four different 
plates into one. After pooling, the beads in the last remaining plate were collected into one well by 
usage of a magnetpen with 8 tips covered with corresponding silicone tips. The bead mixture was 
transferred into a reaction tube and washed in 500 µl Roche buffer on a magnetic separator three 
times (see Figure 9). Finally the washing buffer was discarded and the bead mix was resuspended in 
Roche buffer and adjusted to a concentration of 40 beads/ID/µl. The bead mixes were stored at 4°C 
in the dark.  
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3.3.2.4 DigiWest assay 
For each assay an individual plate layout was designed, comprising the specific conditions like 
amount of samples/bead-mixes and the number of antibodies to be tested. DigiWest assays were run 
in a 96 well, half area microplate. 50 µl of assay buffer were provided into each well and a small 
aliquot of 5 µl of the generated bead mix (see 3.3.2.3) was added, to ensure an amount of 200 beads 
per ID per well. Before running regular assays, the quality of the protein loading onto the beads was 
tested by estimating the on-bead protein amount via detecting their biotinylated sites. Therefore, 
5 µl of the bead mix were incubated with a dilution series of PE-labeled Streptavidin  
(Strep-PE, 4 µg/ml, 1 µg/ml and 0.25 µg/ml) for 1 h at 750 rpm and RT. After washing with PBST three 
times it was possible to simultaneously count the actual number of each bead ID during the readout. 
This resulted in the achievement of information about free biotins represented on the 
Luminex MagPlex® beads and the quality of the bead pooling. Bead sets passing this quality check 
were used to run regular assays. All detection antibodies were diluted in assay buffer in a five times 
higher concentration as recommended for conventional Western blot analysis. Before adding the 
diluted antibody, the microplates were placed on a magnet plate and the supernatant was fiercely 
discarded. 25 µl/well of the antibody dilution was added. The plates were covered with plate sealing 
tape and incubated overnight at 15°C and 750 rpm on a plate shaker. After incubation, the plates 
were washed with 100 µl PBST per well three times. The supernatant in between was discarded by 
placing the microplate on a magnet plate. PE-labeled, species-specific, secondary antibodies were 
also diluted in assay buffer, with a dilution factor of 1:200. The identical volume as used for the 
primary antibody was added to each well and the plate was incubated for 1 h at 23°C and 750 rpm on 
a plate shaker. The washing step was repeated identically. For the readout process, 100 µl of PBST 
were added to each well and the microplate was shaken up vigorously on a plate shaker at 1000 rpm 
for a couple of seconds to avoid a bead accumulation on the bottom of the wells. During readout on 
the Luminex FlexMap 3D, a minimum of 50 beads per ID were counted within a counting volume of 
85 µl per well.  
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3.4 Presentation and analysis of data sets 
3.4.1 Signal quantification  
An in-house developed, Excel-based analysis tool (see 3.1.2) was used for quantification of the 
obtained antibody-specific signals. Herein both the result evaluation and the data analysis were 
performed. This tool allows the reconstruction of primary Western blot lanes, but is also capable to 
identify and quantify antibody-specific signals. An additional advantage of the digital DigiWest data 
generated by the Luminex FlexMap 3D, in comparison with the conventional Western blot analysis, is 
that no image processing and densiometrical analysis is needed for signal quantification. 
Relative median fluorescence intensity (MFI) values are listed in the Luminex output files. Therefore, 
the MFI of each PE-labeled bead-ID out of a bead mix is measured. The analysis tool generates bar 
graphs visualizing the median fluorescence intensity out of 96 distinct obtained values for each initial 
Western blot lane (see Figure 10).  
 
 
Figure 10: Exemplary bar graph for the target protein β-catenin. 
This exemplary bar graph for the untreated β-catenin input was retrieved from the DigiWest analysis tool. On 
the x-axis the calculated molecular weight is plotted, while on the y-axis the median fluorescent intensity (MFI) 
is shown. The highlighted peak in dark gray shows the β-catenin-specific molecular weight (~75-82 kDa). This 
peak corresponds to the β-catenin-band observable in a conventional Western blot (see Figure 25). A baseline 
is calculated by using the local background and the highlighted peak area above this baseline is integrated. The 
integrated signal is based on relative fluorescence and is calculated as 2975 AFI (assembled fluorescence 
intensity). 
 
These bar diagrams are equivalent to Western blot lanes and show antibody-specific peaks, which 
correlate with bands that can be observed in a classical Western blot. Within the analysis tool it is 
possible to evaluate a 384-plex incubated with 96 different antibodies. Additionally, the on-bead 
protein amount can be estimated using the test described earlier (see 3.3.2.4) and subsequent 
evaluation can be carried out by the analysis tool. An automatic subtraction of the assay-specific 
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background is implemented in the analysis tool. A defined molecular weight assigned to the x-axis of 
the generated bar graphs is used for assigning peaks the correct molecular weight. For this purpose, 
an Excel add-in (XLfit) is used to calculate the approximate molecular weight for each protein 
fraction. This can be achieved, by employing the measured positions of an external marker band, 
which was run and blotted together with the samples, or by selecting peak-positions of known 
proteins with a defined molecular weight, providing an internal marker. 
For each tested antibody up to two different peaks can be selected and integrated. Based on their 
assigned molecular weight, a local maximum around this area is scanned automatically; the 
possibility to adjust the integrated area manually is implemented in the software tool. If two MWs 
were assigned to an antibody by the manufacturer and two peaks are observed, these were selected 
and integrated individually by the analysis tool. 
The values of the integrated peaks are given in relative units, called assembled fluorescence intensity 
values (AFI). These values are used to perform further statistics or analysis. 
 
3.4.2 Grayscale data representation 
To obtain an intuitive way to analyze the created bar graphs and numerical values (see 3.4.1), the 
generated data can be transformed into a Western blot like graphic. This is done by a second in-
house developed, Excel-based analysis tool, the DigiWest Viewer (see 3.1.2). The DigiWest Viewer 
facilitates the direct comparison of the DigiWest with a classical Western blot in an intuitive way. The 
background subtracted Luminex raw data is used to generate these Western blot mimics by 
normalizing it to values between 0 and 1. The provided data is converted into a grayscale map by 
applying a grayscale scheme from zero (white) to one (black). To smoothen the grayscale maps and 
for more visual similarity to the original Western blots, the arithmetic mean (from now onwards 
referred to as mean) between two neighboring values of the 96 distinct values for each lane is 
calculated. This mean value is inserted as an additional gray-shaded cell in between the two 
neighboring cells, taken for mean calculation (see Figure 11). 
 
 
Figure 11: Western blot mimic for the target protein β-catenin. 
The identical values used for the bar graph in Figure 10 were used to generate this grayscale Western blot 
mimic in the DigiWest Viewer. The main peak as well as minor side peaks were visualized as lanes. The 
molecular weights were taken from the original bar graph and rounded to a whole number.  
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The DigiWest Viewer facilitates the direct comparison of up to 16 different samples side by side. For 
this, data of the samples is individually exported from the DigiWest analysis tool and inserted into 
the DigiWest Viewer. 
 
3.4.3 Data Evaluation 
The peaks integrated in the DigiWest analysis tool can be exported and further analyzed to gain 
information about alterations in protein expression occurring after drug treatment and to identify 
PPIs with β-catenin. The integrated signal detected at the appropriate molecular weight, was defined 
as a specific signal and further analysis was done.  
During the experiments, the cultured cells were subjected to different treatments (CHIR 99021 and 
MG132 for 24 h). But as different cell lines vary in their protein amount, the differences in protein 
content had to be adjusted using a normalization factor. 
 
3.4.3.1 Strep-PE normalization 
An incubation of the biotinylated samples with Strep-PE labels the free biotins on the bead-bound 
proteins. The measured Strep-PE signal represents freely available biotins from the bound proteins 
on the beads. A linear correlation between the Strep-PE signal and the protein amount loaded to the 
Luminex beads has been shown previously [89]. Thus, a relative on-bead protein determination can 
be performed and the derived factor can be used for data normalization [89]. In order to establish a 
basis to compare different cell lines, all lysates were normalized to the total amount of proteins 
coupled to the bead surface. 
To estimate the total amount of proteins, the beads were incubated for 1 h with three different 
dilutions (4 µg/ml, 1 µg/ml and 0.25 µg/ml) of an anti-Strep-PE antibody, and signal was read out on 
the Luminex FlexMap 3D. By using integrals of all Strep-PE signals, generated of a fixed Strep-PE 
antibody concentration, the median was calculated. An individual normalization factor referring to 
each input sample was calculated by dividing the individual overall Strep-PE signal by this median. To 
ensure a stable individual normalization factor, the average of the three individual normalization 
factors for the same input sample, derived from the three different Strep-PE concentrations, was 
taken. 
Hierarchical cluster analysis was used (euclidian distance (see Equation 1) as a measurement for 
detecting similarity and complete linkage as a clustering method) to generate heatmaps that allow 
the visualization of logarithmized data sets [134]. 
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dab=√∑(eac-ebc)
2
c
 
Equation 1: Formula of the Euclidian distance. 
 
3.4.3.2 Comparable evaluation of cell line specific input samples 
To create a comparable basis between the input data obtained for the different measured cell lines, 
the raw data values exported from the DigiWest analysis tool were normalized as described above 
(see 3.4.3.1). For the ECIP on HEK293T cells or the ICIP performed with stable transfected HEK293T 
cells, neither the normalization nor the comparable evaluation of the input samples was done. 
For the inputs of the untreated samples, the normalized values were subsequently log2 transformed, 
in order to visualize the differences in between the four cell lines for all tested analytes, for signals 
obtained between the lower and the higher range. 
To investigate the influences of treatment on the cells in comparison to the respective untreated 
input sample, a fold change was calculated out of the normalized input values. Therefore, each value 
obtained for an analyte was referred to its respective value received in the untreated input sample 
within the same cell line (see Equation 2). 
 
ratio = 
input (un)treated
input untreated
  
Equation 2: Formula to investigate the influences of treatment. 
 
After taking the logarithm to base 2, the derived values for the untreated sample were 0, while for 
CHIR 99021 and MG132 treatment increases, or decreases, were represented by positive or negative 
values respectively. Again a visualization of the alterations caused through treatment became 
possible both for a wide range of signal intensities on a linear scale. 
 
3.4.3.3 Classification of protein-protein interactions 
For the identification and classification of proteins as interaction partners of β-catenin, all peaks 
showing a signal intensity above 45 AFI in the bound samples were included in further calculations.  
This cutoff limit at 45 AFI was derived from the averaged background level of approximately 11 AFI 
and the identification of signals as significant peaks, which was defined as four times above  
this background level. If duplicates (see 4.3) or triplicates (see 4.4) were analyzed, a two-step  
method was applied. For the two-step method, the sum of both exported AFIs had to be above  
90 AFI (for duplicates) or 135 AFI (for triplicates). In order to receive more stability among the 
replicas and eliminate not reproducible signals, the deviation between the single values had to be 
smaller or equal to 10 AFI in addition. That led to the exclusion of inconsistent and unstable PPIs. 
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Additionally, unspecific binding of proteins to the immunoprecipitation matrix was observed for 
several proteins. To eliminate signals derived from unspecific binding, a second Co-IP was run 
simultaneously to the one, which employed a specific capturing antibody or nanobody against  
β-catenin. This control Co-IP used either an IgG1-isotype control antibody or the GFP-Trap® for 
capturing. Out of these two values, the specific and the unspecific one, the ratio was calculated. If 
the calculated ratio was below 1.5, the obtained binding was defined as unspecific and not included 
in further analysis. Again, a two-step method was applied to experiments where two or more replicas 
were analyzed in parallel. Here, the sum of the ratios had to be additionally above  
2.9 (for duplicates) or 4.3 (for triplicates) and the deviation between the single ratios had to be  
below or equal to 0.2. All these criteria led to the elimination of random noise and instability among 
the individual replicas. Due to these main criteria, many unspecific bound proteins  
(e.g. histone deacetylases, GAPDH and PCNA) were identified and excluded from further analysis. The 
remaining possible interacting proteins were confirmed by manually reviewing and comparing the 
obtained bar graphs for each cell line individually. To acquire information about the proteins that 
were co-immunoprecipitated with the target protein β-catenin, the ratio between the  
β-catenin-specific bound and the respective input was built. With consideration of the enrichment 
throughout Co-IP and the differences in the amount of sample loaded onto the gel, a formula for the 
calculating capturing factor (CF) in percentage was derived (see Equation 3). 
 
capturing factor (CF) = 
bound
0.2
input
0.01
 ∙100 
Equation 3: Formula for calculating the capturing factor (CF). 
 
The signal, obtained for the input sample, was divided by 0.01. This factor was introduced since only 
1 % of the lysate was applied to the gel for electrophoresis. The bound sample was enriched 10 times 
by solving the bead pellet after Co-IP in 50 µl instead of the former 500 µl. Additionally, 10 µl of the 
precipitate mixed with 10 µl of Laemmli buffer were applied to the gel and used for  
generating DigiWest beads. Dividing the bound sample by 0.2 corresponds to 20 % of precipitate 
applied to the gel.  
In experiments with several replicas (see 4.3 and 4.4), the mean of the individually calculated CFs was 
used to classify the strength of the PPI. For defining the strength of an interaction between the target 
protein β-catenin and its binding proteins, four limits were employed. If the result of the ratio 
between bound and input is below 0.1 %, the interaction was defined as weak. A binding factor 
between 0.1 % and 0.5 %, describes an interacting protein, which was referred to as a medium strong 
interactor. Above 0.5 %, the interacting protein was defined as a strong interactor. Very strong 
interactors exceed a CF of 10 %. An illustrating color scheme was chosen and is explained in the later 
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results chapter (see 4.2.2). If proteins did not show a signal in the input sample, but occurred as an 
interacting protein in the bound sample after passing the cutoff criteria, these antibodies were 
marked specifically with “+” in the later results. In this case, the obtained capturing factors are in 
general high and classified as very strong, which is due to the fact that the input value was set to the 
averaged background value of 11 to allow the calculation of a factor.  
For one important antibody, anti-β-catenin 8E7, a signal occurred only in the CHIR 99021-treated 
samples of ECIP and ICIP (see 4.3.2 and 4.4.1). This led to difficulties during the calculation of fold 
changes to evaluate the authenticity of a signal and to gain information about the obtained increase 
after drug treatment. Thus, the mean of the unspecific background signals left and right of the 
received specific signals was calculated and their standard deviation (SD) determined. Signal 
intensities, which were three times higher than the SD, were assessed as specific signals, while signal 
intensities, which were ten times higher than the SD, were rated as quantifiable signals. By dividing 
the values calculated for the integrated peaks by three times of the SD of their averaged background, 
an estimation about the signal increase was achieved. This resulted in values which were specified 
“as greater than this calculated ratio”. 
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4. Results 
Wnt signaling and β-catenin play a crucial role in cancerogenesis [26]. Both are of high interest in 
order to gain a deeper insight into aberrant signaling cascades. Due to the key role of β-catenin in 
multiple cellular processes, it cooperates with a large set of interaction partners in a spatially and 
temporally coordinated manner [112]. Co-IP is one of the most widespread methods to reveal these 
PPIs [112]. 
The combination of this technique with the recently developed high output tool, DigiWest, might 
lead to a novel screening approach requiring only a limited amount of sample volume while a larger 
number of PPIs can be detected. 
 
4.1 Co-Immunoprecipitation and high throughput DigiWest 
The Co-IP approach derives from the classical immunoprecipitation and is performed identically, but 
is expanded by additionally identifying the co-precipitated proteins during subsequent analysis [135]. 
These interacting proteins are typically confirmed in gel or on membranes after blotting by 
immunological methods [94, 136]. By combining this classical approach with the mentioned high 
throughput Western blot, the DigiWest, a promising screening tool is generated. 
By employing this screening tool, the analysis of cellular signal transduction and specific signaling 
cascades of various cell lines is enabled. Especially alterations after drug treatment in the signaling 
state, which is focused on, can be observed, as well as the achievement of broad information on a 
specific pathway by covering different signaling intermediates. Beyond this, direct information of the 
modulation of cellular signaling by changes in protein complexes containing key players of specific 
signaling cascades, like the Wnt pathway and its central protein β-catenin, is obtained. 
 
4.1.1 Analysis of cellular signal transduction in hepatoma cells 
Four different hepatoma cell lines, two mouse and two human, were chosen for a first set of 
experiments in order to establish the combinatory approach and to demonstrate its feasibility. In the 
beginning a comprehensive characterization of signal transduction in these hepatoma cell lines was 
performed. The four cell lines (70.4, 55.1c, HepG2 and HB35) carry different known mutations, most 
of which are associated with Wnt/β-catenin signaling. The aberrant activation of the Wnt/β-catenin 
pathway is known to be an important central mechanism in cancer biology [137]. Just like modulating 
its crosstalk with a variety of other signaling cascades, such as the Hedgehog pathway [138] or the 
Hippo pathway [139], that play crucial roles in the development of cancer. The central role of Wnt 
signaling in cancer makes this pathway an attractive target for the development of novel therapeutic 
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strategies [139]. Hence, a broad proteomic analysis of cancer cell lines, carrying mutations in this 
pathway, can provide essential information for the development of therapeutic approaches. 
 
4.1.1.1 Characterization of the Wnt/β-catenin pathway: identification of specific antibodies 
To be able to characterize the Wnt/β-catenin pathway broadly, it was necessary to identify 
antibodies covering this pathway, which additionally facilitate to display possible crosstalk with other 
signaling cascades, PPIs and PTMs. This choosing was done by performing an extensive database and 
literature research. 
During the early phase of this work, a total number of 344 antibodies were purchased and screened 
for specificity. All of these antibodies belonged to a list of interesting candidates, which was 
generated by reviewing relevant literature and by querying available databases, that list PPIs. Four 
different databases formed the basis for this work: FpClass is a data mining-based method for 
proteome-wide PPI prediction that achieves a good agreement with de facto detected PPIs in the 
experimental setup and proved to be better than previously used PPI prediction methods [118]. This 
method predicts 1721 possible interactions of β-catenin, of which 340 are listed with a total score 
above 0.75. This corresponds to a high predictive value, as the total score represents the probability 
of an interaction based on all evidence [118]. Three other databases, which list verified interaction 
partners of β-catenin were scanned: 1. BioGRID [117], providing 277 binary interactions for human  
β-catenin and 75 for mouse β-catenin; 2. UniProtKB [121], listing 65 binary interactions for  
human β-catenin and 13 for mouse β-catenin and 3. IntAct [119, 120], showing 551 interactions  
of human β-catenin and 155 of mouse β-catenin (see Table 16). After this extensive literature and 
database searching process, a first list was generated. A set of particularly interesting proteins, which 
occurred in several databases or with a high predicted interacting probability, were identified and all 
of the more than 1000 available antibodies were matched with this list. 
 
Table 16: Predicted and verified interacting proteins for β-catenin.  
(retrieved on the 24.01.2016) 
Database Amount of binary interactions Amount of predicted interactions 
FpClass  
1721 in total 
340 with a predicted score of > 0.75 
BioGRID 
277 for human 
75 for mouse 
 
UniProtKB 
65 for human 
13 for mouse 
 
IntAct 
551 for human 
155 for mouse 
 
 
All screened tested antibodies are listed in the appendix (see Suppl. Table A). Antibodies, which 
showed a reproducible signal were processed in the further experimental development. Additionally, 
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antibodies which were of general interest were added. This led to a list of 190 antibodies, which are 
marked in the appendix (see Suppl. Table A) with *. If several antibodies addressed the same protein, 
the NMI number was added in brackets and serves as an unique identifier to for the antibody list  
(see Suppl. Table A). Antibodies, which had two molecular weights assigned by the manufacturer, 
were analyzed for presence of these two proteins and their peaks are treated as two individual 
proteins. Unless otherwise noted, these two peaks always correspond to different isoforms or 
cleaved versions of the same protein (see Suppl. Table B). From the 190 antibodies, corresponding to 
213 peaks, tested on the four screened cell lines, for approximately 160 proteins or peaks, a signal 
was obtained in at least one of the untreated cell lysates (Figure 15). 52 antibodies or bar graphs 
without any signal were excluded from the graphical data presentation. 
 
4.1.1.2 Protein expression analysis – normalization strategy 
As different cell lines express differing amounts of proteins, a normalization had to be performed to 
adjust the raw values and in order to establish a basis to compare the four cell lines and the 
individual influences of treatment. Individual normalization factors for each of the lysates were 
calculated by using the total amount of proteins coupled to the bead surface as determined by 
measuring the Strep-PE signals (see 3.4.3.1). The normalization factors varied between 0.48 and 7.68. 
All obtained raw values were normalized with their corresponding normalization factor. 
 
 
Figure 12: Range of normalization factors of the different cell lines. 
The normalization factors ranged between 0.48 and 7.68 for the individual cell lines and treatments. This range 
is plotted in the bar graphs. For cell line 70.4 these factors are overall higher, than in comparison to the other 
cell lines. 
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The normalization factors determined, show a wide range of variety (see Figure 12). As different cell 
lines show differences in their expression of proteins, the variations in the amount of proteins loaded 
to the DigiWest beads and the thereof derived range in the normalization factors can be explained. 
Cell line 70.4 shows overall small signal intensities, which have to be adjusted in order to be able to 
compare this cell line to cell lines, with a higher protein expression and higher signal intensities. 
After normalization of the raw data, median centering and log2 transformation of 16, randomly 
chosen analytes was performed. This set of data was suitable to perform cluster analysis to detect 
differences and similarities of the normalized samples. 
 
 
Figure 13: Clustering of analytes after normalization. 
The raw data of 16, randomly chosen analytes was normalized by the corresponding normalization factor, 
median centered and log2 transformed. The derived data set was suitable to perform cluster analysis. A 
hierarchical clustering with euclidean distance and complete linkage was applied. 
 
In the clustering (see Figure 13) all 70.4 derived samples are separated from the remaining cell lines, 
which is presumably due to its different mutation status compared to the other three cell lines, 
carrying a heterozygous CTNNB1 deletion. In addition, a clear separation of human and mouse cell 
lines is visible and the cell lines are largely clustered in groups. The clustering shows, that the 
characteristics of the individual cell lines and their response to treatment remained unchanged 
through normalization.  
To additionally prove the accuracy of the strategy chosen for the normalization, the housekeeping 
proteins, β-Actin and GAPDH, were looked at. Housekeeping genes are ubiquitously expressed in all 
tissues and cell types [140]. Thus, they should be equally and high expressed independently from the 
mutational status of the cell line and lead to a similar amount of synthesized protein. After 
GSK3 β pTyr216
β-catenin (BD)
β-Actin
GSK3 β
β-catenin pSer552
β-catenin pSer675
GAPDH
Erk2
Erk1
β-catenin (Millipore)
β-catenin non-phospho Ser33/Ser37/Thr41
α-catenin
Cytokeratin Pan (~60 kDa, # 0588)
STAT3 (86 kDa isoform, # 1736)
STAT3 (79 kDa isoform, # 1736)
E-Cadherin
14.378141
7.1890707
0.0
ly
sa
te
 7
0.
4 
C
H
IR
 9
90
21
ly
sa
te
 7
0.
4 
M
G
13
2
ly
sa
te
 7
0.
4
ly
sa
te
 7
0.
4 
C
H
IR
 9
90
21
ly
sa
te
 7
0.
4
ly
sa
te
 7
0.
4 
M
G
13
2
ly
sa
te
 5
5.
1c
ly
sa
te
 5
5.
1c
ly
sa
te
 5
5.
1c
 M
G
13
2
ly
sa
te
 5
5.
1c
 M
G
13
2
ly
sa
te
 5
5.
1c
 C
H
IR
 9
90
21
ly
sa
te
 5
5.
1c
 C
H
IR
 9
90
21
ly
sa
te
 H
ep
G
2 
M
G
13
2
ly
sa
te
 H
ep
G
2 
C
H
IR
 9
90
21
ly
sa
te
 H
ep
G
2 
C
H
IR
 9
90
21
ly
sa
te
 H
ep
G
2
ly
sa
te
 H
ep
G
2 
M
G
13
2
ly
sa
te
 H
B
35
ly
sa
te
 H
ep
G
2
ly
sa
te
 H
B
35
 C
H
IR
 9
90
21
ly
sa
te
 H
B
35
ly
sa
te
 H
B
35
 M
G
13
2
ly
sa
te
 H
B
35
 M
G
13
2
ly
sa
te
 H
B
35
 C
H
IR
 9
90
21
-2.1         0.0                                            2.1
  Results 
  53 
multiplying the raw values with the corresponding normalization factor, the logarithm with base 2 
was taken and similar values for the different cell lines were obtained (see Table 17). A log2 
transformation is used in order to visualize differences in between the cell lines for all tested analytes 
and to cover a wide signaling range both in the lower and the higher area. 
 
Table 17: Housekeeping proteins after Strep-PE normalization and log2 transformation.  
The log2 transformed values of the Strep-PE normalized housekeeping proteins β-Actin and GAPDH are 
represented. Additionally, the normalized raw values are listed in brackets underneath. 
Analyte 
70.4 
lysate 
55.1c 
lysate 
HepG2 
lysate 
HB35 
lysate 
β-Actin 17.06 
(136625.07) 
16.81 
(114772.65) 
16.83 
(116684.50) 
16.11 
(70542.45) 
GAPDH 16.15 
(72522.82) 
16.12 
(71074.39) 
16.90 
(122559.77) 
16.45 
(89340.40) 
 
In previous studies, it was shown that β-Actin and GAPDH are among the most consistent proteins 
[141]. Hence it can be assumed that this way of normalization is valid, as these two housekeeping 
proteins show similar values for all cell lines. 
 
 
Figure 14: Representation of the normalized DigiWest output graphs. 
Two proteins are represented exemplarily as normalized DigiWest output graphs. On the x-axis the molecular 
weight between ~15 kDa and ~300 kDa is represented, while on the y-axis the signal intensity in MFI values is 
shown. For GAPDH the y-axis is set to a maximum of 90000 MFI; for Erk1/2 it is set to 10000 MFI. The 
normalized values in AFIs, measured for the integrated peaks, are added to the respective peak and written 
inside the graph. 
A: GAPDH, which serves as a control for normalizing the data is shown. For normalization, a normalization 
factor was generated by building the ratio between the specific over all Strep-PE signal for each bead 
population and the median of all derived over all Strep-PE signals.  
B: The same normalization factor was applied to every measured analyte. Erk1/2 is depicted as an example. 
 
The normalization for GAPDH is additionally represented in normalized DigiWest output graphs  
(see Figure 14 A). For the cell lines 70.4 and 55.1c similar signal intensities are calculated by 
normalizing the data (72522.82 AFI vs. 71074.39 AFI). Also the signal for HB35 is very alike 
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(89340.40 AFI). Only the signal obtained for HepG2 is higher compared with the other three cell lines 
(122559.77 AFI). HepG2 are cells, which are chosen in many experimental setups as a standard cell 
line, due to their good and fast growing behavior. It is possible that they gained the ability to express 
a higher level of GAPDH at some point. The second analyte, which is exemplary represented, is 
Erk1/2 (see Figure 14 B). Alterations between the four cell lines are clearly visible, especially for the 
lower peak at ~45 kDa, representing Erk2. The cell line 55.1c shows the highest Erk2 peak  
(signal intensity of 13277.97 AFI), while for HepG2 cells the lowest signal was detected (4362.60 AFI). 
The same can be obtained in Figure 15, where the normalized data is represented after log2 
transformation in a redscale color scheme.  
 
4.1.1.3 Molecular diversity of the examined cell lines. 
Cell lines exhibit considerable differences in their characteristics, like their growth rate or their 
internal signaling status. These differences exist not only between different species or tissues, but 
also within the same organism and the same tissue between normal and altered cells, e.g. cancer 
cells, due to varieties in their mutational status [142]. Thus, it is especially important to have the 
possibility to derive a normalization factor, as described earlier (see 4.1.1.2), in order to compare the 
generated lysates of the four cell lines used in this thesis.  
In Figure 15, the differences in between cells lines, displayed by the DigiWest, are depicted. To 
visualize the differences in between the four cell lines for all tested antibodies, both for the lower 
and the higher range, the normalized raw values were again logarithmized to base 2 and a redscale 
color scheme from zero (white) to the maximum value (= 17.06, intense red) was applied. This led to 
an intense red colorization for extremely high AFIs, measured for some antibodies, and to white cells 
marked with n.d., if no signal was obtained. 
Figure 15 shows, that the DigiWest is able to visualize similarities and discrepancies between 
different cell lines, more generally speaking, between variable sample types. High signal intensities 
were obtained for some of the tested antibodies. As mentioned above a focus was set on proteins, 
which are known to participate in β-catenin signaling. Thus, many of the tested analytes were 
directed against familiar complex partners of the key protein β-catenin, like GKS3 β, α-catenin or  
E-Cadherin. In addition, many analytes were screened, which are associated with important signaling 
pathways, such as the MAPK pathway, or are known transcriptional and epigenetic regulators. 
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Assigned 
category
Analyte Modification
70.4       
lysate
55.1c         
lysate
HepG2      
lysate
HB35      
lysate
β-catenin (BD) 12.52 13.23 12.80 12.63
β-catenin (Millipore) 12.43 9.38 8.50 8.41
β-catenin 
non-pospho 
Ser33/Ser37/Thr41
9.65 5.04 4.41 4.33
β-catenin pSer552 9.64 10.74 11.26 10.04
β-catenin pSer675 10.34 10.74 10.90 9.21
β-catenin pThr41/pSer45 5.50 3.36 4.95 3.91
β-Actin 17.06 16.81 16.83 16.11
GAPDH 16.15 16.12 16.90 16.45
DKK1 (# 1593) n.d. n.d. 8.56 n.d.
DVL2 (# 0687) n.d. 6.34 n.d. n.d.
DVL2 (# 1739) n.d. 4.87 2.52 n.d.
DVL3 (# 0686) n.d. 5.14 4.91 n.d.
Evi (50 kDa isoform) 6.07 6.58 5.10 3.82
Evi (60 kDa isoform) 5.60 8.36 8.78 5.02
Frizzled4 11.18 9.47 11.55 8.96
Frizzled7 6.70 n.d. 5.85 5.26
LGR5 n.d. n.d. n.d. 10.76
LRP6 (# 1750) pSer1490 n.d. 5.24 4.77 n.d.
LRP6 (HD) n.d. 4.74 4.69 2.94
SFRP2 (# 1414) 9.40 14.62 13.75 10.17
Wnt1 6.95 n.d. n.d. n.d.
Wnt11 n.d. 4.74 5.41 n.d.
Wnt16 7.55 n.d. n.d. n.d.
Wnt7b n.d. 5.51 n.d. 5.32
APC 5.27 3.98 4.47 3.81
Axin1 5.50 5.10 4.41 4.59
Axin2                                           
(95 kDa isoform, # 0956)
n.d. n.d. 3.99 n.d.
CK1 α n.d. 8.36 7.27 6.38
CK1 δ 10.92 9.61 9.58 8.79
CK1 ε 7.11 8.15 8.33 6.95
CK2 α 8.39 8.36 8.13 7.64
GSK3 α pTyr279 7.89 8.22 8.46 7.21
GSK3 β pTyr216 10.43 8.90 7.94 6.68
GSK3 β 12.35 11.29 10.85 9.87
GSK3 β pSer9 8.04 6.81 8.57 6.89
PP2A C n.d. 10.85 8.09 6.03
α-catenin 8.08 9.25 10.05 7.45
E-Cadherin 5.70 9.06 9.23 9.29
ATF4 n.d. 8.99 n.d. 9.22
Bax 5.80 8.52 7.02 5.50
Bcl2 n.d. 5.08 n.d. n.d.
Bcl9 n.d. 5.72 5.26 n.d.
Bcl-xL 7.77 10.71 10.11 7.05
cJUN                                          
(43 kDa isoform, # 1187)
7.31 6.86 7.02 7.24
cJUN (# 1162) pSer63 5.18 3.78 3.82 3.46
cJUN (# 1744) pSer63 n.d. 3.70 4.33 3.14
cJUN (HD) n.d. 3.77 4.22 3.41
eIF2 α 7.90 12.15 11.25 9.54
eIF2 α pSer51 8.28 7.48 7.00 10.34
eIF4E 11.56 12.56 10.74 11.77
FoxM1 (# 0949) 5.35 3.85 9.35 3.86
FoxO3a pThr32 n.d. 3.98 n.d. n.d.
FoxO4 pThr28 5.08 5.18 3.41 3.00
GATA4 n.d. n.d. 6.25 n.d.
GLI1 6.18 4.46 4.35 n.d.
HIF1 α n.d. 3.63 n.d. n.d.
HNF1A 8.91 9.70 8.02 9.40
KLF5 8.60 10.22 9.43 7.06
MTA2 3.48 4.36 n.d. 6.45
Pontin52 2.69 3.79 n.d. 4.38
Rb n.d. 5.36 6.03 4.78
Smad1 8.81 9.64 5.71 5.13
Smad2 9.02 10.38 8.74 8.23
Smad2 
pSer245/pSer250/
pSer255 
n.d. 6.90 5.50 3.33
Smad3 8.05 7.93 5.50 4.62
Smad3 pSer423/pSer425 6.88 4.98 n.d. n.d.
Smad3 (# 0879) 8.32 8.73 6.96 8.48
Smad4 n.d. 7.98 7.30 5.02
Smad5 n.d. 7.85 n.d. n.d.
Src 13.10 12.63 11.42 11.63
Src pTyr527 13.19 11.85 11.93 12.20
Src pTyr416 6.82 6.63 6.44 4.78
TAZ (# 1626) 9.66 11.32 14.34 14.44
TAZ (# 1737) n.d. 4.63 n.d. 3.99
TCF1 (# 1673) 5.99 4.50 4.82 3.86
TCF1 (# 1746) n.d. 3.97 3.46 n.d.
TCF4                                          
(50 kDa isoform, # 1727)
7.19 n.d. n.d. n.d.
TCF4                                           
(50 kDa isoform, # 1753)
n.d. n.d. 8.55 8.13
TCF4                                           
(60 kDa isoform, # 1481)
6.13 3.26 5.63 8.35
TCF4                                                
(60 kDa isoform, # 1727)
n.d. n.d. 7.90 n.d.
TCF4                                          
(60 kDa isoform, # 1753)
n.d. n.d. 10.46 7.20
TCF4                                           
(70 kDa isoform, # 1481)
5.93 4.36 3.91 3.46
TCF7L2 (30 kDa isoform) n.d. n.d. 2.26 2.82
3
1
4
6
5
2
Assigned 
category
Analyte Modification
70.4       
lysate
55.1c         
lysate
HepG2      
lysate
HB35      
lysate
14-3-3 ε 7.41 13.13 8.81 10.97
14-3-3 ζ δ 9.84 13.45 10.89 11.49
A-Raf 7.37 7.36 7.27 n.d.
BMP4 n.d. n.d. 8.33 8.23
CD133 5.88 5.61 5.75 6.95
c-Raf 8.02 8.01 7.12 8.36
DUSP1 8.78 9.83 10.16 10.06
DUSP16 n.d. n.d. 9.15 n.d.
DUSP4 10.35 11.81 10.42 9.73
DUSP5 14.04 n.d. 13.61 n.d.
DUSP6 8.50 9.15 11.20 10.96
DUSP7 8.88 n.d. n.d. n.d.
DUSP9 8.64 7.28 11.89 11.60
Elk-1 7.92 9.63 8.99 8.70
Erk1 10.90 11.65 7.77 9.06
Erk2 12.47 13.70 12.09 12.95
Erk3 4.50 3.26 n.d. n.d.
Ha-ras 13.08 14.40 13.00 12.97
IMP 5.08 3.70 3.52 n.d.
JNK/SAPK                                
(46 kDa isoform)
7.01 7.20 8.13 6.45
JNK/SAPK                                
(54 kDa isoform)
8.35 7.46 9.06 10.57
JNK1 (46 kDa isoform) n.d. 7.39 6.63 5.34
JNK1 (54 kDa isoform) n.d. 5.63 5.44 4.91
MAPKAPK-2 n.d. 6.68 5.88 5.44
MAPKAPK-3 n.d. 5.67 7.90 5.48
MAPKAPK-5 n.d. 5.38 5.69 n.d.
MDM2 (60 kDa isoform) 4.99 4.88 3.41 5.81
MDM2 (90 kDa isoform) 5.64 4.21 5.07 n.d.
MEK1 n.d. 10.78 n.d. n.d.
MEK2 6.91 9.41 9.41 7.71
MEKK3 5.76 3.70 4.35 3.09
MKK4 n.d. 9.97 6.99 6.45
MKK6 7.04 8.13 7.30 7.17
MKK7 7.29 6.83 6.99 5.60
Mnk1 6.85 6.21 6.31 4.13
MSK1 (61 kDa isoform) pThr589  n.d. 2.70 n.d. n.d.
p38/MAPK 9.09 9.84 9.50 9.41
p38/MAPK α n.d. 7.92 7.27 5.40
p38/MAPK γ n.d. n.d. 5.56 n.d.
p38/MAPK δ n.d. n.d. 8.65 7.61
Ras 7.31 9.33 7.78 9.40
SPRY2 n.d. 9.42 7.59 5.52
TAK1 5.64 5.50 4.87 3.65
STAT3 pSer727 5.99 5.67 8.12 6.58
STAT3                                         
(79 kDa isoform, # 1736)
5.99 8.73 10.07 9.75
STAT3                                         
(86 kDa isoform, # 1736)
6.19 7.51 8.73 8.13
STAT3                                        
(79 kDa isoform, # 1192)
pTyr705 6.08 6.09 4.07 5.87
STAT3 (79 kDa isoform,            
TK # 054)
10.09 9.21 11.11 10.39
STAT4 pTyr693 3.17 n.d. 3.52 3.04
DNMT1 8.12 6.96 8.04 6.93
Ezh2 8.91 9.94 8.62 7.72
HDAC1 (# 1165) 5.99 7.47 4.35 5.63
HDAC2 5.50 5.07 5.71 3.25
HDAC3 8.32 7.77 5.47 4.21
HDAC6 (# 0739) 7.01 9.58 11.34 10.85
HELLS n.d. 7.41 9.57 8.50
LSD1 9.74 9.80 10.00 10.56
PRMT4 9.97 9.64 9.04 8.07
Cytokeratin Pan                   
(~55 kDa, # 0474)
11.28 15.03 17.00 16.34
Cytokeratin Pan                  
(~46 kDa, # 0474)
n.d. 5.91 10.65 8.57
Cytokeratin Pan                                      
(~57 kDa, # 0261) 
n.d. n.d. 16.99 15.53
Cytokeratin Pan                                  
(~60 kDa, # 0588) 
10.19 14.20 16.46 14.60
Vimentin 9.60 12.30 5.11 2.59
FAK 6.99 6.36 7.61 5.96
FAS 6.64 4.95 n.d. n.d.
p21 5.93 n.d. 7.59 8.95
p53 9.99 n.d. 7.64 7.98
p53 pSer15 7.29 4.31 4.47 4.62
PARP                                         
(116 kDa isoform, # 1358)
n.d. n.d. 5.70 5.04
PARP                                         
(24 kDa isoform, # 1358)
n.d. 5.63 4.96 n.d.
PCNA 10.37 15.03 13.38 14.58
PTCH1 n.d. n.d. 4.14 3.53
PTCH2 6.85 n.d. 4.41 3.53
ILK1 13.16 11.46 9.80 9.39
LATS1 n.d. n.d. n.d. 5.17
MOB1 n.d. 6.18 n.d. n.d.
Mst1 n.d. 6.16 6.55 5.64
YAP (# 1605) 6.13 5.16 4.78 4.40
YAP/TAZ n.d. 5.63 n.d. n.d.
Yes n.d. n.d. 6.73 6.37
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Figure 15: Overview of all available tested antibodies, which showed a signal, on lysates of different cell 
lines. 
The shown proteins were sorted into thematically related:  
Category 1: The target protein β-catenin; Category 2: Housekeeping proteins; Category 3: Proteins associated 
with membranouse Wnt-signal transduction; Category 4: Proteins participating in the β-catenin destruction 
complex; Category 5: Proteins present in the membrane-associated β-catenin complex;  
Category 6: Transcriptional regulators and factors; Category 7: Proteins associated with MAPK signaling; 
Category 8: Proteins associated with JAK/STAT signaling; Category 9: Epigenetic regulators; Category 10: Tumor 
markers; Category 11: Apoptosis; Category 12: Hedgehog pathway: Category 13: Hippo pathway. 
The presented values were calculated by normalizing the raw data with the total amount of protein loaded 
onto the beads and taking the logarithm with base 2. In brackets the molecular weight and the distinct NMI 
number are noted, if needed for differentiation. A signal below the detection limit is represented with n.d. and 
a white cell, while the intensity of the received raw signal is visualized with an analog intensification of red. 153 
antibodies, detecting 163 individual peaks, which were used on the four different cell lysates, are seen in this 
figure. Proteins, which did not show a signal were not included in the graph. 
 
Transcriptional regulators and factors are proteins, which bind to DNA sequences and influence the 
transcriptional activity thereby. They can act in a promoting or inhibiting way either individually or 
within a bigger protein complex. Due to their vital role in a large variety of cellular processes, their 
alteration has substantial effects on the development of diseases, such as cancer [143], as it often 
results in inactivity or an increased activity of transcription. On the other hand, epigenetic regulators, 
such as histone deacetylases and methyltransferases, play a fundamental role in the accessibility of 
the DNA for regulatory proteins [144]. 
Besides the high similarities between the different cell lines after normalization for the housekeeping 
proteins (see Table 17), also several β-catenin antibodies (BD, pSer552 and pSer675) as well as 
antibodies detecting other proteins such as eIF4E, Erk2, Ha-ras, LSD1 and Src (pTyr527) show similar 
and high signal intensities (mean > 10) (see Figure 16).  
 
 
Figure 16: Visualization of high signal intensities obtained for the different lysates.  
Calculation and presentation of the values was done analog to Figure 15. Analytes are ordered by their mean in 
an ascending manner. All presented signals are around or above 10 for each individual cell line, which 
corresponds to a high signal intensity. Additionally, the similarity between the values for different analytes in 
the four cell lines is high after normalization according to the colorization of the cells. 
 
Analyte Modification
70.4       
lysate
55.1c         
lysate
HepG2      
lysate
HB35      
lysate
LSD1 9.74 9.80 10.00 10.56
β-catenin pSer675 10.34 10.74 10.90 9.21
β-catenin pSer552 9.64 10.74 11.26 10.04
eIF4E 11.56 12.56 10.74 11.77
Src pTyr527 13.19 11.85 11.93 12.20
β-catenin (BD) 12.52 13.23 12.80 12.63
Erk2 12.47 13.70 12.09 12.95
Ha-ras 13.08 14.40 13.00 12.97
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Those similarities can also be obtained with lower signal intensities for additional 19 proteins, e.g. 
APC, CK1 ε, Elk-1, HNF1A, MKK7, p38/MAPK and YAP (# 1605) (see Figure 17). 
 
 
Figure 17: Visualization of lower signal intensities obtained for the different lysates.  
Calculation and presentation of the values was done analog to Figure 15. Sorting is done ascendingly by the 
mean. The values for the analytes show high similarities between the different cell types, although the signal 
intensities are lower than in Figure 16. 
 
Besides the listed similarities, the DigiWest also reveals differences, between the four cell lines. Some 
proteins are detected only in a single cell line, e.g. Bcl2, DUSP16, DUSP7, GATA4, HIF1 α, LGR5, MEK1 
and Wnt16 (see Figure 18), while others show a significant difference between mouse and human 
cells (see Figure 19). Examples for these differences are amongst others BMP4, 
Cytokeratin Pan (~57 kDa, # 0261), Erk3, p38/MAPK δ and PTCH1. 
 
Analyte Modification
70.4       
lysate
55.1c         
lysate
HepG2      
lysate
HB35      
lysate
cJUN (# 1162) pSer63 5.18 3.78 3.82 3.46
APC 5.27 3.98 4.47 3.81
Axin1 5.50 5.10 4.41 4.59
YAP (# 1605) 6.13 5.16 4.78 4.40
CD133 5.88 5.61 5.75 6.95
MKK7 7.29 6.83 6.99 5.60
FAK 6.99 6.36 7.61 5.96
cJUN                                   
(43 kDa isoform, # 1187)
7.31 6.86 7.02 7.24
JNK/SAPK                         
(46 kDa isoform)
7.01 7.20 8.13 6.45
MKK6 7.04 8.13 7.30 7.17
DNMT1 8.12 6.96 8.04 6.93
CK1 ε 7.11 8.15 8.33 6.95
c-Raf 8.02 8.01 7.12 8.36
GSK3 α pTyr279 7.89 8.22 8.46 7.21
CK2 α 8.39 8.36 8.13 7.64
Elk-1 7.92 9.63 8.99 8.70
HNF1A 8.91 9.70 8.02 9.40
p38/MAPK 9.09 9.84 9.50 9.41
DUSP1 8.78 9.83 10.16 10.06
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Figure 18: Exemplary visualization of signals occurring only in one cell line.  
Calculation and presentation of the values was done analog to Figure 15. Several analytes detect a signal only 
in one of the cell lines, eight exemplary analytes were picked to illustrate that. 
 
Individual signals, which occur only in one cell line (see Figure 18), have to be seen as significant. The 
different mutational status of the cell lines form the basis of these distinctions and the expression of 
a protein in just one cell line is a consequence of this genetic difference. The DigiWest is able to 
detect these differences and visualize them in a direct comparison. 
 
 
Figure 19: Visualization of several signals derived only for mouse or human cell types.  
Calculation and presentation of the values was done analog to Figure 15. Several analytes detect signals only 
for one of the two species, of which the cell lines were derived. The signals observed vary in their intensity. 
 
In Figure 19 represents species-specific detection of proteins by antibodies. The antibodies 
addressing BMP4, p38/MAPK δ and PTCH1, are verified by manufacturer for human, but not for 
mouse. It is possible, that they are not able to identify the murine protein. On the other hand, it is 
possible, that the addressed proteins were not present in the mouse samples and thus cannot be 
detected by the antibody. This is likely to be the case for Cytokeratin Pan (~57 kDa, # 0261) and Erk3, 
which both are verified to recognize human and murine proteins, but only detect a protein in one of 
the species here. 
In addition to the detected and presented similarities and discrepancies, many others can be found 
by the DigiWest and are visualized in the overall graphic above (see Figure 15). 
 
Analyte Modification
70.4       
lysate
55.1c         
lysate
HepG2      
lysate
HB35      
lysate
Bcl2 n.d. 5.08 n.d. n.d.
DUSP16 n.d. n.d. 9.15 n.d.
DUSP7 8.88 n.d. n.d. n.d.
GATA4 n.d. n.d. 6.25 n.d.
HIF1 α n.d. 3.63 n.d. n.d.
LGR5 n.d. n.d. n.d. 10.76
MEK1 n.d. 10.78 n.d. n.d.
Wnt16 7.55 n.d. n.d. n.d.
Analyte Modification
70.4       
lysate
55.1c         
lysate
HepG2      
lysate
HB35      
lysate
BMP4 n.d. n.d. 8.33 8.23
Cytokeratin Pan                    
(~57 kDa, # 0261) 
n.d. n.d. 16.99 15.53
Erk3 4.50 3.26 n.d. n.d.
p38/MAPK δ n.d. n.d. 8.65 7.61
PTCH1 n.d. n.d. 4.14 3.53
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4.1.2 Modulation of protein levels by drug treatment 
To analyze β-catenin and its binding partners two drugs, known to influence the stability of  
β-catenin, were applied. Both CHIR 99021 and MG132 are inhibitors, which lead to an enrichment in 
the amount of available proteins. CHIR 99021 as a GSK3 inhibitor simulates the ON status of the 
canonical Wnt/β-catenin signaling by prohibiting the phosphorylation of β-catenin by GSK3. Thus, 
preferentially non-phosphorylated β-catenin is enriched. MG132 on the other side inhibits the 
proteasome and blocks the degradation of proteins that use this pathway. Therefore, no specific  
β-catenin variant should be enriched, but the entity of β-catenin available in the cell be increased. 
Based on earlier experiments, a set of antibodies was defined, which recognize different epitopes of 
β-catenin. Additionally, all antibodies that either showed a signal in the untreated bound sample or 
were of a particular interest, were tested further on the treated samples.  
Again, the raw data values were normalized with the corresponding normalization factor calculated 
by the obtained total Strep-PE signal, as described above (see 4.1.1.2). To visualize these effects, 
every treated lysate was referred to its corresponding untreated lysate. By calculating the ratio 
between treated and untreated lysates, fold change values were derived. Of these, the logarithm to 
base 2 was taken, to be able to present them equally distributed on either side of the baseline 
(log2 = 0). It was possible to visualize increase and decrease in protein expression after treatment on 
a color map, starting with a white colorization for no obtained signal (value = 0), intense red for a 
high signal increase and intense dark green for a decreased signal intensity (Figure 25). Colorization 
was done individually for each cell line, as the calculated maximal and minimal values vary among the 
different cell lines and the colorization would have been distorted otherwise. 
Proteins that didn’t show a signal in any of the samples, leading to a white cell for all eight columns, 
were extracted from the image. Of the 117 tested antibodies with 133 possible signals to derive, 119 
signals remained and were visualized in Figure 20. 
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CHIR 99021 MG132 CHIR 99021 MG132 CHIR 99021 MG132 CHIR 99021 MG132
β-catenin (BD) 0.48 0.99 0.75 1.68 0.11 1.09 0.87 2.23
β-catenin (Millipore) 0.03 0.59 2.22 1.58 2.21 1.65 2.33 2.90
β-catenin pSer552 0.59 -0.11 -0.56 0.95 -3.08 -2.69 -0.21 1.35
β-catenin pSer675 -0.26 -0.97 -1.01 0.21 -3.65 -3.12 0.09 0.96
β-catenin pThr41/pSer45 -5.50 -5.50 -3.36 1.39 -1.11 -1.11 1.51 -3.91
β-catenin 
non-pospho 
Ser33/Ser37/Thr41
-1.46 -1.00 3.02 1.90 2.29 1.78 2.53 2.77
β-Actin 0.76 1.14 0.69 0.86 0.09 0.15 2.25 2.03
GAPDH 0.36 -0.82 0.74 0.90 0.43 0.21 0.41 1.65
DVL1 n.d. n.d. 6.80 n.d. n.d. n.d. n.d. n.d.
DVL2 (# 1739) n.d. n.d. 2.28 2.91 2.88 -2.52 5.68 n.d.
Evi (50 kDa isoform) 4.25 4.32 1.19 2.34 2.06 -5.10 4.80 -3.82
Evi (60 kDa isoform) 2.74 4.16 -0.70 0.22 -1.89 -0.77 1.94 -5.02
Frizzled4 -11.18 -11.18 3.58 3.40 0.17 -0.06 -8.96 3.06
Frizzled7 1.23 -6.70 6.19 6.39 0.84 0.01 -5.26 -5.26
LRP6 (# 1750) pSer1490 6.73 7.40 0.85 1.35 1.40 1.10 6.10 5.30
LRP6 (180 kDa isoform,             
# 1567)
pSer1490 n.d. 7.80 5.52 6.76 4.69 5.87 5.68 5.53
LRP6 (210 kDa isoform,             
# 1567)
pSer1490 n.d. n.d. n.d. 4.98 4.64 4.49 n.d. 5.30
LRP6 (HD) n.d. 6.26 0.82 1.37 1.77 1.13 3.56 2.92
Wnt1 -6.95 -6.95 3.65 n.d. 5.67 n.d. n.d. n.d.
Wnt11 n.d. n.d. -4.74 1.31 0.57 -0.10 7.62 6.99
Wnt16 -7.55 -7.55 7.37 n.d. 9.73 11.75 n.d. n.d.
Wnt3A n.d. n.d. n.d. 6.87 n.d. n.d. n.d. n.d.
Wnt7b n.d. n.d. 1.63 -5.51 n.d. 8.14 -5.32 3.36
APC -5.27 -5.27 -3.98 1.07 -4.47 -0.53 2.10 1.20
Axin1 1.40 1.53 -1.23 0.73 -4.41 -4.41 -4.59 -4.59
Axin2                                                      
(95 kDa isoform, # 956)
n.d. 6.64 n.d. n.d. -0.25 1.17 n.d. n.d.
Axin2                                                      
(98 kDa isoform, # 956)
n.d. 6.26 n.d. n.d. 3.52 3.65 n.d. n.d.
CK1 α 6.98 7.80 0.19 -0.09 -3.63 -3.18 0.04 -1.00
CK1 δ 0.20 1.29 1.57 2.26 0.70 1.42 2.46 1.91
GSK3 α pTyr279 -0.58 0.72 -3.70 0.65 -8.46 -1.11 -7.21 1.14
GSK3 β pTyr216 -4.00 -0.62 -0.97 0.63 -2.07 -0.20 0.47 1.80
GSK3 β -0.99 0.03 0.03 0.78 -0.84 -0.13 0.86 1.46
GSK3 β pSer9 -1.31 0.19 -2.50 0.36 -2.77 -3.30 -6.89 1.62
α-catenin -0.96 0.94 0.73 0.85 -2.27 -1.04 1.45 3.98
E-Cadherin -5.70 1.49 1.22 1.63 -0.23 0.89 -0.90 0.28
ATF4 n.d. n.d. -8.99 -0.58 n.d. n.d. -0.80 0.03
Bcl9 n.d. n.d. 0.57 1.36 1.18 0.87 n.d. n.d.
CDK2 n.d. 6.53 n.d. 4.39 n.d. 3.65 n.d. n.d.
cJUN                                                       
(43 kDa isoform, # 1187)
1.04 4.55 0.53 2.27 2.21 2.50 -0.28 2.87
cJUN (# 1162) pSer63 -5.18 4.85 0.53 2.94 1.76 3.22 2.96 4.82
cJUN (# 1744) pSer63 n.d. 8.75 1.27 2.69 1.20 2.34 3.35 3.28
eIF2 α 4.36 4.18 1.78 1.58 2.07 1.64 2.54 3.13
eIF2 α pSer51 0.21 -1.63 -0.23 -0.08 3.38 1.53 -3.11 -4.49
eIF4E -1.18 -1.88 -0.20 -0.67 -0.15 0.91 -3.03 -1.37
FoxO3a pSer413 n.d. n.d. n.d. n.d. n.d. 3.43 5.91 n.d.
GATA4 n.d. 6.53 4.92 5.94 3.63 3.01 n.d. 6.46
GLI1 -6.18 0.76 -4.46 -0.55 -0.82 -0.50 6.01 5.38
HNF1A 0.80 0.72 -1.80 0.39 1.59 1.68 -0.81 -2.70
MTA2 n.d. 8.72 2.13 2.42 2.71 3.11 -3.48 4.35
Pontin52 n.d. 7.47 3.07 2.56 1.64 2.01 5.91 n.d.
Rb 8.09 n.d. -5.36 -5.36 -6.03 -6.03 2.74 -4.78
Smad1 -1.13 2.21 0.81 2.08 0.36 2.02 -5.13 3.05
Smad2 0.41 0.68 0.91 0.97 -0.81 -0.01 -8.23 0.25
Smad2 
pSer245/pSer250/ 
pSer255 
n.d. 8.19 -0.19 1.47 3.36 3.02 2.94 3.58
Smad3 pSer423/pSer425 0.24 0.97 -1.01 0.93 3.85 5.30 6.85 5.30
Smad3 (# 0879) -8.32 -8.32 -0.27 0.89 0.68 0.38 -8.48 -0.48
Smad3 (# 1237) -8.05 -0.78 -1.96 0.33 -1.97 -5.50 1.29 1.05
Smad4 6.98 8.70 1.25 2.56 0.27 1.25 1.08 3.64
Smad5 7.98 8.26 2.03 1.83 4.11 5.30 7.14 6.70
Snail n.d. n.d. n.d. n.d. 5.19 n.d. 7.49 n.d.
SOX17 (30 kDa isoform) n.d. n.d. n.d. n.d. 6.24 n.d. n.d. n.d.
SOX17 (44 kDa isoform) n.d. n.d. n.d. n.d. 6.51 n.d. n.d. n.d.
Src -1.13 -0.21 -0.59 0.05 0.77 1.05 -0.28 0.31
Src pTyr416 1.08 0.98 -2.48 -1.40 -0.91 -1.79 2.67 1.74
1
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CHIR 99021 MG132 CHIR 99021 MG132 CHIR 99021 MG132 CHIR 99021 MG132
Src pTyr527 -0.81 0.55 -0.24 0.71 0.63 0.80 0.14 0.86
TAZ (# 1626) -2.84 -1.81 -6.01 -4.88 -1.01 -0.85 -5.42 -2.14
TAZ (# 1737) n.d. n.d. 1.08 -4.63 6.01 5.34 3.47 3.15
TCF1 (# 1673) -5.99 -5.99 -0.19 1.22 -0.18 -4.82 -3.86 1.43
TCF1 (# 1746) 6.73 n.d. 2.03 2.43 0.80 0.85 5.68 6.07
TCF4                                                          
(50 kDa isoform, # 1753)
-7.19 -7.19 n.d. n.d. n.d. n.d. n.d. n.d.
TCF4                                                        
(50 kDa isoform, # 1727)
n.d. n.d. 7.93 8.41 -7.90 -0.25 n.d. n.d.
TCF4                                                        
(60 kDa isoform, # 1481)
0.18 1.06 1.93 1.32 -0.26 -0.08 -8.35 -2.68
TCF4                                                        
(60 kDa isoform, # 1727)
-5.93 -5.93 -4.36 -0.19 0.03 1.66 3.10 -3.46
TCF4                                                        
(60 kDa isoform, # 1753)
n.d. n.d. n.d. n.d. -0.11 0.76 -7.20 3.14
TCF4                                                  
(70 kDa isoform, # 1481)
n.d. n.d. n.d. n.d. 1.64 1.17 -8.13 1.75
TCF7L2 (30 kDa isoform) n.d. n.d. n.d. 4.67 2.38 -2.26 2.98 -2.82
TCF7L2 (50 kDa isoform) n.d. n.d. n.d. 5.54 4.11 4.24 n.d. 4.53
14-3-3 ζ δ -1.83 -3.31 -0.54 -1.50 0.59 -0.34 -4.58 -1.23
A-Raf -7.37 1.00 1.68 1.65 -0.40 0.13 8.37 8.61
c-Raf -1.29 0.62 0.36 0.00 0.40 1.66 -0.90 -3.83
DUSP1 -8.78 1.01 0.51 0.61 -0.33 -0.14 0.11 0.37
DUSP4 4.22 -10.35 1.10 0.94 2.69 -0.44 0.40 1.43
DUSP6 1.09 -0.20 -0.64 -0.49 -3.42 -3.38 -2.69 -5.66
DUSP9 -8.64 -8.64 -7.28 0.47 0.16 -0.65 0.40 -2.23
Elk-1 0.56 1.88 -0.03 -0.30 -0.60 -0.91 0.14 0.19
Erk1 0.02 0.76 1.56 1.00 2.93 2.88 0.22 0.32
Erk2 -1.15 -0.09 0.80 0.44 1.77 0.01 -1.41 -0.12
Ha-ras -1.20 -1.18 -0.53 -0.22 0.82 0.55 -0.67 0.08
JNK/SAPK                                               
(46 kDa isoform)
-7.01 1.32 2.48 2.60 -0.34 -0.01 2.56 3.11
JNK/SAPK                                               
(54 kDa isoform)
-0.76 0.82 1.92 2.74 4.34 1.71 0.55 -0.82
MAPKAPK-5 6.54 7.90 2.72 2.57 2.30 3.17 8.17 9.39
MDM2 (60 kDa isoform) -4.99 -4.99 -4.88 -4.88 -3.41 -3.41 -5.81 -5.81
MDM2 (90 kDa isoform) 1.00 2.21 1.31 1.99 1.88 0.63 6.35 5.11
MKK7 -7.29 1.49 0.68 0.89 -1.56 -1.69 1.71 1.49
MSK1 (61 kDa isoform) pThr589  n.d. n.d. 2.17 1.69 n.d. 4.02 n.d. n.d.
MSK1 (85 kDa isoform) pThr589  n.d. n.d. 3.39 4.39 n.d. n.d. n.d. n.d.
p38/MAPK -0.58 -1.56 -0.02 -0.77 -0.33 -0.97 -2.45 -0.45
STAT3 pSer727 1.20 1.71 1.00 0.73 0.61 0.19 -6.58 1.69
STAT3                                                     
(79 kDa isoform, # 1192)
pTyr705 -6.08 -6.08 -1.56 -6.09 0.39 1.17 0.93 -0.34
STAT3                                                     
(79 kDa isoform, # 1736)
1.69 -5.99 1.30 0.98 0.67 0.96 1.77 1.78
STAT3                                                   
(86 kDa isoform, # 1736)
3.32 4.44 3.25 2.96 2.29 2.96 3.04 4.04
STAT3 (79 kDa isoform,           
TK # 054)
-0.58 -0.34 0.43 -0.12 -1.00 -0.78 -0.22 0.58
STAT4 n.d. n.d. 4.76 n.d. 5.46 n.d. 8.21 n.d.
STAT4 pTyr693 -3.17 -3.17 n.d. n.d. 1.33 -3.52 -3.04 2.92
Ezh2 0.01 0.87 -0.66 0.00 -1.47 -1.16 -1.38 0.02
HDAC1 (# 1165) -5.99 0.66 -0.90 -1.19 0.12 -0.92 0.37 0.22
HDAC2 1.04 1.76 -1.10 0.87 -0.15 -0.50 2.94 2.54
HDAC3 -1.78 -1.05 -0.42 -0.22 -0.36 -0.49 2.28 1.58
HDAC6 (# 739) 0.11 1.39 -0.80 -0.75 -2.35 -1.32 -1.94 -2.04
HELLS n.d. 8.80 0.00 0.01 -2.54 -2.29 -1.27 -0.17
LSD1 0.05 1.00 0.06 0.18 -0.28 0.62 -2.33 -0.81
PRMT4 -1.81 -1.60 -0.98 0.02 -2.03 -0.74 0.20 1.41
Cytokeratin Pan                            
(~46 kDa, # 474)
8.19 12.99 7.16 8.09 5.22 6.53 6.96 9.21
Cytokeratin Pan                            
(~55 kDa, # 474)
-11.28 -2.14 -1.68 -5.79 -1.39 0.01 -2.75 0.44
Cytokeratin Pan                               
(~60 kDa, # 588) 
1.68 4.13 0.44 1.26 0.31 0.96 1.65 2.99
Vimentin 2.89 4.73 -0.77 -0.28 -1.47 -0.94 3.68 2.87
11 PCNA 0.86 0.85 0.30 -0.80 1.64 -1.55 -2.66 -0.92
12 PTCH2 0.20 0.18 4.65 5.98 -0.88 -0.56 2.66 -3.53
13 ILK1 -2.02 -1.86 -0.18 0.16 -0.52 -0.58 -0.12 0.12
6
55.1c lysate HepG2 lysate
9
HB35 lysate
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Figure 20: Overview of all measured proteins and protein variants on the cell lines, which showed differences  
in abundance after treatment. 
The shown proteins were sorted into thematically related:  
Category 1: The target protein β-catenin; Category 2: Housekeeping proteins; Category 3: Proteins associated 
with membranouse Wnt-signal transduction; Category 4: Proteins participating in the β-catenin destruction 
complex; Category 5: Proteins present in the membrane-associated β-catenin complex;  
Category 6: Transcriptional regulators and factors; Category 7: Proteins associated with MAPK signaling; 
Category 8: Proteins associated with JAK/STAT signaling; Category 9: Epigenetic regulators; Category 10: Tumor 
markers; Category 11: Apoptosis; Category 12: Hedgehog pathway: Category 13: Hippo pathway. 
The increase or decrease in protein concentration after treatment with CHIR 99021 and MG132 is shown within 
a 3-color scale. White representing cells with no signal detected, marked with n.d.; intense red visualizing the 
highest increase and intense green the highest decrease. Colorization was done for each cell line individually. In 
brackets the molecular weight and the distinct NMI number are listed, if needed for differentiation. The 
represented factors were calculated by normalizing the raw data with the total amount of protein loaded onto 
the beads. After calculating, the ratio between treated and untreated sample and the logarithm with base 2 
was taken. Proteins, which did not show a signal or remained unchanged after treatment, compared to the 
untreated sample, were not included in the graph. 
 
In Figure 20 above, the increases and decreases in protein expression in the different cell types after 
treatment with CHIR 99021 or MG132 are shown. The differences in the amount of the housekeeping 
proteins are low, indicating a good quality of the prepared sample extracts (see Figure 21). 
 
 
Figure 21: Housekeeping proteins after treatment in the different cell lysates. 
The housekeeping proteins β-Actin and GAPDH are suitable to serve for the normalization of the different 
samples. Calculation and presentation is done analog to Figure 20. 
 
The signals obtained for GAPDH are similar between the different cell lines and treatments, which 
confirms the way of normalizing the raw values. The second used housekeeping protein,  
β-Actin, shows some variation after treatment, as the calculated values for HB35 are around two 
after treatment.  
Some proteins show increased values after treatment in all screened cell lines, prominent examples 
are Cytokeratins, MAPKAPK-5 and Smad5. The reverse is also observed, resulting in a decreased 
signal after treatment, visible in all samples. Examples are MDM2 (60 kDa isoform) and TAZ (# 1626) 
(see Figure 22). 
  
CHIR 99021 MG132 CHIR 99021 MG132 CHIR 99021 MG132 CHIR 99021 MG132
β-Actin 0.76 1.14 0.69 0.86 0.09 0.15 2.25 2.03
GAPDH 0.36 -0.82 0.74 0.90 0.43 0.21 0.41 1.65
HB35 lysate
Analyte Modification
70.4 lysate 55.1c lysate HepG2 lysate
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Figure 22: Visualization of analytes which increased or decreased after treatment in all cell lines similarly. 
The analytes having the clearest enrichment or reduction after treatment with CHIR 99021 and MG132 for all 
samples similarly are shown. Calculation and presentation is done analog to Figure 20. 
 
 
Figure 23: Behavior of β-catenin after treatment for the different lysates. 
The antibodies against total β-catenin or active β-catenin show an increase after both treatments, CHIR 99021 
and MG132, in all cell lines, except 70.4. Antibodies directed against C-terminal phosphorylations show a 
decrease in the amount of detected β-catenin only for HepG2 and minor alterations otherwise. Calculation and 
presentation is done analog to Figure 20. 
 
Figure 23 comprises the effects of treatment on the amount of β-catenin detected in the cell lysates. 
The antibodies addressing total β-catenin show a slight increase for both treatments, CHIR 99021 and 
MG132, in all cell lines. Thereby it varies, if the enrichment for CHIR 99021 or MG132 treatment is 
higher. For the anti-β-catenin antibody directed against the active variant of the protein, 
unphosphorylated at Ser33/Ser37/Thr41, a minor decrease is visible for 70.4 cells and a high 
increase, especially after CHIR 99021 treatment for the other cell lines. β-catenin phosphorylated at 
Ser552 or Ser675, both located C-terminally, show only a small change under any treatment. Only 
HepG2 cells show a decrease in the amount of the phosphorylated protein for both treatments. 
For many proteins, differences are found after treatment or between the various cell lines. In  
Figure 24, a few analytes, showing the discrepancies between the treatments or the cell lines, are 
listed.  
 
  
Figure 24: Diverse behavior of various analytes after treatment for the different lysates. 
Analytes showing the most striking discrepancies in behavior after treatment are picked from Figure 20 and 
outlined separately. Calculation and presentation is done analog to Figure 20. 
 
CHIR 99021 MG132 CHIR 99021 MG132 CHIR 99021 MG132 CHIR 99021 MG132
Cytokeratin Pan                            
(~46 kDa, # 474)
8.19 12.99 7.16 8.09 5.22 6.53 6.96 9.21
Smad5 7.98 8.26 2.03 1.83 4.11 5.30 7.14 6.70
MAPKAPK-5 6.54 7.90 2.72 2.57 2.30 3.17 8.17 9.39
TAZ (# 1626) -2.84 -1.81 -6.01 -4.88 -1.01 -0.85 -5.42 -2.14
MDM2 (60 kDa isoform) -4.99 -4.99 -4.88 -4.88 -3.41 -3.41 -5.81 -5.81
HB35 lysate
Analyte Modification
70.4 lysate 55.1c lysate HepG2 lysate
CHIR 99021 MG132 CHIR 99021 MG132 CHIR 99021 MG132 CHIR 99021 MG132
β-catenin (BD) 0.48 0.99 0.75 1.68 0.11 1.09 0.87 2.23
β-catenin (Millipore) 0.03 0.59 2.22 1.58 2.21 1.65 2.33 2.90
β-catenin pSer552 0.59 -0.11 -0.56 0.95 -3.08 -2.69 -0.21 1.35
β-catenin pSer675 -0.26 -0.97 -1.01 0.21 -3.65 -3.12 0.09 0.96
β-catenin pThr41/pSer45 -5.50 -5.50 -3.36 1.39 -1.11 -1.11 1.51 -3.91
β-catenin 
non-pospho 
Ser33/Ser37/Thr41
-1.46 -1.00 3.02 1.90 2.29 1.78 2.53 2.77
HB35 lysate
Analyte Modification
70.4 lysate 55.1c lysate HepG2 lysate
CHIR 99021 MG132 CHIR 99021 MG132 CHIR 99021 MG132 CHIR 99021 MG132
A-Raf -7.37 1.00 1.68 1.65 -0.40 0.13 8.37 8.61
Axin1 1.40 1.53 -1.23 0.73 -4.41 -4.41 -4.59 -4.59
Evi (50 kDa isoform) 4.25 4.32 1.19 2.34 2.06 -5.10 4.80 -3.82
GSK3 α pTyr279 -0.58 0.72 -3.70 0.65 -8.46 -1.11 -7.21 1.14
GSK3 β pSer9 -1.31 0.19 -2.50 0.36 -2.77 -3.30 -6.89 1.62
STAT3                                                     
(79 kDa isoform, # 1192)
pTyr705 -6.08 -6.08 -1.56 -6.09 0.39 1.17 0.93 -0.34
TAZ (# 1737) 1.08 -4.63 6.01 5.34 3.47 3.15
HB35 lysate
Analyte Modification
70.4 lysate 55.1c lysate HepG2 lysate
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The first protein listed in Figure 24, A-Raf, shows minor changes for most of the signals after 
treatment. Noticeable is a high decrease in the signal intensity (-7.37) for CHIR 99021-treated 70.4 
cells, while HB35 cells show a contrary high signal increase for both treatments (> 8), compared to 
the untreated sample. The signal observed for Axin1 shows little deviation after treatment in the 
mouse cells, but a striking decrease in the human cells for both treatments. Noticeable is the 
identical value, calculated for both treatments in HepG2 and HB35 cells (-4.41 and -4.59). Here, no 
peak was detected in the treated samples, which results in identical values after referring the treated 
to the untreated sample by building ratios. The third selected protein, Evi (50 kDa isoform) shows 
another peculiarity: for both mouse cell lines, an increased signal is obtainable for CHIR 99021 and 
MG132 treatment, which is higher for 70.4 cells (> 4), while the human cell lines show an increase of 
Evi (50 kDa isoform) only after CHIR 99021 (2.06 and 4.80) and a strong decrease after MG132 
treatment (< -3.5). For GSK3 α (pTyr279) and GSK3 β (pSer9) a decrease in the signal, received after 
CHIR 99021 treatment compared to the untreated sample is obtained for all cell lines. This decrease 
is stronger for the human cell types. For the MG132 treatment, only HepG2 cells show a decreased 
signal, while all other cell lines show a slightly increased signal in comparison with the untreated 
cells. STAT3 (pTyr705, 79 kDa isoform, # 1192) shows a decreased signal intensity especially for the 
mouse cells, the identical value calculated for both treatments in 70.4 (-6.08) is due to the missing 
peak in the untreated sample. Values for STAT3 (pTyr705, 79 kDa isoform, # 1192) detected in human 
cells are colored in a pale color, which implies that signals obtained for treated and untreated sample 
don’t differ much and the calculated and logarithmized ratio is between -1 and 1. The last protein, 
TAZ (# 1737) shows no signal in 70.4 lysate, represented by white cells in Figure 24. In the 55.1c cell 
line, a slight increase after CHIR 99021 and a stronger decrease after MG132 treatment is observed. 
Striking however is the intense increase for both human cell lines after treatment, always slightly 
higher for CHIR 99021 than for MG132 treatment. 
 
4.1.3 Summary 
A modulation of protein amount after drug treatment in the different cell lysates is observed. In 
addition, differences between the cell lines and their individual response to treatment were 
apparent.  
The increased amount of β-catenin detected after treatment by antibodies against total β-catenin, 
was an expected reaction of the cell lines to drug treatment. For CHIR 99021 it is known, that the 
active variant of β-catenin accumulates in the cytosol; this was visible, as higher amounts of  
β-catenin, unphosphorylated at the SSTS-motif, were detected by specific antibodies (see Figure 23). 
For MG132, all β-catenin variants are expected to increase, since this drug leads to the inhibition of 
the proteasomal degradation pathway. The general increase of different β-catenins is indeed seen 
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and is especially visible for total β-catenin (see Figure 23). GSK3 was exemplarily chosen to visualize 
the effects of drug treatment on interacting proteins of β-catenin. This kinase regulates a great 
variety of proteins [145], thus inhibition of GSK3 by a specific inhibitor such as CHIR 99021, led to 
major alterations of several proteins, which are influenced by the kinase activity of GSK3 (see Figure 
20). Another example for visualizing the response of the screened cell lines towards drug treatment, 
was the increase of Cytokeratins upon MG132 treatment (see Figure 22). The intracellular 
accumulation of Cytokeratins after application of MG132 was shown before [146]. Cytokeratins 
belong to the group of proteins, which use the proteasomal degradation way, inhibited by MG132. 
Several results were confirmed, which were expected based on reviewing literature. Additionally, 
novel effects were obtained, which lack an explanation so far, and have to be put into greater 
context. 
The quality of the material, used during screening to obtain differences in between cell lines and 
alterations upon differing drug treatment, was verified. This led to further analysis in terms of 
performing Co-IPs on these cell lines.  
  
Results   
66 
 
  
  Results 
  67 
4.2 Targeted Co-Immunoprecipitation of hepatoma cell lines 
After analyzing the signaling state of four different cell lines and being able to both visualize 
differences between cell lines and modulations in the detected proteins caused by drug treatment, 
the cell lysates were processed further. A Co-IP addressing β-catenin was performed to detect PPIs as 
well as changes in the amount of captured proteins and dynamic alterations of the PPIs under drug 
treatment. 
 
4.2.1 Isolation of β-catenin containing protein complexes 
The immunoprecipitate (bound sample) generated during Co-IP was first analyzed for the presence of 
the target protein β-catenin. For this analysis, the total cell lysate as described above, was used for 
the precipitation reaction. It will be referred to as input sample from now on. The bound fraction  
(or bound) represents the protein complexes precipitated with β-catenin, while the non-bound 
fraction (or non-bound) is the by Co-IP material depleted supernatant. 
For performing Co-IPs, it is important to use a well characterized high-quality monoclonal antibody 
recognizing a defined epitope to dissect real interactions from unspecific binding and to avoid 
interference with potential binding partners [112]. An antibody against total β-catenin (BD), 
recognizing the target protein at its C-terminus (aa 571 – 781), was used to address a wide range of  
β-catenin variants. At the N-terminus many activating mutations are located [147], as a central 
regulatory domain of β-catenin, the SSTS-motif, is found here. Especially in HCC or HB cell lines, 
mutations in this region occur frequently [74]. Some of the cell lines (55.1c, HepG2 and HB35) harbor 
a mutation here, which could affect the binding of a capturing antibody addressing this region. 
Binding of the BD antibody at the C-terminus is not directly affected by these mutations and it is able 
to address many of the posttranslationally modified β-catenin variants as well as N-terminally 
truncated proteins.  
To check the quality of the Co-IP, Western blots were performed that demonstrated the success of 
the Co-IP (see Figure 25). For this analysis, 1 % of the input, 1 % of the non-bound and 20 % of the 
bound samples of each cell line were loaded onto a gel (loading volumes as described in 3.2.5). After 
gel electrophoresis and blotting, the blots were incubated with the capturing antibody against  
β-catenin and a control antibody addressing GAPDH. 
In both blots, no GAPDH signal (red) was detected in the precipitates, which demonstrates the 
efficiency of washing. GAPDH is not interacting with β-catenin and a fluorescent signal in the bound 
fraction would imply a carry over of unspecific proteins into the precipitate. The β-catenin signal 
(green) is seen in all lanes (Figure 25 A); an enrichment after Co-IP is visible in the precipitate for all 
cell lines, although there is still an intense, yet reduced signal visible in the non-bound lane. This 
indicates that the amount of available β-catenin in the lysate is too high to be depleted completely 
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during Co-IP performance. Due to the high amount of β-catenin available in the cells, a complete  
β-catenin harvesting is difficult to achieve. The incomplete harvesting has to be taken into 
consideration. We assumed that the different β-catenin complexes are addressed and precipitated in 
equal proportions and a representative sample was generated. Thus, the Co-IP samples were used 
for further analysis. In the corresponding Co-IP control (see Figure 25 B), no  
β-catenin signal was obtained in the bound fraction. Here, IP was performed with an IgG1-isotype 
control antibody to detect unspecific protein binding to the bead surface during Co-IP. Such an 
unspecific binding signal is visible for the bound lane of the cell line 55.1c. Here a signal at 
approximately 70 kDa is detected, which did not reoccur during the performance of the DigiWest 
assays. This fluorescent signal might be caused by overfilling the well containing the non-bound 
sample during loading and a thereof derived contamination of the bound lane. Signals seen at a 
molecular weight of approximately 50 kDa and 25 kDa are derived from the secondary  
species-specific antibody detecting mouse antibodies and fragments of it. In this case, the heavy and 
light chains of the capture-antibody used during the Co-IP performance are detected; this signal was 
not taken into account. 
 
 
Figure 25: Control Western blot for the Co-IP. 
All samples were processed as described earlier (see 3.2.2 and 3.2.3). To check the quality of the Co-IP, all 
samples were applied onto a NuPAGE gel (1 % input, 1 % non-bound and 20 % bound sample) and a Western 
blot with subsequent immunoblotting and -detection was performed. Blots were incubated with anti-GAPDH 
(red band at ~38 kDa) and anti-β-catenin (BD, green band at ~92 kDa). A shows the enrichment of β-catenin 
during Co-IP in the bound lane, while no GAPDH signal is obtained. B represents the negative control of the Co-
IP performed with an IgG1-isotype control antibody, to eliminate unspecific protein binding. No β-catenin or 
GAPDH signal appear in the bound lane.  
 
The Western blots show truncated β-catenin variants, indicated by the additional lower green bands 
on the blot; they are observed in the cell lines 55.1c, HB35 and HepG2. This is caused by the 
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heterozygous deletion of the N-terminal region of CTNNB1 and the existence of additional  
truncated β-catenin variants in these cells. 
It was shown previously, that signals obtained by the well-established Western blot method and the 
novel DigiWest approach are comparable [91]. This was proven here. For the combination of Co-IP 
and DigiWest, both Western blots and DigiWests were run in parallel (see 4.3.1). The reproducibility 
of the results for biological duplicates (see 4.3) or triplicates (see 4.4) was shown later.  
In a first analysis the different β-catenin pools, which were precipitated during the Co-IP with an 
antibody recognizing the C-terminus of total β-catenin (BD), were looked at. Assays with eight 
different antibodies against β-catenin were performed. The antibodies differed in having distinct 
binding sites on the protein or were recognizing different PTMs.  
The integrated and exported peak values from the DigiWest analysis tool provided the basis to 
estimate the amount of the different captured β-catenin variants and to calculate a capturing rate. 
This capturing rate provides information about the strength of precipitation of the target protein  
β-catenin and later also about the strength of interaction between β-catenin and the  
co-immunprecipitated interaction partners. A formula for calculating the capturing factor (CF) was 
derived in consideration of the enrichment through the Co-IP and the differences in the amount of 
sample loaded onto the gel (see Equation 3). The CF was denoted in percentage (for further details 
on the calculations, see 3.4.3.3). Six anti-β-catenin antibodies remained for further analysis  
(see Table 18). All CFs, along with the obtained raw values for the differently treated input and 
bound samples, are listed in the appendix (see Suppl. Table C – Suppl. Table F). 
 
Table 18: Caught β-catenin variants on the different cell lines.  
The capturing rate for the different β-catenin antibodies is represented, calculated as described in 3.4.3.3, 
Equation 3. Additionally, the raw values (input/bound), of which the CFs were derived, are displayed below. For 
some antibodies, no signal was obtained. These antibodies were either excluded completely from the table 
(e.g. two antibodies recognizing a β-catenin variant phosphorylated at Ser33/Ser37/Thr41) or the cell was 
marked with “-“.  
Analyte Modification 70.4 55.1c HepG2 HB35 
β-catenin (BD) - 
18.01 
(2596/9349) 
22.68 
(14047/63725) 
2.78 
(8037/4464) 
5.31 
(12678/13472) 
β-catenin 
(Millipore) 
- 
24.26 
(2434/11812) 
28.51 
(969/5525) 
2.83 
(410/232) 
5.62 
(680/764) 
β-catenin 
non-p Ser33/ 
Ser37/Thr41 
66.47 
(354/4706) 
113.33 
(48/1088) 
- 
9.75 
(40/78) 
β-catenin pThr41/pSer45 
13.75 
(20/55) 
- - - 
β-catenin pSer552 
41.30 
(353/2916) 
47.18 
(2497/23560) 
4.30 
(2775/2384) 
14.56 
(2102/6121) 
β-catenin pSer675 
41.31 
(572/4726) 
61.84 
(2491/30807) 
4.61 
(2161/1994) 
13.18 
(1179/3107) 
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Both antibodies against total β-catenin (BD and Millipore) show a similar percentage of capturing 
within the same cell line. Anti-β-catenin non-phospho Ser33/Ser37/Thr41 recognizes an active  
β-catenin variant, which is unphosphorylated at the SSTS-motif. The detected capturing rate was high 
in both mouse cell lines, while for HepG2 the obtained signal was very low (below the determined 
cutoff levels) and for HB35 the signal intensity was also much lower in comparison to the murine cell 
lines (input: 40 AFI, bound: 78 AFI). All cell lines, apart from HepG2, showed a higher enrichment for 
the unphosphorylated β-catenin variant, when compared to the rate of total β-catenin (factor > 1.5). 
β-catenin pThr41/pSer45 was only detected in cell line 70.4 and a CF was calculated. This was caused 
by the very low signal intensities (between 15 and 55 kDa) received for the integrated signal peaks 
for this antibody in all cell lines. As the cutoff limit was defined at a minimum of 45 AFI in the bound 
samples (see 3.4.3.3), only cell line 70.4 surmounts this limit and a CF of 13.75 was derived from the 
calculated bound/input ratio. The cutoff limit was defined at 45 AFI, as the averaged background 
level was approximately at 11 AFI and signals four times above this background average were 
identified as significant peaks. For the C-terminal phosphorylation forms of β-catenin at Ser552 and 
Ser675, similar capturing rates were detected within the same cell line. Yet, it is interesting to note 
that these signals displayed a fold change of two or higher when compared to the CFs derived for 
total β-catenin. 
 
4.2.2 Co-precipitated β-catenin interaction partners 
Besides the semi-quantitative detection of different β-catenin variants, it was possible to screen for 
interacting proteins, starting with the final screening list (see 4.1.1.3), containing 189 antibodies and 
179 antibody-based signals pointing to possible interactors of β-catenin. Among the screened 
analytes were proteins, whose interaction with β-catenin is well-documented, like α-catenin or 
GSK3 β. Furthermore, less charaterized or only predicted interaction partners of β-catenin were seen. 
All bound signals with an intensity above 45 AFI were included into further calculations (see 3.4.3.3). 
Additionally, an unspecific binding of proteins during Co-IP was identified by building the ratio of 
specific values over values, measured for the negative control; only ratios above 1.5 were considered 
to be indicative of an interaction. To determine actual interactors, the capturing rate, defining the 
strength of an interaction between β-catenin and a binding protein, was calculated (see 3.4.3.3, 
Equation 3 and 4.2.1). To classify this strength of interactions, four distinct limits were defined to 
evaluate the received CF during analysis. According to this classification, a colorization of the cells, 
containing the CFs, was done (see 3.4.3.3 and Table 19). 
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Table 19: Definition criteria for the strength of a PPI.  
The classification and colorization for defining the strength of a PPI are visualized.  
Green illustrates a weak interaction, with a calculated ratio beneath 0.1 %. Interactions between 0.1 % and 
0.5 % are marked in yellow and referred to as a medium interaction. A strong interaction above 0.5 % is 
represented in lighter red, while an intense red indicates a very strong interaction with a CF > 10 %. 
x = (
bound
0.2
input
0.01
 ∙100) Strength of PPI 
x < 0.1 % weak 
0.1 % < x < 0.5 % medium 
0.5 % < x strong 
x > 10 % very strong 
 
After analyzing the results for all cell lines, only one protein was consistantly found in all precipitates: 
α-catenin. All other observed PPIs showed variations for the different cell lines. In some cases, 
proteins were only detectable in the precipitate, when they were enriched during Co-IP. These 
interaction partners are specifically marked with “+”. In this case, the obtained capturing factors are 
high and classified as very strong. This is due to the fact that the input value was set to the averaged 
background value of 11 to allow the calculation of a factor. Although it is not always consistent with 
the signals obtained in raw data. The values depicted for CFs in the following chapters, are always 
given as percentage of capturing, calculated and classified with the mentioned criteria (see 3.4.3.3, 
Equation 3 and Table 19), but the percent sign was omitted in the following chapters. 
The interacting proteins for each of the different cell lines were arranged into eight possible, defined 
groups, describing either β-catenin comprising complexes or are based on a common characteristic, 
like participation in a specific pathway or a shared function. It has to be mentioned, that most 
proteins have different functions and could be assigned to several of the groups below. 
 
1. Housekeeping proteins 
2. Proteins associated with membranous Wnt signal transduction 
3. Proteins participating in the β-catenin destruction complex 
4. Proteins present in the membrane-associated β-catenin complex 
5. Transcriptional regulators and factors 
6. Proteins associated with MAPK signaling 
7. Proteins associated with JAK/STAT signaling 
8. Epigenetic regulators 
9. Tumor markers 
 
α-catenin, as the only protein that was detected as an interaction partner in all untreated cell lines, 
was assigned to the group of proteins present in the membrane-associated β-catenin complex  
(see Figure 2). 
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Table 20: Co-immunoprecipitated proteins together with β-catenin in all cell lines.  
The CFs and raw values for α-catenin are represented, the red background indicates α-catenin as a strong 
interactor of β-catenin. A more intense red color shows the difference between a strong and very strong 
interaction. CFs were calculated with the formula described in 3.4.3.3, Equation 3. 
Analyte Modification 70.4 55.1c HepG2 HB35 
α-catenin  
7.29 
(120/175) 
16.20 
(888/2878) 
0.55 
(1200/133) 
1.14 
(350/80) 
 
α-catenin [148, 149] was defined as a strong interactor with the cutoff limits, specified above. The 
amount of α-catenin enriched through Co-IP is highest for 55.1c cells. α-catenin was classified as a 
very strong interactor (CF = 16.20) in these cells. Already in the raw data, a high amount of this 
protein was detected in the input sample. Another possibility could be a better recognition of the 
murine α-catenin by the antibody than of the human variant. 
 
4.2.2.1 Protein-protein interactions in the cell line 70.4 
The 70.4 cell line is the only cell line which carries no mutational activation of the Wnt pathway, but 
a p53 mutation instead [76]. Here only few PPIs with β-catenin were detectable. As mentioned 
before (see 4.2.1, Table 18), β-catenin was captured with a high CF (18.01 for the BD antibody (input 
signal of 2596 AFI and 9349 AFI for the bound); 24.26 for the Millipore antibody (input: 2434 AFI, 
bound: 11812 AFI); both recognizing total β-catenin (see Table 21)). Besides the captured target  
β-catenin and its binding partner α-catenin (see Table 20) as an interactor, eight more interactors 
were identified (see Table 21), which all were classified as strong or very strong. No medium or weak 
interacting proteins could be found. 
The cell line 70.4 showed only few interacting proteins in the untreated samples, thus the proteins 
are only sorted and listed, but the characteristics of the groups are described in the next chapters. 
 
Table 21: Co-immunoprecipitated proteins in 70.4.  
The CFs and raw values for cell line 70.4-specific β-catenin interacting proteins are represented, calculated with 
the formula described in 3.4.3.3, Equation 3. The colorized background indicates the strength of the PPI (see 
Table 19). In brackets the molecular weight and the distinct NMI number are listed, if the analytes need to be 
differentiated. Proteins, which were only detected in the bound sample, are marked with a “+”. If more than 
one protein was assigned to a category, they were sorted in an ascending order. 
Analyte Modification 
CF 
(AFI input/AFI bound) 
Captured only in 
bound sample 
Proteins associated with membranous Wnt signaling 
Wnt11  
20.45 
(11/45) 
+ 
Proteins comprising the β-catenin destruction complex 
APC   
26.18 
(17/89) 
 
Proteins associated with the membrane-associated β-catenin complex 
β-Actin  
4.77 
(60390/57646) 
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Analyte Modification 
CF 
(AFI input/AFI bound) 
Captured only in 
bound sample 
Proteins associated with the membrane-associated β-catenin complex 
α-catenin  
7.29 
(120/175) 
 
Transcriptional regulators and factors 
GLI1  
7.50 
(32/48) 
 
Elk-1   
8.93 
(107/191) 
 
Proteins associated with MAPK pathway 
DUSP6  
2.56 
(160/82) 
 
Proteins associated with JAK/STAT signaling 
STAT4   
28.64 
(11/63) 
+ 
Tumor markers 
Vimentin   
6.78 
(343/465) 
 
 
Wnt11 [38, 150] was a strong interaction protein (CF of 20.45). It has to be pointed out that Wnt 11 is 
marked with a “+”, which means that it showed no signal in the input sample and only a small peak 
(45 AFI) was obtained for the bound sample. Another very strong interacting protein, APC  
[41, 151, 152], was caught together with β-catenin (CF of 26.18). The third group “proteins 
associated with the membrane-associated β-catenin complex” is represented with two members for 
cell line 70.4, both being classified as strong interactors. β-Actin [153-155] (CF of 4.77) and α-catenin 
with a 1.5 times higher CF (CF = 7.29). GLI1 [156], which is an effector of hedgehog signaling and 
additionally a transcription factor, and the transcription factor Elk-1 (ETS domain-containing protein) 
[29, 157] are strong interacting proteins (CFs of 7.50 and 8.93). Both belonging to the group of 
“transcriptional regulators and factors”. The obtained PPI for β-catenin in 70.4: DUSP6 (dual 
specificity phosphatase 6) [29, 158], associated with the MAPK signaling, is classified as strong (CF of 
2.56). STAT4 [159], associated with the JAK/STAT pathway, is a very strong interacting protein 
(CF = 28.64). It is also a protein, with no signal detectable in the input sample, but it emerges as a 
complex partner of β-catenin in the bound sample with a raw value of 63 AFI, which led to its 
classification as a very strong interactor. The last group contains the tumor markers received for 70.4 
cells, with only one protein: the intermediate filament Vimentin [160-163], with a capturing rate of 
6.78, portraying it as a strong interacting protein. 
 
4.2.2.2 Received protein-protein interactions in 55.1c cells 
A high number of PPIs was detected for cell line 55.1c. Additionally, the highest signal for detecting 
β-catenin was achieved here. This cell line harbors a heterozygous β-catenin exon 3 deletion and an 
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additional b-raf mutation [78]. The BD antibody led to a CF of 22.68 derived from an input signal of 
14047 AFI and a bound signal of 63725 AFI, while the Millipore anti-β-catenin antibody resulted in a 
CF of 28.51 (input: 969 AFI, bound: 5525 AFI) (see 4.2.1, Table 18). Thus, the input signal detected by 
the BD antibody was approximately five times higher for 55.1c cells than it was for the 70.4 cells  
(see Table 22). In total 33 interacting proteins were found, which are displayed in in the tables below, 
ordered by the categories defined in 4.2.2.1. No weak interacting proteins were identified. Three 
medium interactors were found and 30 strong ones, of which 16 are further classified as very strong. 
 
Table 22: Co-immunoprecipitated proteins in 55.1c.  
The CFs and raw values for β-catenin interacting proteins caught in cell line 55.1c are shown. Calculation, 
representation and sorting were done analog to Table 21. 
Analyte Modification 
CF 
(AFI input/AFI bound) 
Captured only in 
bound sample 
Proteins associated with membranous Wnt signaling 
Evi (60 kDa isoform)  
4.49 
(503/452) 
 
LRP6 (# 1750) pSer1490 
5.78 
(58/67) 
 
Wnt7b  
38.36 
(70/537) 
 
Wnt3a  
47.73 
(11/105) 
+ 
Proteins comprising the β-catenin destruction complex 
CK1 α  
2.32 
(480/223) 
 
GSK3 α pTyr279 
8.56 
(436/746) 
 
GSK3 β  
10.97 
(3653/8018) 
 
APC   
11.74 
(23/54) 
 
GSK3 β pTyr216 
15.09 
(696/2100) 
 
Axin2 (# 1724)  
40.91 
(11/90) 
+ 
Axin1   
75.80 
(50/758) 
 
Proteins associated with the membrane-associated β-catenin complex 
α-catenin  
16.20 
(888/2878) 
 
E-Cadherin   
21.31 
(781/3328) 
 
Transcriptional regulators and factors 
eIF4E  
0.11 
(8820/189) 
 
Smad4  
0.93 
(387/72) 
 
Smad5  
1.32 
(355/94) 
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Analyte Modification 
CF 
(AFI input/AFI bound) 
Captured only in 
bound sample 
Transcriptional regulators and factors 
Smad3 (# 0879)  
1.53 
(618/189) 
 
HNF1A  
1.61 
(1211/391) 
 
Src  
2.02 
(9241/3738) 
 
TCF4 (70 kDa isoform, # 1481)  
12.83 
(30/77) 
 
TAZ   
14.09 
(3726/10502) 
 
TCF4 (60 kDa isoform, # 1727)  
133.64 
(11/294)  
+ 
Proteins associated with MAPK pathway 
JNK/SAPK (54 kDa isoform)  
1.52 
(256/78) 
 
MKK7   
2.44 
(166/81) 
 
A-Raf   
2.94 
(240/141) 
 
MAPKAPK-5   
4.45 
(64/57) 
 
MDM2 (60 kDa isoform)  
10.47 
(43/90) 
 
DUSP6   
11.29 
(831/1876) 
 
Proteins associated with JAK/STAT signaling 
STAT3 (79 kDa isoform, TK # 054)  
0.42 
(862/73) 
 
Epigenetic regulators 
Ezh2  
0.38 
(1435/109) 
 
HDAC2  
8.47 
(49/83) 
 
Tumor markers 
Vimentin  
16.38 
(7346/24060) 
 
Cytokeratin (~46 kDa, # 0474)  
65.33 
(92/1202) 
 
 
Evi (60 kDa isoform), also known as G protein-coupled receptor 177 (GPR177) or Wntless [164], fits 
into both categories “transcriptional regulators and factors” and “proteins, associated with 
membranous Wnt signal transduction”. As it modulates Wnt in a positive feedback loop [164], it was 
filed into the latter group. Together with the phosphorylated LRP6 [49, 152, 165, 166], it represents a 
strong interactor (CFs of 4.49 and 5.78). Wnt3a [53] and Wnt7b [167] are ligands of the Wnt pathway 
family, which bind to receptor proteins like LRP5/6 and FZD, both in turn build a complex and 
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facilitate Wnt signaling [152, 167]. Wnt3a and Wnt7b count as very strong interacting proteins (CFs 
above 35), but for Wnt3a signal was only obtained in the bound sample (peak size of 105 AFI). 
All proteins listed in the second group, are part of the β-catenin destruction complex, which targets 
β-catenin by phosphorylation at the SSTS-motif, leading to degradation by the proteasome. The 
found proteins can bind to Axin1 and its homolog Axin2 (also called Axil or Conductin) [36, 152, 168]. 
For Axin1 and Axin2 the highest capturing ratios are obtained. The CF for Axin1 is 75.80, categorizing 
it as very strong interactor. Axin2, also a strong interacting protein of β-catenin, was only detectable 
in the bound sample with a value of 90 AFI, resulting in a CF of 40.91. CK1 α [49, 169] is the kinase, 
which performs the initial phosphorylation at Ser45, before GSK3 starts to phosphorylate further 
sites on the SSTS-motif. Both, CK1 α and GSK3 α (pTyr279) [170, 171], were detected as strong 
interacting proteins (CFs of 2.32 and 8.56), while GSK3 β and GSK3 β (pTyr216) [171-173] were 
classified as very strong interactors (CFs above 10). APC represents another strong interactor 
(CF = 11.74), which is also part of the destruction complex, but is also able to bind β-catenin directly. 
It influences the binding affinity of β-catenin to the destruction complex [41, 152]. 
β-catenin also exists in a membrane-associated complex together with E-Cadherin [36, 149, 174, 175] 
and α-catenin. Both represent very strong interactors in 55.1c cells (CFs of 16.20 and 21.31).  
α-catenin provides a possible link to the cytoskeletal β-Actin, which was not detectable in this case. 
Additionally, various transcription factors and transcriptional regulators were captured in 55.1c 
lysate. One medium, five strong and three very strong PPIs were detected after Co-IP. The only 
medium interactor (CF = 0.11) is eIF4E (Eukaryotic translation initiation factor 4E) [176, 177]. The CFs 
of the strong interacting proteins vary from 0.93 to 2.02. Three members of the Smad family 
(Mothers against decapentaplegic homolog): Smad4 and 5, as well as Smad3 (# 0879) [178-182] were 
identified as strong interactors. Additionally, the transcription factor HNF1A (hepatocyte nuclear 
factor 1 homeobox A) [183] and the proto-oncogen Src (a tyrosine kinase) [184-186] were captured. 
Three very strong interactors, two isoforms of TCF4 with different MWs, detected by different 
antibodies and TAZ (WW domain-containing transcription regulator protein 1) [187], were found. For 
TCF4 (60 kDa isoform, # 1727) [36, 54, 55] a signal occurs only in the bound sample (294 AFI), but not 
the input sample. This results in an extremely high CF of 133.64, while the signals of the other two 
proteins lead to CFs of 12.83 and 14.09. 
The MAPK pathway is an important and intensively studied signaling pathway, which is deregulated 
in various diseases, e.g. cancer [188]. For cell line 55.1c six proteins were immunoprecipitated with  
β-catenin, which are in some way associated with MAPK signaling. Among these six proteins, four 
strong and two very strong interactors were found. JNK/SAPK (the 54 kDa isoform of the cJUN  
N-terminal and stress activated protein kinases, also called MAPK8) [189, 190], MKK7 (dual specificity 
mitogen-activated protein kinase 7) [190-195], A-Raf (Ser/Thr-protein kinase A-Raf) [196, 197] and 
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MAPKAPK-5 (MAP kinase-activated protein kinase 5) [198] were classified as strong interacting 
proteins (CFs between 1.52 and 4.45). Additionally, two very strong interactors, MDM2 (the 60 kDa 
isoform or cleaved version of mouse double minute 2 homolog) [199, 200] (CF of 10.47) and again 
DUSP6 (CF = 11.29), were captured. 
One medium interactor, STAT3 (79 kDa isoform, TK # 054) [201, 202] (CF of 0.42), associated with the 
JAK/STAT signaling, was detected. This pathway is activated by cytokines and growth factors and can 
mediate their signals directly to target gene promoters in the nucleus. By that, it provides a 
mechanism for transcriptional regulation, which works without a second messenger. Beyond that, 
MAPKs can phosphorylate STATs and modulate their functioning [203]. 
The histone deacetylase HDAC2 [204-207] and the histone-lysine N-methyltransferase Ezh2 [208] can 
both be addressed as epigenetic regulators, due to their capability of transferring functional groups 
posttranslational to histones and other proteins. By doing that, they are able to modify the proteins’ 
activity and its function. 
Vimentin is an accepted marker for EMT (Epithelial–mesenchymal transition) and generally a 
biomarker in tumor detection. It shows a CF of 16.38, indicating it as a strong interactor of  
β-catenin. The Cytokeratin family also comprises various tumor markers [209] and the obtained CF of 
65.33 for a ~46 kDa-variant is assessed as very strong. As all Cytokeratin antibodies were Pan 
antibodies recognizing a variety of different Cytokeratins, the evaluated peak is marked by noting the 
specific MW in brackets. 
 
4.2.2.3 β-catenin interactors in the cell line HepG2 
The human HepG2 cell line carries a heterozygous β-catenin exon 3-4 deletion [74, 79, 82, 85]. In 
comparison to the 55.1c cells, a decrease for both antibodies recognizing total β-catenin (see 4.2.1, 
Table 18) was seen in HepG2 cells. The BD antibody directed against β-catenin resulted in a CF of 
2.78 (input: 8037 AFI, bound: 4464 AFI) and the Millipore antibody showed even smaller raw values 
(input: 410 AFI and bound: 232 AFI), although the detected CF of 2.83 was almost identical  
(see Table 23). For the cell line HepG2, it was possible to detect 14 PPIs, among which one weak, two 
medium, five strong and six very strong interactors were found. 
 
Table 23: Co-immunoprecipitated proteins in HepG2.  
The CFs and raw values for β-catenin interacting proteins caught in cell line HepG2 are shown. Calculation, 
representation and sorting were done analog to Table 21. 
Analyte Modification 
CF 
(AFI input/AFI bound) 
Captured only in 
bound sample 
Housekeeping proteins 
GAPDH  
0.01 
(138556/386) 
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Analyte Modification 
CF 
(AFI input/AFI bound) 
Captured only in 
bound sample 
Proteins associated with membranous Wnt signaling 
LRP6 (180 kDa isoform, # 1567) pSer1490 
24.09 
(11/53) 
+ 
Wnt7b  
32.27 
(11/71) 
+ 
Proteins comprising the β-catenin destruction complex 
CK1 δ  
0.27 
(867/46) 
 
GSK3 β  
0.59 
(2085/244) 
 
GSK3 β pTyr216 
1.15 
(278/64) 
 
Proteins associated with the membrane-associated β-catenin complex 
α-catenin  
0.55 
(1200/133) 
 
E-Cadherin   
1.64 
(679/223) 
 
Transcriptional regulators and factors 
eIF4E   
0.14 
(1930/54) 
 
HNF1A  
1.02 
(293/60) 
 
FoxO3a  pSer413 
24.55 
(11/54) 
+ 
ATF4   
41.82 
(11/92) 
+ 
Snail  
53.18 
(11/117) 
+ 
Proteins associated with JAK/STAT signaling 
STAT4  
23.64 
(11/52) 
+ 
 
GAPDH is one of the housekeeping proteins, which was used for normalization earlier. It was 
detected here as a weak interactor. It is seen as a false positive since the huge signal obtained in the 
input sample (138556 AFI) is a likely cause for the comparatively small carry over into the bound 
sample (386 AFI). 
Only two interacting proteins, which are associated with the membranous Wnt signaling were 
detected in the bound samples for HepG2 cells. Both, LRP6 (pSer1490, 180 kDa isoform, # 1567) and 
Wnt7b, were classified as very strong interactors, but their raw values (53 and 71 AFI) in the bound 
are rather small, resulting in a very high CF. 
For HepG2, only three proteins of the β-catenin destruction complex were captured during Co-IP. 
CK1 δ was a medium interactor (CF = 0.27) belonging to the CK1 kinase family. Like CK1 α, it is 
capable of phosphorylating β-catenin at Ser45 [49, 169]. Additionally, total GSK3 β and the Tyr216 
  Results 
  79 
phosphorylated, active form of GSK3 β were detected as strong interacting proteins (CFs of 0.59  
and 1.15). 
Similar to the caught members of the membrane-associated complex in 55.1c, α-catenin  
and E-Cadherin are captured for HepG2 as well. Both are classified as strong interactors with CFs 
above 0.5.  
Five proteins were sorted into the category “transcriptional regulators and factors” for HepG2 cells. 
One medium, one strong and three very strong PPIs were obtainable. Similar to the received 
interactors in 55.1c, again eIF4E was captured with a medium strength of interaction (CF = 0.14) and 
HNF1A, classified as a strong interactor (CF of 1.02). Additionally, three novel interacting proteins 
were detected with a very strong interaction: The transcription factors FoxO3a (pSer413) (Forkhead 
box O3) [210-212] and ATF4 (Activating transcription factor 4) [213, 214], as well as the 
transcriptional repressor Snail [36, 215]. They show CFs between 24.55 and 53.18, but for these three 
proteins only signals in the bound samples, ranking between 54 and 117 AFI, were measured. 
Only one interacting protein captured for HepG2 was assigned to the category “proteins associated 
with JAK/STAT signaling”, which is STAT4. STAT4 was also only detected in the bound sample, not  
the input sample, with a peak intensity of 52 AFI, which led to its classification as a very  
strong interactor (CF = 23.64). 
 
4.2.2.4 Interactors of β-catenin in HB35 cells 
HB35, a recently established cell line with a known heterozygous β-catenin exon 3 deletion [83], 
shows a variety of PPIs. This cell line showed in general a high capturing rate for β-catenin, as the BD 
and the Millipore antibody have CFs of 5.31 (input: 12678 AFI, bound: 13472 AFI) and 5.62 
(input: 680 AFI, bound: 764 AFI) (see Table 24). Thus, the input signal for the BD antibody was 
approximately 1.5 times higher than observed in HepG2 cells. Of the 16 detected interacting 
proteins, three interactions were classified as low strength, three as medium and 11 as strong or very 
strong (see Table 24). 
 
Table 24: Co-immunoprecipitated proteins together with β-catenin in HB35.  
The CFs and raw values for β-catenin interactors in cell line HB35 are shown. Calculation, representation and 
sorting were done analog to Table 21. 
Analyte Modification 
CF 
(AFI input/AFI bound) 
Captured only in 
bound sample 
Housekeeping proteins 
GAPDH  
0.02 
(178263/848) 
 
Proteins comprising the β-catenin destruction complex 
GSK3 α  pTyr279 
3.34 
(295/197) 
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Analyte Modification 
CF 
(AFI input/AFI bound) 
Captured only in 
bound sample 
Proteins comprising the β-catenin destruction complex 
GSK3 β   
10.80 
(1868/4036) 
 
GSK3 β pTyr216 
20.76 
(204/847) 
 
Axin1   
23.96 
(48/230) 
 
Proteins associated with the membrane-associated β-catenin complex 
β-Actin  
0.04 
(140755/1250) 
 
α-catenin  
1.14 
(350/80) 
 
E-Cadherin   
4.32 
(1246/1077) 
 
Transcriptional regulators and factors 
eIF4E   
0.05 
(6969/74) 
 
Src pTyr527 
0.10 
(9362/188) 
 
Smad2  
0.78 
(598/93) 
 
cJUN (43 kDa isoform)  
1.28 
(301/77) 
 
TCF1  
10.69 
(29/62) 
 
TAZ (HD)  
15.19 
(27/82) 
 
Snail  
84.09 
(11/185) 
+ 
Proteins associated with JAK/STAT signaling 
STAT3 (79 kDa isoform, TK # 054)  
0.17 
(2679/92) 
 
STAT3 (86 kDa isoform, # 1736)   
0.61 
(475/58) 
 
Epigenetic regulators 
LSD1   
0.16 
(3015/97) 
 
Tumor markers 
Cytokeratin (~55 kDa, # 0474)  
0.01 
(140930/277) 
 
 
As described in the results for the HepG2 cell line, GAPDH was detected as a weak false positive 
interactor. Its classification as an interacting protein is explained with the huge signal obtained for 
the input (178263 AFI) and a carry over into the bound fraction (848 AFI). 
Four proteins of the β-catenin destruction complex were detected and rated as strong or very strong 
PPIs: Phosphorylated GSK3 α (pTyr279) is a strong interactor (CF = 3.34), while GSK3 β, 
GSK3 β (pTyr216) and Axin1 are very strong interacting proteins, with CFs between 10.80 and 23.96. 
Thereby a similar distribution, as seen before for 55.1c cells (see 4.2.2.2), was obtained. While 
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GSK3 α showed a lower CF as GSK3 β, the CF calculated for the activated, phosphorylated form of 
GSK3 β was even higher. 
All three tested proteins, belonging to the group “associated with the membrane-associated  
β-catenin complex” showed interactions. β-Actin was classified as a weak interacting protein  
(CF of 0.04), while the CFs for α-catenin and E-Cadherin were high (CF = 1.14 and 4.32), which 
defined them as strong interactors. 
Seven of the detected proteins were assigned to the group of the “transcriptional regulators and 
factors”. eIF4E occurred as a weak interactor (CF of 0.05); Src (pTyr527) was found with a medium 
strength (CF = 0.10), while Smad2 [178, 216] and the transcription factor cJUN (43 kDa isoform)  
[36, 217-219] are strong interacting proteins (CFs of 0.78 and 1.28). Three very strong interactors, 
TCF1 (CF = 10.69) [36, 54, 55], TAZ (HD) (CF = 15.19) and Snail (CF = 84.09) [36, 215] were detected. 
Interestingly Snail was not detectable in the input sample, but showed a bound signal of 185 AFI. 
Two different isoforms of STAT3, detected with two different antibodies, were obtained for HB35 
cells: STAT3 (79 kDa isoform, TK # 054), a medium strong interacting protein (CF of 0.17) and 
STAT3 (86 kDa isoform, # 1736) as a strong interactor (CF = 0.61).  
For the 55.1c cells, the epigenetic regulators HDAC2 and Ezh2 were identified as PPIs. Here another 
epigenetic regulator, the lysine-specific histone demethylase 1A (LSD1) [127, 220], was identified as a 
medium interactor (CF of 0.16). 
One tumor marker was found, which belongs to the Cytokeratin family. Since it represents a weak 
interaction (CF = 0.01), it might present a weak false positive caused by a carry over  
(input: 140930 AFI, bound: 848 AFI). 
 
4.2.3 Changes in β-catenin precipitation by drug treatment 
As described (see 4.1.2) samples from differently treated cells were generated and compared. The 
applied inhibitors, CHIR 99021 and MG132, led to changes in the distribution of the available and 
captured β-catenin variants during Co-IP and the CFs were calculated as described earlier (see 3.4.3). 
CHIR 99021 inhibits GSK3 in a highly specific and potent manner [221, 222] and leads to activated 
Wnt signaling. When Wnt signaling is active, GSK3 is inhibited in general [222]. The inhibition of GSK3 
leads to an accumulation of unphosphorylated β-catenin in the cytosol and its further translocation 
into the nucleus [36]. MG132 on the other side is a potent proteasome inhibitor, which blocks the 
ubiquitin-proteasomal degradation of ubiquitinated proteins [223, 224]. As β-catenin is among the 
proteins, targeted towards this degradation pathway [45], it gets enriched together with other 
proteins using this inhibited degradation way. 
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Table 25: Caught β-catenin variants and their enrichment after treatment in 70.4.  
The CFs and raw values are represented for both treatments in comparison to the untreated sample. 
Calculation is done analog to Table 18. For some antibodies, no signal was obtained. These were either directly 
excluded in the table or the cell was marked with “-“.  
Analyte Modification untreated CHIR 99021 MG132 
β-catenin (BD) 
 
18.01 
(2596/9349) 
30.01 
(1239/7437) 
44.76 
(1519/13598) 
β-catenin 
(Millipore)  
24.26 
(2434/11812) 
38.17 
(846/6459) 
40.30 
(1076/8672) 
β-catenin 
non-p Ser33/ 
Ser37/Thr41 
66.47 
(354/4706) 
250.11 
(44/2201) 
231.54 
(52/2408) 
β-catenin pThr41/pSer45 
13.75 
(20/55) 
- - 
β-catenin pSer552 
41.30 
(353/2916) 
55.86 
(181/2022) 
89.32 
(96/1715) 
β-catenin pSer675 
41.31 
(572/4726) 
67.76 
(163/2209) 
84.07 
(86/1446) 
 
 
Figure 26: Caught β-catenin variants and their enrichment after treatment in 70.4. 
The CFs listed in Table 25, are represented for both treatments (CHIR 99021 in red; MG132 in green) in 
comparison to the untreated sample (blue). For some antibodies with no signal obtained, no bar is displyed.  
 
Antibodies detecting total β-catenin (BD and Millipore) showed similar capturing rates after both 
treatments. The raw values reveal that peak intensity decreased after treatment; however, the signal 
obtained after Co-IP for the bound fraction is proportionately increased. Thus, higher CFs are 
obtained. Anti-β-catenin non-phospho Ser33/Ser37/Thr41 showed a higher CF (= 66.47), which 
almost quadruples for CHIR 99021 treatment (CF = 250.11) and is nearly as high after MG132 
treatment (CF = 231.54). Only in the untreated sample for the 70.4 cells, the signal for β-catenin 
pThr41/pSer45 was found above the cutoff limit of 45 AFI (see 4.2.3), for the treated samples, the 
signals are below this defined limit. Both antibodies recognizing C-terminal phosphorylations of  
β-catenin (Ser552 and Ser675) recorded an increase after treatment. The increase for MG132 
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treatment was much higher than for CHIR 99021, although the raw values obtained from the peaks 
after CHIR 99021 treatment were only slightly higher than for MG132 (see Suppl. Table C). 
 
Table 26: Caught β-catenin variants and their enrichment after treatment in 55.1c.  
The CFs and raw values are represented for both treatments in comparison to the untreated sample. 
Calculation and presentation of data are analog to Table 18. 
Analyte Modification untreated CHIR 99021 MG132 
β-catenin (BD) 
 
22.68 
(14047/63725) 
12.21 
(15515/37887) 
18.11 
(20615/74652) 
β-catenin 
(Millipore)  
28.51 
(969/5525) 
21.79 
(2955/12880) 
33.23 
(1320/8773) 
β-catenin 
non-p Ser33/ 
Ser37/Thr41 
113.33 
(48/1088) 
109.22 
(255/5570) 
155.79 
(82/2555) 
β-catenin pSer552 
47.18 
(2497/23560) 
28.47 
(1114/6343) 
41.97 
(2206/18517) 
β-catenin pSer675 
61.84 
(2491/30807) 
38.01 
(810/6157) 
53.34 
(1317/14049) 
 
 
Figure 27: Caught β-catenin variants and their enrichment after treatment in 55.1c. 
The CFs listed in Table 26, are represented for both treatments (CHIR 99021 in red; MG132 in green) in 
comparison to the untreated sample (blue). For some antibodies with no signal obtained, no bar is displayed.  
 
For 55.1c cells, five of the employed β-catenin antibodies gave a signal in the bound fraction. Total  
β-catenin, detected using the BD antibody, showed a decrease in the detected CF for both 
treatments. For CHIR 99021 this decrease was also clearly visible in the raw values, which declined 
from a signal above 60000 AFI to approximately 38000 AFI (see Suppl. Table D). For the MG132 the 
raw values increased, but the portion of β-catenin captured within the addressed complexes still 
resulted in a lower CF (= 18.11) for MG132 treatment than for the untreated sample. For the 
Millipore antibody against the total β-catenin, the signal decreased for the CHIR 99021 treatment, 
but increased for the MG132 treatment. Looking into the raw data, the CHIR 99021-treated sample 
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showed a 2.5-fold increase in the recognition of β-catenin in the CHIR 99021-treated sample 
(~13000 AFI) compared to the untreated sample (~5500 AFI), while for MG132 the obtained signal in 
the bound stays around 9000 AFI. The CFs derived from the signals of the anti-β-catenin non-
phospho Ser33/Ser37/Thr41 were similar for the untreated and CHIR 99021-treated sample (CFs of 
approximately 100), but for MG132 treatment the CF (= 155.79) was notably increased. The raw 
values showed a 5.5 times higher value for the obtained bound signal after CHIR 99021 treatment, 
than for the untreated sample, but also the protein amount measured in the input increased 
simultaneously. Antibodies against C-terminal phosphorylations showed both for the CFs and the raw 
values a decrease after CHIR 99021 treatment. For MG132 treatment, the decrease was also existent, 
but not as strong. The CFs for phosphorylation at Ser675 were higher than for the phosphorylated 
Ser552 variant. 
 
Table 27: Caught β-catenin variants and their enrichment after treatment in HepG2.  
The CFs and raw values are represented for both treatments in comparison to the untreated sample. 
Calculation and presentation of data are analog to Table 18. 
Analyte Modification untreated CHIR 99021 MG132 
β-catenin (BD) 
 
2.78 
(8037/4464) 
15.76 
(8021/25290) 
27.49 
(16848/92633) 
β-catenin 
(Millipore)  
2.83 
(410/232) 
25.10 
(1752/8796) 
31.36 
(1271/7972) 
β-catenin 
non-p Ser33/ 
Ser37/Thr41 
- 
192.13 
(108/4150) 
142.78 
(81/2313) 
β-catenin pSer552 
4.30 
(2775/2384) 
42.79 
(303/2593) 
104.14 
(422/8789) 
β-catenin pSer675 
4.61 
(2161/1994) 
37.52 
(159/1193) 
75.57 
(245/3703) 
 
 
Figure 28: Caught β-catenin variants and their enrichment after treatment in HepG2. 
The CFs listed in Table 27, are represented for both treatments (CHIR 99021 in red; MG132 in green) in 
comparison to the untreated sample (blue). For some antibodies with no signal obtained, no bar is displayed. 
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The CFs for HepG2 cells were in general lower than for the mouse cell lines. A high increase of  
β-catenin was observed: The BD antibody showed approximately 5.6 times higher CF for the 
CHIR 99021 (= 15.76) and a circa 9.9 times higher CF for the MG132 treatment (= 27.49), while the 
Millipore antibody showed an increase as well, but the difference between the CFs of the two 
treatments (CF = 25.10 and 31.36) was less pronounced. Non-phosphorylated β-catenin was only 
detected after treatment. CHIR 99021 treatment led to high values for the CF (= 192.13) and the raw 
value (4150 AFI, see Suppl. Table E), a lower increase was observed for MG132 (CF = 142.78, 
2313 AFI). The CFs for the C-terminal phosphorylated β-catenin variants were eight to ten times 
higher after CHIR 99021 treatment than without treatment. For MG132 treatment, this factor rose 
up to 16 to 22 times. Both the CFs and the raw values for the Ser552 phosphorylation show, that a 
higher amount of this posttranslational modified variant is detected, than of the pSer675 variant. 
 
Table 28: Caught β-catenin variants and their enrichment after treatment in HB35.  
The CFs and raw values are represented for both treatments in comparison to the untreated sample. 
Calculation and presentation of data are analog to Table 18. 
Analyte Modification untreated CHIR 99021 MG132 
β-catenin (BD) - 
5.31 
(12678/13472) 
15.54 
(2710/8423) 
13.42 
(12872/34538) 
β-catenin 
(Millipore) 
- 
5.62 
(680/764) 
17.38 
(401/1394) 
19.64 
(1098/4313) 
β-catenin 
non-p Ser33/ 
Ser37/Thr41 
9.75 
(40/78) 
54.44 
(27/294) 
106.53 
(59/1257) 
β-catenin pSer552 
14.56 
(2102/6121) 
29.81 
(212/1264) 
25.99 
(1166/6061) 
β-catenin pSer675 
13.18 
(1179/3107) 
36.36 
(147/1069) 
32.41 
(497/3222) 
 
 
Figure 29: Caught β-catenin variants and their enrichment after treatment in HB35. 
The CFs listed in Table 28, are represented for both treatments (CHIR 99021 in red; MG132 in green) in 
comparison to the untreated sample (blue). For some antibodies with no signal obtained, no bar is displayed. 
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HB35 cells showed increased CFs for both total anti-β-catenin antibodies after treatment; the CFs in 
the untreated samples for both analytes were similar (between 5 and 6). Unphosphorylated  
β-catenin, detected by the non-phospho Ser33/Ser37/Thr41 antibody, showed an increase; the rise 
after MG132 treatment was approximately double the increase observed for CHIR 99021. The 
antibodies binding the phosphorylated C-terminus of β-catenin, showed similar CF values for both 
antibodies, dependent on the treatment. In contrast to the other three cell lines, in HB35 no clear 
distinction between the two treatments was observed for these two antibodies. 
 
4.2.4 Effect drug treatment on β-catenin protein complex formation 
Besides changes in the captured β-catenin pools, changes in the amount of other proteins detected 
after treatment with CHIR 99021 and MG132 were found. A comparison of the alterations of 
interaction partners of β-catenin found upon treatment is given below. Interacting proteins, which 
were detected only after treatment, are discussed in detail. Proteins, which occurred as interactors 
of β-catenin only in the untreated samples without persisting after treatment, are listed, but are not 
discussed further. Ratios for the PPIs were calculated as before and the sorting into categories  
(see 4.2.2.1) was performed analog. 
 
4.2.4.1 Altered protein-protein interactions in cell line 70.4  
For cell line 70.4, the capturing of β-catenin increased after treatment (see 4.2.3). For CHIR 99021 the 
rise of the CF was approximately two (BD antibody) and 1.5 times (Millipore antibody). The increase 
observed for MG132 was slightly higher: 2.5 times for the BD antibody and 1.7 times for the Millipore 
antibody. However, the amount of β-catenin available in the input sample, decreased for both 
treatments (1239 AFI and 846 AFI for CHIR 99021; 1519 AFI and 1076 AFI for MG132) (see 4.2.3, 
Table 25). 19 interactions were detected, 15 were seen after treatment only, while four were already 
detected in the untreated sample. The categories for the detected PPIs are shown in Table 29. 
 
Table 29: Co-immunoprecipitated proteins in 70.4 after treatment.  
The CFs and raw values for cell line 70.4-specific β-catenin interacting proteins are represented. Calculation, 
representation and sorting were done analog to Table 21.  
Analyte Modification untreated + CHIR 99021 + MG132 + 
Proteins associated with membranous Wnt signaling 
Wnt11  
20.45 
(11/45) 
+ - 
 
- 
 
DVL1  - 
 40.00 
(11/88) 
+ - 
 
Evi (50 kDa isoform)  - 
 
- 
 1.49 
(175/52) 
 
LRP6  
(210 kDa isoform, # 1567) 
pSer1490 - 
 
- 
 21.36 
(11/47) 
+ 
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Analyte Modification untreated + CHIR 99021 + MG132 + 
Proteins associated with membranous Wnt signaling 
Wnt7b  - 
 
- 
 31.36 
(11/69) 
+ 
DVL2 (# 1739)  - 
 
- 
 138.64 
(11/305) 
+ 
Proteins comprising the β-catenin destruction complex 
CK1 δ  - 
 1.07 
(336/72) 
 1.61 
(615/198) 
 
APC   
26.18 
(17/89) 
 
- 
 
- 
 
GSK3 β  - 
 
- 
 0.43 
(694/60) 
 
Proteins associated with the membrane-associated β-catenin complex 
β-Actin  
4.77 
(60390/57646) 
 0.47 
(34895/3304) 
 0.01 
(39159/81) 
 
α-catenin  
7.29 
(120/175) 
 25.48 
(21/107) 
 15.07 
(68/205) 
 
Transcriptional regulators and factors 
GLI1  
7.50 
(32/48) 
 
- 
 
- 
 
Elk-1   
8.93 
(107/191) 
 
- 
 
- 
 
cJUN (# 1744) pSer63 - 
 
- 
 7.68 
(56/86) 
 
cJUN (HD)  - 
 
- 
 8.15 
(84/137) 
 
Proteins associated with MAPK pathway 
DUSP6  
2.56 
(160/82) 
 
-  -  
A-Raf  - 
 21.82 
(11/48) 
+ -  
Proteins associated with JAK/STAT signaling 
STAT4   
28.64 
(11/63) 
+ 
35.45 
(11/78) 
+ 
24.09 
(11/53) 
+ 
STAT3  
(86 kDa isoform, # 1736) 
 - 
 2.45 
(110/54) 
 
473.23 
(206/19497) 
 
STAT3  
(79 kDa isoform, # 1736) 
 - 
 
- 
 2495.00 
(11/5489) 
+ 
Tumor markers 
Vimentin   
6.78 
(343/465) 
 0.88 
(871/153) 
 
- 
 
Cytokeratin  
(~46 kDa # 0474) 
 - 
 6.82 
(44/60) 
 
- 
 
Cytokeratin  
(~55 kDa, # 0474) 
 - 
 
- 
 42.05 
(73/614) 
 
Cytokeratin   
(~60 kDa, # 0588) 
 - 
 
- 
 68.93 
(2665/36739) 
 
 
As a result of CHIR 99021 treatment, DVL1 (dishevelled1) [48, 219, 225] appeared as a new and very 
strong interacting protein in 70.4 cells (CF of 40). This protein belongs to the category of proteins 
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being associated with membranous Wnt signaling. MG132 treatment resulted in the identification of 
four interactors: The 50 kDa isoform of the Evi protein emerged as a strong interactor (CF = 1.49), 
while LRP6 (pSer1490, 210 kDa isoform, #1567), Wnt7b and DVL2 were classified as very strong PPIs 
(CFs between circa 20 and approximately 140). Both forms of DVL, DVL1 and DVL2, can link the 
membrane-bound Wnt receptor complex to the cytosolic β-catenin destruction complex. For all new, 
very strong interacting proteins, a signal was obtainable only in the enriched bound sample  
(raw values between 47 and 305 AFI). 
APC was the only member of the β-catenin destruction complex detected in 70.4 in untreated cells. 
After treatment this protein was not seen anymore, but new interactors were detected. Both 
treatments showed CK1 δ as an interacting protein with a CF above one. GSK3 β was found only in 
MG132-treated cells, as a medium interactor (CF of 0.43). 
The occurrence of α-catenin and β-Actin, participating in the membrane-associated β-catenin 
complex, was consistent throughout different treatments of 70.4 cells. The CF for α-catenin was circa 
3.5 times higher for CHIR 99021 treatment (CF = 25.48) and approximately double for MG132 
(CF = 15.07) compared to the untreated sample. The interaction with β-Actin, on the other hand, 
decreased both for the detected CFs and the obtained raw values. After CHIR 99021 treatment, it still 
represented a medium interacting protein (CF = 0.47), while for MG132 treatment the PPI is weak 
(CF = 0.01). 
The PPIs obtained for GLI1 and Elk-1, both transcriptional regulators found in the untreated sample, 
did not reoccur after treatment. cJUN and its activated phospho-variant, cJUN (pSer63), were found 
to be strong interactors of β-catenin after MG132 treatment (CFs of 7.68 and 8.15) instead. 
The DUSP6 interaction in the untreated sample, was not obtained after treatment. Yet, one other 
protein associated with the MAPK signaling, A-Raf, occurred as a very strong interactor in the 
CHIR 99021-treated bound sample (CF of 21.82). 
STAT4 was only detected in the bound samples as a β-catenin complex partner and not visible in 
input, yet seen for the treated and untreated bound samples. Additional proteins that appeared as 
strong or very strong interactors after treatment were the two STAT3 isoforms. The 86 kDa isoform 
of STAT3 (# 1736) was visible after CHIR 99021 and MG132 treatment as a strong interactor  
(CF of 2.45) or a very strong interactor (CF = 473.23), while the 79 kDa isoform of STAT3 (# 1736) was 
a very strong interacting protein only after MG132 treatment (CF = 2495.00). This 79 kDa isoform, 
only showed a strong signal in the bound sample (5489 AFI), but not in the input.  
Vimentin remained as a strong interacting protein (decreased CF of 0.88 after CHIR 99021 
treatment), but disappeared for MG132 treatment. Two different peaks were measured in the 
differently treated cells for the Cytokeratin Pan (# 0474) antibody. For CHIR 99021 the Cytokeratin 
with a MW of ~46 kDa represented a strong interactor (CF = 6.82), while the interaction for  
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the ~55 kDa-sized Cytokeratin was increased for MG132 and classified as very strong (CF = 42.05). 
Additionally, another Cytokeratin (~60 kDa, # 0588) was rated as a very strong PPI (CF = 68.93) in the 
MG132-treated sample. 
 
4.2.4.2 Modulation of β-catenin interactions in 55.1c by drug treatment 
In 55.1c cells a decrease in the capture of β-catenin after treatment was observed for CHIR 99021 
and MG132. The CF for CHIR 99021 dropped to 0.5 (BD antibody) and to 0.8 (Millipore antibody). 
MG132 resulted in a 0.8 fold decrease (BD antibody), while the Millipore antibody detected a  
1.2 times increase. Both treatments measured an increase in the obtained raw values (see 4.2.3, 
Table 26). 13 PPIs were detected only after treatment and 17 interactions, which already occurred in 
the untreated sample, could be confirmed. The interacting proteins were assigned to seven of the 
eight categories (see 4.2.2.2); no interactions with the “epigenetic regulators” were found. 
 
Table 30: Co-immunoprecipitated proteins in 55.1c after treatment.  
The CFs and raw values for cell line 55.1c-specific β-catenin interacting proteins are represented. Calculation, 
representation and sorting were done analog to Table 21. 
Analyte Modification untreated + CHIR 99021 + MG132 + 
Proteins associated with membranous Wnt signaling 
Evi (60 kDa isoform)  
4.49 
(503/452) 
 10.80 
(193/417) 
 12.17 
(254/618) 
 
Wnt7b  
38.36 
(70/537) 
 181.63 
(135/4904) 
 38.18 
(11/84) 
+ 
LRP6 (# 1750) pSer1490 
5.78 
(58/67) 
 
- 
 
- 
 
Wnt3a  
47.73 
(11/105) 
+ - 
 
- 
 
Evi (50 kDa isoform)  - 
 18.88 
(209/789) 
 
- 
 
Frizzled4  - 
 
- 
 10.51 
(4960/10430) 
 
Proteins comprising the β-catenin destruction complex 
GSK3 α pTyr279 
8.56 
(436/746) 
 20.23 
(22/89) 
 3.38 
(312/211) 
 
GSK3 β  
10.97 
(3653/8018) 
 5.72 
(2442/2795) 
 4.84 
(2856/2767) 
 
CK1 α  
2.32 
(480/223) 
 1.31 
(360/94) 
 
- 
 
GSK3 β pTyr216 
15.09 
(696/2100) 
 
- 
 5.42 
(493/534) 
 
Axin1   
75.80 
(50/758) 
 
- 
 40.39 
(38/307) 
 
APC   
11.74 
(23/54) 
 
- 
 
- 
 
Axin2 (# 1724)  
40.91 
(11/90) 
+ - 
 
- 
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Analyte Modification untreated + CHIR 99021 + MG132 + 
Proteins associated with the membrane-associated β-catenin complex 
α-catenin  
16.20 
(888/2878) 
 7.77 
(968/1504) 
 18.88 
(732/2764) 
 
E-Cadherin   
21.31 
(781/3328) 
 6.27 
(1191/1493) 
 11.39 
(1102/2511) 
 
β-Actin  - 
      13.24 
(176674/467673) 
      12.13 
(138494/335905) 
Transcriptional regulators and factors 
HNF1A  
1.61 
(1211/391) 
 2.68 
(288/122) 
 6.06 
(726/880) 
 
TCF4  
(60 kDa isoform, # 1727) 
 
133.64 
(11/294)  
+ 
8.29 
(234/388) 
 11.70 
(227/531) 
 
Smad5  
1.32 
(355/94) 
 1.00 
(902/181) 
 
- 
 
Smad3 (# 0879)  
1.53 
(618/189) 
 0.25 
(2394/119) 
 
- 
 
Src  
2.02 
(9241/3738) 
 1.35 
(4022/1085) 
 
- 
 
TAZ   
14.09 
(3726/10502) 
 
- 
 25.43 
(58/295) 
 
Src pTyr527 - 
 1.62 
(2982/968) 
 0.68 
(4024/550) 
 
Elk-1  - 
 18.46 
(742/2740) 
 18.74 
(428/1604) 
 
Src pTyr416 - 
 39.71 
(17/135) 
 10.20 
(25/51) 
 
eIF4E  
0.11 
(8820/189) 
 
- 
 
- 
 
Smad4  
0.93 
(387/72) 
 
- 
 
- 
 
TCF4  
(70 kDa isoform, # 1481) 
 
12.83 
(30/77) 
 
- 
 
- 
 
ATF4   - 
 381.36 
(11/839) 
+ - 
 
Proteins associated with MAPK pathway 
DUSP1   - 
 27.20 
(1236/6724) 
 25.30 
(926/4686) 
 
JNK/SAPK (54 kDa isoform)  
1.52 
(256/78) 
 
- 
 
- 
 
MKK7   
2.44 
(166/81) 
 
- 
 
- 
 
A-Raf   
2.94 
(240/141) 
 
- 
 
- 
 
MAPKAPK-5   
4.45 
(64/57) 
 
- 
 
- 
 
MDM2 (60 kDa isoform)  
10.47 
(43/90) 
 
- 
 
- 
 
DUSP6   
11.29 
(831/1876) 
 
- 
 
- 
 
DUSP9  - 
 1210.00 
(11/2662) 
+ - 
 
DUSP4   - 
 
- 
 6.46 
(4590/5930) 
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Analyte Modification untreated + CHIR 99021 + MG132 + 
Proteins associated with JAK/STAT signaling 
STAT3  
(79 kDa isoform, TK # 054) 
 
0.42 
(862/73) 
 0.31 
(761/47) 
 
- 
 
Tumor markers 
Vimentin  
16.38 
(7346/24060) 
 25.05 
(2818/14117) 
 16.49 
(2763/9111) 
 
Cytokeratin   
(~46 kDa, # 0474) 
 
65.33 
(92/1202) 
 0.76 
(8223/1257) 
 0.31 
(10909/682) 
 
Cytokeratin   
(~60 kDa, # 0588) 
 - 
 5.00 
(24510/24522) 
 
- 
 
Cytokeratin   
(~55 kDa, # 0474) 
 - 
 
- 
 23.35 
(403/1882) 
 
 
After CHIR 99021 treatment both isoforms of Evi occurred as very strong interacting proteins 
(CF = 18.88 and 10.80) in the category of “proteins associated with the membranous Wnt signaling”. 
The 60 kDa isoform was detected in the untreated sample and occurred after MG132 treatment as a 
very strong interactor, while the 50 kDa variant is only present in the CHIR 99021-treated sample. 
Wnt7b was an interactor, which appeared in all three conditions. For CHIR 99021 treatment, a  
five-fold increase (CF = 181.63) was seen, while MG132 caused no changes in the  calculated CF. It 
has to be noted, that MG132 caused a strong drop in absolute signal of Wnt7b. Frizzeld4, a central 
regulator in the Wnt pathway [150, 226, 227], was detected as a very strong interactor (CF of 10.51) 
after MG132 treatment. Frizzled4 was also detectable in the other samples with a strong interaction, 
but the signals were eliminated from further analysis due to the defined cutoff criteria (see 3.4.3.3). 
Five of the seven PPIs, participating in the β-catenin destruction complex, seen in the untreated 
sample, reappeared as interacting proteins after one or both treatments. Phosphorylated GSK3 α 
showed a strong increase after CHIR 99021 treatment and is classified as a very strong interactor 
(CF = 20.23). For MG132 the obtained CF was reduced, but it still remained as a strong interactor 
(CF = 3.38). The phosphorylated GSK3 β was detected after MG132 treatment, but not after 
CHIR 99021 application (strong interactor (CF = 5.42)). This is similar to GSK3 β, were the measured 
CF decreased for both treatments, but the interaction still remained strong (CFs of 5.72 and 4.84). 
CK1 α and Axin1 occurred only for one of the treatments each: CK1 α was detected after CHIR 99021 
application as a strong interactor (CF of 1.31), while Axin represented a very strong PPI in the 
MG132-treated sample (CF of 40.39). 
Both E-Cadherin and α-catenin interactions were found in the treated samples. The CF decreased for 
both proteins after CHIR 99021 treatment and classified them as strong interactors. For α-catenin the 
CF increased slightly after MG132 treatment compared to the untreated sample. On the other hand, 
it decreased for E-Cadherin; however, both remained very strong interactors, according to their CFs 
above 10. 
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In the category “transcriptional regulators and factors” four new interactions after treatment were 
detected. HNF1A remained a strong interactor, which increased for CHIR 99021 (CF = 2.68) and 
further for MG132 treatment (CF = 6.06). The CF for TCF4 (# 1727) decreased after treatment, since it 
was now already detectable in the input sample. Thus, the calculated ratio was smaller, but it 
remained as a very strong interactor after MG132 treatment, while it was classified only as a strong 
interactor for CHIR 99021 treatment. Smad5 and Src represent strong interacting proteins, which 
remained after CHIR 99021 with only a minor decrease (CF = 1.00 vs. 1.32 and 1.35 vs. 2.02), but 
disappeared after the application of MG132. Smad3 (# 0879) was seen after CHIR 99021 treatment, 
but the CF dropped to 0.25 and did not qualify it as a strong interactor anymore. This interacting 
protein didn’t appear after MG132 treatment. TAZ on the other side was not detectable after 
CHIR 99021 treatment, but MG132 led to an increased CF of 25.43. Besides the total Src, also 
phosphorylated variants were detected as strong or very strong interactors after both treatments. 
The inactive version, phosphorylated at Tyr527, showed high signals in the raw values, but the 
capturing rates were low (CF = 1.62 and 0.68). Src, phosphorylated at Tyr416, represents the active 
variant of the kinase. Here higher CFs are derived, especially after CHIR 99021 treatment 
(CF = 39.71). Elk-1 was a very strong interactor for both treatments, but not detectable in the 
untreated sample. The CFs were slightly above 18 in both cases. Additionally, ATF4 appeared after 
CHIR 99021 treatment as interacting protein. It occurred as a protein, which is only detectable in the 
bound sample with 839 AFI as a very strong interactor (CF = 381.36). 
None of the earlier occurring PPIs associated with the MAPK pathways, were detected again after 
treatment. But three new interacting proteins were found: for both treatments DUSP1 was a very 
strong interactor; DUSP9 was detected as a very strong interactor after CHIR 99021 treatment, 
whereas DUSP4 was seen as a strong interactor after MG132 treatment. The raw values revealed, 
that DUSP1 was already detected in the untreated sample, but was eliminated based on the defined 
cutoff limits. DUSP9 showed no signal in the input sample, but a huge peak in the bound sample after 
CHIR 99021 treatment (2262 AFI), which resulted in an enormous CF of 1210.00. DUSP4 remained 
only for the MG132-treated cells as an interactor, although the obtained raw values were similar for 
all treatments, but the earlier mentioned cutoff limits (see 3.4.3.3) removed this protein as an 
interactor of β-catenin before calculating a CF for the other treatments. 
STAT3 (79 kDa isoform, TK # 54) remained as a medium interactor after CHIR 99021 treatment  
(CF of 0.31), being assigned to the group of proteins associated with JAK/STAT signaling. 
The capturing rate for the EMT marker Vimentin stayed unchanged for MG132 treatment compared 
to the untreated sample (CF = 16.38 vs. 16.49), but an increase through the application of 
CHIR 99021 (CF = 25.05) was detected. In all conditions, it represented a very strong interacting 
protein. Various Cytokeratins were measured after treatment. The very strong interaction of 
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Cytokeratin (~46 kDa, # 0474) in the untreated sample, decreased to a strong interaction in the 
CHIR 99021-treated (CF = 0.76) and even further in the MG132-treated sample (medium interaction; 
CF = 0.31). Additionally, two other Cytokeratins were detected: Cytokeratin (~60 kDa, # 0588), as a 
strong interacting protein after CHIR 99021 treatment (CF = 5.00), and Cytokeratin 
 (~55 kDa, # 0474), as a very strong interactor after MG132 treatment (CF = 23.35). As described 
above for the DUSPs, again high signals were obtained for the Cytokeratins also in the remaining 
treatments, but were eliminated, because of the determined cutoff levels (see 3.4.3.3).  
 
4.2.4.3 Modification of β-catenin interactions in HepG2 after drug treatment 
In HepG2 cells frequently a rise in both, the CFs after treatment and the obtained raw values of  
β-catenin are observed. The increase of the CF was approximately five to eight fold after CHIR 99021 
treatment and ten fold for MG132 for both antibodies detecting total β-catenin (BD and Millipore). 
The PPIs detected here, were classified in nine groups. The category six, eight and nine were newly 
added, as proteins assigned to these groups were occuring after treatment. 14 novel proteins were 
found and five reoccurring interactors from the untreated sample were detected (see 4.2.2.3).  
 
Table 31: Co-immunoprecipitated proteins in HepG2 after treatment.  
The CFs and raw values for cell line HepG2-specific β-catenin interacting proteins are represented. Calculation, 
representation and sorting were done analog to Table 21. 
Analyte Modification untreated + CHIR 99021 + MG132 + 
Proteins associated with membranous Wnt signaling 
Evi (60 kDa isoform)  - 
 3.27 
(124/81) 
 6.32 
(288/364) 
 
LRP6  
(180 kDa isoform, # 1567) 
pSer1490 
24.09 
(11/53) 
+ - 
 
- 
 
Wnt7b  
32.27 
(11/71) 
+ - 
 
- 
 
Proteins comprising the β-catenin destruction complex 
GSK3 β  
0.59 
(2085/244) 
 
2.95 
(1072/632) 
 
12.05 
(1873/4515) 
 
GSK3 β pTyr216 
1.15 
(278/64) 
 
4.75 
(61/58) 
 
19.50 
(239/932) 
 
CK1 δ  
0.27 
(867/46) 
 -  -  
Axin2  
(98 kDa isoform, # 0956) 
 -  
20.00 
(12/48) 
 -  
GSK3 α pTyr279 -  -  
8.37 
(181/303) 
 
Axin2  
(95 kDa isoform, # 0956) 
 -  -  
8.38 
(40/67) 
 
Axin1  -  -  
52.73 
(11/116) 
+ 
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Analyte Modification untreated + CHIR 99021 + MG132 + 
Proteins associated with the membrane-associated β-catenin complex 
α-catenin  
0.55 
(1200/133) 
 6.64 
(229/304) 
 6.67 
(576/768) 
 
E-Cadherin   
1.64 
(679/223) 
 4.69 
(533/500) 
 14.91 
(1235/3683) 
 
β-Actin  - 
 
- 
 0.16 
(144040/4539) 
 
Transcriptional regulators and factors 
HNF1A  
1.02 
(293/60) 
 2.30 
(816/375) 
 1.71 
(924/316) 
 
TCF4  
(60 kDa isoform, #  1481) 
 - 
 16.40 
(43/141) 
 60.19 
(52/626) 
 
eIF4E   
0.14 
(1930/54) 
 
- 
 
- 
 
FoxO3a  pSer413 
24.55 
(11/54) 
+ - 
 
- 
 
ATF4   
41.82 
(11/92) 
+ - 
 
- 
 
Snail  
53.18 
(11/117) 
+ - 
 
- 
 
TCF4  
(70 kDa isoform, # 1481) 
 - 
 
- 
 14.91 
(53/158) 
 
TCF1  - 
 
- 
 128.64 
(11/283) 
+ 
Proteins associated with MAPK pathway 
JNK/SAPK  - 
 
- 
 1.88 
(309/116) 
 
Proteins associated with JAK/STAT signaling 
STAT3  
(79 kDa isoform, # 1736) 
 - 
 3.66 
(1778/1303) 
 25.92 
(2318/12015) 
 
STAT4  
23.64 
(11/52) 
+ - 
 
- 
 
Epigenetic regulators 
LSD1  - 
 0.66 
(881/116) 
 0.48 
(1758/170) 
 
Tumor markers 
Cytokeratin   
(~60 kDa, # 0588) 
 - 
 
- 
 1.49 
(196115/5851
4) 
 
Vimentin  - 
 
- 
 14.00 
(20/56) 
 
 
LRP6 (180 kDa isoform, # 1567) and Wnt7b defined as very strong interactors, yet with low absolute 
measured signals, were not found after treatment. An isoform of the Evi protein appeared newly as a 
strong interactor in the “membranous Wnt signaling” category that responded to CHIR 99021 and 
MG132 treatment. Its capturing rate was higher after MG132 treatment (CF of 6.32) than after 
CHIR 99021 treatment (CF = 3.27). 
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Two of the three interactors detected in the untreated sample classified as members of the β-catenin 
destruction complex, occurred after treatment. The CFs for GSK3 β and GSK3 β (pTyr216) showed a 
four- to five-fold rise after CHIR 99021 treatment and remained as strong interactors, while under 
MG132 treatment they increased further and represented very strong interactors (CF = 12.50 and 
19.50). Several interactors were only detected for one of the treatments. The 98 kDa isoform of 
Axin2 was identified as very strong interactor after CHIR 99021 treatment (CF = 20.00). Three 
interacting proteins were only measured in the MG132-treated sample: the GSK3 α (pTyr279) as a 
strong interactor (CF of 8.37); the 95 kDa isoform of Axin2, a strong interacting protein (CF = 8.38) 
and Axin1 as a very strong PPI (CF = 52.73), which is only measurable in the bound sample. 
A strong interaction for α-catenin and E-Cadherin was seen. The CFs for α-catenin were very similar 
after CHIR 99021 and MG132 treatment (CF = 6.64 and 6.67, representing a 12-fold change 
compared to the untreated sample). For E-Cadherin, a three-fold rise after CHIR 99021 treatment 
was seen and after MG132 the CF was more than nine times higher. That classified E-Cadherin as a 
strong interactor for CHIR 99021 (CF = 4.69) and a very strong interactor for MG132 treatment 
(CF = 14.91). In addition, β-Actin was captured as a medium interacting protein (CF of 0.16) for the 
MG132-treated samples. 
Among the group of “transcriptional regulators and factors”, HNF1A was detected with an increased 
capturing rate after both treatments. It remained a strong interactor for both, CHIR 99021 (CF = 2.30) 
and MG132 treatment (CF = 1.71). TCF1 and TCF4 detected by different antibodies were the 
newfound PPIs after treatment. The 60 kDa isoform of TCF4 was seen for both treatments with CFs of 
16.40 and 60.19 indicating a very strong interaction, while the 70 kDa isoform was visible only for the 
MG132-treated sample again as a very strong interactor (CF = 14.91). TCF1 only occurred as complex 
partner of β-catenin in the bound sample of the MG132-treated sample, representing another very 
strong PPI (CF of 128.64, obtained raw value of 283 AFI). 
JNK/SAPK, the only protein occurring as associated to the MAPK pathway, appeared only after 
MG132 application as a strong interacting protein of β-catenin (CF of 1.88). 
STAT3 was seen as a new strong PPI for the HepG2 cell line after CHIR 99021 treatment (CF = 3.66) 
and increased to a very strong interactor with a factor of approximately seven for MG132 treatment 
(CF = 25.92).  
The epigenetic regulator LSD1 was caught as an interacting protein. For CHIR 99021 this interaction 
was classified as strong (CF of 0.66), while the capturing rate decreased for MG132 treatment and 
the interaction was rated as a medium one (CF = 0.48). 
After MG132, treatment two different tumor markers were precipitated together with β-catenin in 
HepG2 cells. Cytokeratin (~60 kDa, # 0588) was detected as a strong interactor (CF of 1.49) and 
Vimentin as a very strong interacting protein (CF = 14.00).  
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4.2.4.4 Changed protein-protein interactions in HB35 by drug treatment 
In HB35 cells CHIR 99021 treatment led to a decrease in the total amount of β-catenin detected for 
both antibodies targeting total β-catenin (BD and Millipore). For MG132, the amount of β-catenin 
stayed similar for the BD antibody, while the Millipore antibody showed an increase. The CFs in turn 
increased approximately three times after CHIR 99021 and MG132 treatment for both antibodies 
(see 4.2.3, Table 28). In the treated HB35 sample, nine induced and five known interaction partners 
(see 4.2.2.4) were seen and sorted into the six groups (see 4.2.2.1). The last group, comprising the 
tumor markers, was excluded here as no interacting proteins were detected after treatment. 
 
Table 32: Co-immunoprecipitated proteins in HB35 after treatment.  
The CFs and raw values for cell line HB35-specific β-catenin interacting proteins are represented. Calculation, 
representation and sorting were done analog to Table 21. 
Analyte Modification untreated + CHIR 99021 + MG132 + 
Proteins associated with membranous Wnt signaling 
DVL1  - 
 21.36 
(11/47) 
+ 
28.18 
(11/62) 
+ 
Evi (60 kDa isoform)  - 
 9.31 
(29/54) 
 
- 
 
LRP6  
(180 kDa isoform, # 1567) 
pSer1490 - 
 
- 
 14.25 
(20/57) 
 
Proteins comprising the β-catenin destruction complex 
GSK3 β   
10.80 
(1868/4036) 
 0.77 
(397/61) 
 0.93 
(1113/208) 
 
GSK3 α  pTyr279 
3.34 
(295/197) 
 
- 
 
- 
 
GSK3 β  pTyr216 
20.76 
(204/847) 
 
- 
 
- 
 
Axin1   
23.96 
(48/230) 
 
- 
 
- 
 
Proteins associated with the membrane-associated β-catenin complex 
α-catenin  
1.14 
(350/80) 
 8.53 
(112/191) 
 7.59 
(1198/1819) 
 
E-Cadherin   
4.32 
(1246/1077) 
 11.99 
(78/187) 
 9.77 
(328/641) 
 
β-Actin   
0.04 
(140755/1250) 
 
- 
 
- 
 
Transcriptional regulators and factors 
HNF1A  - 
 4.50 
(90/81) 
 15.56 
(45/140) 
 
eIF4E   
0.05 
(6969/74) 
 
- 
 
- 
 
Src pTyr527 
0.10 
(9362/188) 
 
- 
 
- 
 
Smad2  
0.78 
(598/93) 
 
- 
 
- 
 
cJUN (43 kDa isoform)  
1.28 
(301/77) 
 
- 
 
- 
 
TCF1  
10.69 
(29/62) 
 
- 
 
- 
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Analyte Modification untreated + CHIR 99021 + MG132 + 
Transcriptional regulators and factors 
TAZ (HD)  
15.19 
(27/82) 
 
- 
 
- 
 
Snail  
84.09 
(11/185) 
+ 
- 
 
- 
 
cJUN (# 1162) pSer63 - 
 
- 
 1.93 
(135/52) 
 
Smad5  - 
 
- 
 5.00 
(45/45) 
 
Bcl9  - 
 
- 
 32.73 
(11/72) 
+ 
Proteins associated with JAK/STAT signaling 
STAT3  
(79 kDa isoform, TK # 054) 
 
0.17 
(2679/92) 
 
- 
 0.40 
(870/70) 
 
STAT3  
(86 kDa isoform, # 1736)  
 
0.61 
(475/58) 
 
- 
 
- 
 
STAT3  
(79 kDa isoform, # 1736)  
 - 
 4.26 
(685/583) 
 
- 
 
Epigenetic regulators 
LSD1   
0.16 
(3015/97) 
 
- 
 
- 
 
HDAC6  - 
 
- 
 1.21 
(194/47) 
 
 
Proteins associated with the membranous Wnt signaling arose only after treatment. DVL1 occurred 
for both treatments as a very strong interactor (CF between 20 and 30). Signals were only obtained in 
the bound samples each (AFIs of 47 and 62). For CHIR 99021 treatment, Evi (60 kDa isoform) 
occurred as a strong interacting protein belonging to this group (CF of 9.31). LRP6 (pSer1490, 
180 kDa isoform, # 1567) represented a very strong interactor of β-catenin after MG132 treatment 
(CF = 14.25). 
Only one of the interacting proteins participating in the β-catenin destruction complex, measured in 
the untreated sample reoccurred after treatments, which is GSK3 β. Classified as a very strong 
interactor in the untreated sample, it still remained as a strong interactor after treatments, but the 
CF was decreased more than ten times to 0.77 for CHIR 99021 and 0.93 for MG132. 
Both α-catenin and E-Cadherin reappeared with an increased CF after treatment. For α-catenin the 
CF rose for both treatments by a factor of approximately 7 (CF = 8.53 and 7.59). The CF for  
E-Cadherin in the CHIR 99021-treated classified it as a very strong interactor (CF = 11.99), while it was 
increased for MG132 as well, but stayed a strong interacting protein (CF of 9.77). 
None of the PPIs, defined as “transcriptional regulators and factors”, detected for the untreated 
HB35 sample recurred after treatment. With HNF1A a strong interactor / very strong interactor  
(CF of 4.50 after CHIR 99021 treatment; CF of 15.56 after MG132 treatment) was found. Additionally, 
two strong and one very strong interactor occurred for the MG132 treatment. As strong interactors, 
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the phosphorylated cJUN (CF = 1.93) and Smad5 (CF = 5.00) were measured, while Bcl9 [36, 64, 228], 
the B-cell CLL/lymphoma 9 protein, was found an interaction partner of β-catenin for the first time. It 
appeared only in the MG132-treated, bound sample (72 AFI) as a very strong PPI (CF = 32.73). 
STAT3 (79 kDa isoform, TK # 054) appeared as a medium interactor, with a slightly increased CF of 
0.40 after MG132 treatment. In addition, STAT3 (79 kDa isoform, # 1736) a new isoform of STAT3 
was detected as a strong interactor (CF = 4.26). 
One protein, HDAC6 [229-231], assigned to the group of “epigenetic regulators”, was captured in 
HB35 cells after MG132 treatment. HDAC6 belongs to the cytosolic histone deactylases and is able to 
deacetylase β-catenin directly. It represents a strong interactor (CF of 1.21). No PPIs, belonging to 
this category, were obtained after application of CHIR 99021. 
 
4.2.5 Summary 
Differences in between the cell lines appear for the different amounts of β-catenin detected by 
various antibodies after Co-IP and additionally after treatment (see 4.2.1 and 4.2.3). These 
differences can be obtained for the CFs as well. In general, antibodies against total β-catenin 
achieved higher raw signal intensities both for the untreated samples as well as after drug treatment. 
On the other hand, the CFs for the phosphorylated variants of the protein are increased in 
comparison to the CFs received by the antibodies detecting total β-catenin, although the raw values 
show a lower signal intensity. The signal intensity of the raw values for the detected β-catenin 
decrease generally after treatment, while the derived CFs normally rise. It can be assumed, that a 
higher portion of the different β-catenin variants were captured during Co-IP, although the 
treatment caused a decrease in the raw values. 
All cell lines showed major differences in the precipitated interaction partners of β-catenin  
(see 4.2.2), both among each other and upon drug treatment. They all share, that proteins belonging 
to various well-known β-catenin-complexes were identified but vary in the individual proteins 
detected. The variation among the cell lines is increased after treatment (see 4.2.4). 
By the possibility of covering a signaling cascade and its spatial cellular surrounding with antibodies, 
links to other important pathways, such as the MAPK pathway, as well as the identification of 
unknown crosstalks in between signaling pathways, are enabled. Additionally, the ability of screening 
for a multitude of potential PPIs and PTMs of these proteins, might lead to new insights into the 
cellular network. The huge differences observed for the chosen cell lines and the two treatments 
were not expected to this extent, but employing this novel screening approach to illustrate these 
differences will allow to gain a deeper understand of the cellular signaling network in the long run. 
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4.3 Immunoprecipitation with high-affinity nanobody 
For the development of a novel way of detecting intracellular PPIs, two fundamental experimental 
conditions were changed: First, the cell line employed for performing the Co-IP was changed; 
HEK293T providing a more general cell model for the extracellular Co-IP (ECIP). Second, the capturing 
antibody was replaced by a high-affinity, β-catenin-specific nanobody. The employed capturing 
molecule BC1 binds β-catenin at the N-terminal region, targeting aa 61 – 87; a different epitope than 
the antibody that was used during the described immunoprecipitations (see 4.2). This approach uses 
the possibility to perform intracellular Co-IPs (ICIPs) for the first time (see 4.4). The properties of the 
nanobody BC1 in Western blots have been tested [112] and in a first step the comparability between 
the conventional Western blot approach and the DigiWest was tested. As control for the ECIP, a 
nanobody-specific for GFP (GFP-Nanotrap®) was employed. 
The analysis of HEK293T cells treated with CHIR 99021 were included. The nanobody BC1 has a 
preference for binding β-catenin, which is unphosphorylated at the SSTS-motif; thus it seems to be 
particularly well suitable as a capturing molecule during Co-IP on CHIR 99021-treated cell lysates. The 
ability to screen for treatment-induced differences in the occurring β-catenin complexes seemed to 
be promising. 
 
4.3.1 Comparison between classical Western blot and DigiWest 
To compare the signals obtained in Western blots with signals received by the novel DigiWest 
approach, both approaches were used for sample analysis and detection of PPIs. Aliquots of the 
samples, generated by Co-IP employing the nanobody BC1 or the GFP-Nanotrap®, were applied to 
different gels and processed in Western blot and DigiWest individually. Antibodies against the  
Co-IP-target protein β-catenin and well-known interactors like α-catenin, GSK3 β, TCF1 and Axin2, as 
well as the housekeeping protein, GAPDH, as control, were used for the comparison. Figure 30 A 
shows the results obtained for the classical Western blot next to the bar graphs, resulting from the 
DigiWest (Figure 30 B). In addition, the DigiWest bar graphs were transformed into grayscale 
Western blot mimics (see Figure 30 C), as described in 3.4.2, to give a more familiar, Western blot 
alike, visual impression of the obtained results. 
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Figure 30: Direct comparison between conventional Western blot, digitalized Western blot and Western blot 
mimics.  
Direct comparison between the same samples on conventional Western blot (A) and the DigiWest (B,C) is 
represented. The bar graphs of the digitalized Western blot (B) and after transforming the obtained AFI values 
into Western blot mimics (C) are shown.  
Co-IP was performed with an anti-β-catenin nanobody, called BC1, or an unspecific nanobody recognizing GFP 
as a negative control. Besides the target protein β-catenin, various antibodies are presented: α-catenin, 
GSK3 β, TCF1 and Axin2 represent known interacting proteins of β-catenin, while GAPDH serves as a negative 
control. For the DigiWest bar graphs (B), the molecular weight between ~15 kDa and ~300 kDa is plotted on the 
x-axis, while the signal intensity is shown on the y-axis, as explained in Figure 10 in detail. The signal maxima for 
the different antibodies differ, thus for β-catenin it is defined at 1200 MFI, for α-catenin at 300 MFI, for GSK3 β 
at 2000 MFI, for TCF1 at 120 MFI, for Axin2 at 200 MFI and for GAPDH at 30000 MFI.  
 
As it was difficult to directly compare the Western blot lanes Figure 30 A with the DigiWest bar 
graphs Figure 30 B, it was very helpful to have digitalized Western blot mimics Figure 30 C, which 
visualize the similarity between the individual antibodies. The target protein β-catenin showed 
intense lanes for the input and BC1-bound sample both in the conventional Western blots and the 
Western blot mimics. In addition, the side bands observed for the BC1-bound sample were visible 
and show a high similarity in all three representations. A low, unspecific signal for β-catenin in the 
control sample can be seen in both approaches as well. For α-catenin similar observations can be 
made: A strong signal in the input sample is received, while a lower one in the BC1-bound. The GFP-
bound serves as a negative control, without any visible signal. For GSK3 β, the signals seem to differ 
slightly between Western blot and DigiWest, as the Western blot shows a low signal in both bound 
lanes and the DigiWest seems to show no signal in the bound lanes at all. A closer inspection of the 
raw data reveals a measured signal of 368 AFI (BC1-bound) and 117 AFI (control bound), which is not 
easily visible in the Western blot mimics (see Suppl. Table G). 
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TCF1 and Axin2 show no signal in the Western blot and the DigiWest; for Axin2 already in the input 
lane no signal is measurable. GAPDH, serving as negative control for the Co-IP, shows no signal in any 
of the bounds, neither in Western blot nor in the DigiWest. 
One of the main advantages of the DigiWest is the easy obtainment of semi-quantitative intensity 
values, which can be used for further analysis. In order to compare these values to the signals 
obtained during the conventional Western blot, a densiometrical analysis was done, employing the 
Image Studio v4 software. For antibodies with measurable signals in both approaches, the ratio of 
input or BC1-bound values over the corresponding GFP-bound was calculated (data not included in 
this work). For TCF1 and Axin2 this was not possible, as there was no measurable signal in one of the 
approaches. Thus, these antibodies were not included in further calculations. The calculation showed 
similar fold changes for both approaches and indicated good comparability of both methods. 
Based on these results, a wider ranging analysis of the immunoprecipitation was performed to 
identify further interaction partners. A set of 75 antibodies was screened on the samples  
(two replicas existing of input, BC1-bound and GFP-bound each). The antibodies are marked in the 
appendix (see Suppl. Table A) with “**”. The duplicate samples were screened for PPIs with  
β-catenin, but as duplicates were used, the cutoff limits were adjusted as described in detail in 
3.4.3.3, in order to make sure that no false positive interactions were picked up. As a result all peaks 
showing a signal intensity above 45 AFI were evaluated as specific signals. In addition, the sum of the 
duplicate signals had to be above 90 AFI with a deviation of smaller or equal to 10 AFI between 
individual signals, to guarantee stability among the replicas. Signals of proteins that bound unspecific 
to the immunoprecipitation matrix were identified and excluded from analysis by defining a 
specificity limit; a signal intensity of at least 1.5-fold above the negative control for an individual peak 
qualified a peak as specific. In addition, the sum of both individual ratios had to be above 2.9 with a 
deviation of the single ratios below 0.2, which led to a higher consistency in between the different 
replicas. For calculating the average of the CFs, the formula, described in 3.4.3.3, Equation 3, was 
applied to each individual replica and the mean was taken afterwards. All CFs for the duplicates, 
along with the obtained raw values for the different input and bound samples, are listed in the 
appendix (see Suppl. Table G). 
During these experiments, it was possible to detect different β-catenin variants (see 4.3.2) and to 
define 21 proteins interacting with β-catenin in HEK293T cells (see 4.3.3 and 4.3.4). 
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4.3.2 Detection of different β-catenin variants  
In analogy to chapter 4.2.1 the different β-catenin pools detected by different antibodies were 
viewed first. The capturing nanobody detects β-catenin preferably at an unphosphorylated epitope 
close to the N-terminally SSTS-motif. Therefore, the addressed β-catenin pools might differ from 
those, detected after precipitating with an antibody recognizing the C-terminus. Besides the same  
β-catenin antibodies as tested in previous experiments, an antibody against total β-catenin (8E7) was 
added. This monoclonal antibody recognizes β-catenin N-terminally (aa 36 – 44). To evaluate the 
amount of each precipitated β-catenin variant, the CFs were calculated (see Table 33). 
 
Table 33: Caught β-catenin variants during ECIP on untreated and CHIR 99021-treated HEK293T cells.  
The capturing rate is represented for the untreated sample and after CHIR 99021 treatment. For calculating the 
average of the CFs, the formula described in 3.4.3.3, Equation 3, was applied to each individual replica. 
Subsequently the mean of the duplicate was calculated. The different β-catenin variants detected, were sorted 
in an ascending order referring to their average CF obtained for the untreated sample. β-catenin variants, 
which were only detected in the bound sample, are marked with a “+”. For one antibody no signal was 
obtained without treatment. This cell was marked with “-“. 
Analyte Modification untreated + CHIR 99021 + 
increase 
(fold change) 
β-catenin pSer675 3.98  17.30  4.35 
β-catenin (BD)  5.56  21.57  3.88 
β-catenin pSer552 6.47  91.07  14.08 
β-catenin (Millipore)  7.60  36.29  4.78 
β-catenin  
non-p Ser33/ 
Ser37/Thr41 
8.76  156.00  17.81 
β-catenin (8E7)  -  3800.23 + > 80 
 
Two antibodies directed against total β-catenin were used (BD and Millipore), showing similar 
capturing rates in the untreated sample (CF = 5.56 and 7.6) and also a similar increase after 
CHIR 99021 treatment. For both an approximately four- to five-fold rise was observed, which led to a 
CF of 21.57 and 36.29 after treatment. Two antibodies directed against C-terminal phosphorylations 
(pSer552 and pSer675) showed CFs of 6.47 and 3.98 in the untreated sample. While for the Ser675 
phosphorylated variant of β-catenin, the CF increased approximately four-fold after CHIR 99021 
treatment, the increase for the pSer552-version was 14.08-fold. This corresponds to a CF of 91.07 
after CHIR 99021 treatment detected by the anti-β-catenin pSer552 antibody. Anti-β-catenin  
non-phospho Ser33/Ser37/Thr41 and anti-β-catenin (8E7) address an active β-catenin variant, 
unphosphorylated at the SSTS-motif. Anti-β-catenin non-phospho Ser33/Ser37/Thr41 showed the 
highest CF (8.76) in the untreated sample and also the highest increase for CHIR 99021. Here a CF of 
156.00 was detected, while the CHIR 99021 treatment led to an increase of a factor of 17.81. The 
antibody 8E7 recognizes β-catenin at the residues aa 36 – 44. It showed no signal in three of the 
samples: the untreated input, the untreated bound and the CHIR 99021-treated input; but a 
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substantial increase was obtained after the application of CHIR 99021 in the amount of β-catenin 
detected by this antibody in the bound sample after CHIR 99021 treatment (CF = 3800.23). As there 
is no signal obtained for the untreated sample, no fold change can be calculated that provides 
information about the increase by drug treatment. Thus, a new criteria was introduced to estimate 
and visualize this increase: The means of the background signals were calculated and their SD derived 
for each replica. The integrated peak values for the anti-β-catenin (8E7) antibody were devided by 
three times of their individual SD value, which led to an estimated increase of more than  
80 compared with three times the SD. 
 
4.3.3 Extracellularly detected interacting proteins on HEK293T 
Besides the differences in precipitation of β-catenin variants, a variety of interacting proteins were 
identified. Nine interactors were detected both in the untreated and the CHIR 99021-treated 
HEK293T cells (see Table 34). 
 
Table 34: Co-immunoprecipitated proteins in untreated and CHIR 99021-treated HEK293T cells.  
The CFs for interacting proteins precipitated in untreated and CHIR 99021-treated HEK293T cells are 
represented, calculated with the formula described in 3.4.3.3, Equation 3. The colorized background stands for 
the strength of the PPI (see Table 19). Proteins were sorted referring to their CF in an ascending order in the 
untreated sample. The averaged CF of the duplicate is shown. In brackets the molecular weight and the distinct 
NMI number are listed, if the analytes need to be differentiated. 
Analyte Modification untreated + CHIR 99021 + 
increase 
(fold change) 
PCNA  0.02  0.02  1.00 
PP2A C  0.11  0.14  1.27 
GSK3 β  0.22  1.98  9.00 
CDK2  0.22  0.41  1.86 
Src pTyr527 0.25  0.31  1.24 
MTA2  0.29  0.25  0.86 
LSD1  0.40  0.27  0.68 
Src  0.65  1.22  1.88 
α-catenin  2.48  9.29  3.75 
 
PCNA showed up with a low CF of 0.02 in both, the untreated and the CHIR 99021 sample. It seems 
likely, that the PCNA signal is a weak false positive interactor, derived from a protein carry over into 
the bound sample. The signal obtained for the input is above 50000 AFI, while the measured signal in 
the precipitate is below 300 AFI indicating such an unspecific enrichment. 
Six proteins showed a medium enrichment in the untreated sample, five of which stayed nearly 
unchanged after CHIR 99021 treatment, while one (GSK3 β) rose from a medium interaction 
(CF = 0.22) to a strong PPI (CF = 1.98) after treatment. This nine-fold increase was the largest 
observed effect of CHIR 99021 after ECIP on HEK293T cells. The other five medium interactors 
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(PP2A C, CDK2, Src pTyr527, MTA2 and LSD1) showed CFs between 0.11 and 0.40 in the untreated 
samples, remaining nearly unchanged after CHIR 99021 treatment (CFs between 0.14 and 0.41). It 
has to be pointed out, that only PP2A C, CDK2 and Src pTyr527 showed an increase between 
untreated and CHIR 99021 treatment, while for MTA2 and LSD1 a decrease was observed. Total Src 
and α-catenin were identified as strong interacting proteins of β-catenin. Src with a CF of 0.65, which 
increased to a CF of 1.22 after the application of CHIR 99021 (1.88-fold increase). The 3.75-fold 
increase obtained for α-catenin derived from the CF of 9.29 after CHIR 99021 treatment and a lower 
CF (CF = 2.48) for the untreated sample. 
 
4.3.4 Protein interactions of β-catenin induced by drug treatment 
Besides the nine interacting proteins detected in the untreated and the CHIR 99021-treated sample, 
twelve additional PPIs were identified only after treatment (see Table 35). One medium, nine strong 
and two very strong interacting proteins. 
 
Table 35: Co-immunoprecipitated proteins only in CHIR 99021-treated HEK293T cells.  
The averaged CFs for interacting proteins precipitated only after CHIR 99021 treatment in HEK293T cells, are 
represented. Calculation, representation and sorting was done analog to Table 34. 
Analyte Modification untreated + CHIR 99021 + 
HDAC2  -  0.21  
HELLS  -  0.51  
Smad1  -  0.52  
Pontin52  -  0.96  
HDAC3  -  1.18  
GSK3 β pTyr216 -  1.93  
Smad2 
pSer245/pSer250/ 
pSer255 
- 
 
2.04  
TCF1  -  3.13  
TCF4 (60 kDa isoform, # 1481)  -  3.34  
GSK3 α pTyr279 -  8.16  
Axin1  -  10.82  
Axin2 (95 kDa isoform, # 0956)  -  35.88  
 
HDAC2 qualified as a medium strong interactor (CF = 0.21). Nine proteins appeared as strong 
interactors. Among these, HELLS (also called lymphoid-specific presumptive helicase (Lsh)), Smad1 
and Pontin52 (also called Ruvbl1) showed a CF below one. HDAC3 had a CF of 1.18 and for 
Smad2 (pSer245/pSer250/pSer255) a CF of 2.04 was detected. The CFs of the transcription factors 
TCF1 and TCF4 were above three, which marked them as strong interacting proteins. 
GSK3 α (pTyr279) and GSK3 β (pTyr216), as the remaining of the strong interacting proteins, showed 
a CF of 1.93 for the β-variant, which is much lower than the CF for the α-polypeptide of the  
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GSK3 protein (CF = 8.16). Additionally, two very strong interactions were seen: Axin1 and Axin2. For 
Axin1 the CF was just above 10, while the CF of 35.88 for Axin2 was much higher.  
 
4.3.5 Summary  
Interacting proteins were precipitated during Co-IP against β-catenin with the employed high-affinity 
nanobody BC1. The number of interactors increased after CHIR 99021 treatment and frequently the 
CF increased accordingly.  
The raw signal intensities measured for the different β-catenin antibodies rose after treatment. 
Especially the signal observed for the anti-β-catenin (8E7) antibody was striking. Signal for this 
antibody was only detected in the CHIR 99021-treated bound sample (see Table 33). The estimation 
of the CF gave a value of 80 or higher, if comparing the raw values with three times of the SD values 
of the averaged background signal (see 3.4.3.3). 
Differences for the precipitated interaction partners of β-catenin were obvious when comparing the 
results to the cell line screening. Proteins like Pontin52, HDAC3 and MTA2 represent novel 
interactors after ECIP. This might be due to the HEK293T cell line. Besides these, still many of the 
well-known PPIs of β-catenin (GSK3 β, TCF4 and Axin) are seen (see 4.3.3 and 4.3.4). 
The obtained results laid the basis to proceed with the development of the combination of 
intracellular Co-IP with DigiWest. 
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4.4 Intracellular Immunoprecipitation of transfected HEK293T cells 
As shown above (see 4.3), the use of a nanobody as a capturing molecule in a conventional Co-IP 
approach is possible. It is also feasible to express the nanobody BC1 intracellularly to bind to the 
target protein β-catenin and its complex partners before cell lysis. This opens the possibility to 
perform intracellular Co-IPs (ICIPs). Therefore, a version of the nanobody fused to a fluorescent 
protein, resulting in the BC1-chromobody, was used and expressed inside living cells [112]. The 
intracellular expression leads to the advantage of the nanobody binding to native β-catenin 
complexes, before meeting other possible interacting proteins with a higher affinity during cell lysis, 
which are normally spatially separated. 
A stable HEK293T cell line was generated (received from Björn Tränkle, Pharmaceutical 
biotechnology department, Eberhard Karls University of Tübingen), showing a good expression of the 
BC1-chromobody. It was shown, that the BC1-chromobody does not block the functional activity of 
β-catenin and still captures preferably unphosphorylated β-catenin. As a negative control, a HEK293T 
cell line expressing GFP only was used [112]. The growth conditions and treatment were comparable 
to the previous ECIP on HEK293T cells (see 3.2.1). Additionally, the same set of 75 antibodies was 
screened on the samples (three replicas, existing of BC1-input, BC1-bound, GFP-input and GFP-
bound). This set of antibodies is marked in the appendix (see Suppl. Table A) with “**”. In analogy to 
the evaluation done in 4.3, the performed triplicate experiments were screened for PPIs with  
β-catenin. The cutoff limits were adjusted according to the usage of triplicates (see 3.4.3.3) to avoid 
the identification of false positive interactions. Thus, all peaks showing a signal intensity above 45 AFI 
were treated as specific signals. Additionally, the sum of the triplicate signals had to be above 140 AFI 
with a deviation of smaller or equal to 10 AFI in between the individual signals, to guarantee more 
stability among the replicas. Signals of proteins, that bound unspecific to the immunoprecipitation 
matrix were eliminated by defining a specificity limit of the signal intensity being 1.5-fold above the 
negative control for an individual peak. In addition, the sum of all three ratios had to be above 4.3 
with a deviation between the single ratios being beneath or equal to 0.2, which led to a higher 
consistency in between the different replicas. To classify the strength of a PPI, the mean of the 
individually CFs of the triplicates was calculated. For calculating the average of the CFs, the formula, 
described in 3.4.3.3, Equation 3, was applied to each individual replica and the mean was taken 
afterwards. All CFs for the triplicates, along with the obtained raw values for the different input and 
bound samples, are listed in the appendix (see Suppl. Table H). 
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4.4.1 Precipitation of β-catenin variants  
Different β-catenin variants were detected by using the different anti-β-catenin antibodies on the 
immunoprecipitate. The relevant difference to the previous ECIP experiment on HEK293 was the 
intracellular binding of the β-catenin N-terminus by the BC1-chromobody. After calculating the CFs 
and sorting the antibodies in an ascending order according to the mean of the obtained CFs of the 
untreated samples, the same order was obtained as already seen for ECIP in 4.3.2.  
 
Table 36: Caught β-catenin variants during ICIP on untreated and CHIR 99021-treated HEK293T cells.  
The capturing rate is represented for the untreated sample and after CHIR 99021 treatment. For calculating the 
average of the CFs, the formula, described in 3.4.3.3, Equation 3, was applied to each individual replica. 
Subsequently the mean of the triplicate was calculated. The different β-catenin variants detected, were sorted 
in an ascending order referring to their average CF obtained for the untreated sample. β-catenin variants, 
which were only detected in the bound sample, are marked with a “+”. For one antibody no signal was 
obtained without treatment. This cell was marked with “-“. 
Analyte Modification untreated + CHIR 99021 + 
increase 
(fold change) 
β-catenin pSer675 6.83  14.05  2.06 
β-catenin (BD)  9.66  18.16  1.88 
β-catenin pSer552 10.60  52.62  4.96 
β-catenin (Millipore)  11.07  32.31  2.92 
β-catenin  
non-p Ser33/ 
Ser37/Thr41 
31.49  136.82  4.34 
β-catenin (8E7)  -  677.88 + > 12 
 
All antibodies directed towards different β-catenin variants showed much higher CFs on the 
untreated samples in the ICIP experiments than in comparison to the CFs calculated for ECIP  
(1.45 to 3.59-fold increase (see 4.3.2)). This might be caused by the earlier intracellular binding of the 
nanobody to its target protein β-catenin. The two antibodies detecting total β-catenin (BD and 
Millipore) showed similar CFs (9.66 and 11.07) in the untreated samples again and the increase after 
CHIR 99021 treatment is similar as well. A two- to three-fold increase was observable, which resulted 
in CFs of 18.16 and 32.31 for these two antibodies. The antibodies recognizing C-terminal 
phosphorylations at Ser675 and Ser552 of β-catenin, had CFs of 6.83 and 10.60 in the  
untreated sample. These CFs experienced a two to five-fold increase after CHIR 99021 treatment  
(CFs of 14.05 and 52.65). Anti-β-catenin non-phospho Ser33/Ser37/Thr41 was one of the antibodies 
identifying active β-catenin. As in the ECIP results previously, it showed the highest CF (31.49) in the 
untreated sample, but not the highest fold change after the application of CHIR 99021. Here  
the increase was 4.34-fold, which derived in a CF of 136.82 for the CHIR 99021-treated sample.  
Anti-β-catenin (8E7), the second antibody recognizing active β-catenin, showed again no signal in the 
untreated sample or in the input of the CHIR 99021-treated cells, but an enormous increase in the 
amount of recognized β-catenin by this antibody after CHIR 99021 treatment was visible 
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(CF = 677.88). The same difficulty of calculating a fold change arose. As seen before (see 4.3.2) the 
means of the background signals were calculated and their SDs derived to estimate the obtained 
increase. The integrated peak values for the anti-β-catenin (8E7) antibody in each replica were 
devided by three times their individual SD value. This led to an estimated increase of more than 12 of 
the measured peak compared to three times of the SDs of the averaged background signal. 
 
4.4.2 Interacting proteins on HEK293T detected by ICIP 
In comparison to the results obtained for the ECIP, for ICIP only one interacting protein was 
measurable in the untreated and the CHIR 99021-treated sample (see Table 37). 
 
Table 37: Co-immunoprecipitated proteins in untreated and CHIR 99021-treated HEK293T cells.  
The CFs for interacting proteins precipitated in untreated and CHIR 99021-treated HEK293T cells are 
represented, calculated with the formula described in 3.4.3.3, Equation 3. The colorized background stands for 
the strength of the PPI (see Table 19). Proteins were sorted referring to their CF in an ascending order in the 
untreated sample. The averaged CF of the triplicate is shown. In brackets the molecular weight and the distinct 
NMI number are listed, if the analytes need to be differentiated. 
Analyte Modification untreated + CHIR 99021 + 
increase 
(fold change) 
α-catenin  4.38  10.89  2.49 
 
α-catenin represented a strong interactor of β-catenin, with a high capturing rate for both the 
untreated sample (CF = 4.38) and the sample after CHIR 99021 treatment (CF = 10.89). After 
treatment, the interaction surmounted the cutoff limit of 10 and thus α-catenin was classified as a 
very strong interacting protein. Calculating the ratio between the two different treatments resulted 
in an 2.49-fold increase. 
 
4.4.3 Modulation of β-catenin protein complexes after drug treatment 
Also the number of PPIs detected after CHIR 99021 was lower than the interactors observed for ECIP. 
Only five interacting proteins were seen, of which three were classified as strong and two as very 
strong interactors. 
 
Table 38: Co-immunoprecipitated proteins only in CHIR 99021-treated HEK293T cells.  
The averaged CFs for interacting proteins precipitated only after CHIR 99021 treatment in HEK293T cells, are 
represented. Calculation, representation and sorting was done analog to Table 34. 
Analyte Modification untreated + CHIR 99021 + 
GSK3 β    2.62  
TCF1  -  3.16  
GSK3 β pTyr216 -  3.28  
Axin1  -  50.44  
Axin2 (95 kDa isoform, # 0956)  -  113.79  
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The three strong interacting proteins, GSK3 β, TCF1 and GSK3 β (pTyr216), showed very similar values 
for the CFs (between 2.62 and 3.28). Axin1 and Axin2 were categorized as very strong interactors of 
β-catenin, with CFs above 10. Axin1 had a CF of 50.44 after CHIR 99021 treatment, while for Axin2 
the CF was even higher with a value of 113.79. 
 
4.4.4 Comparison of extracellular and intracellular Immunoprecipitation 
Comparing the interacting proteins received from ECIP and ICIP it became apparent, that less PPIs 
were detected by ICIP for both treatments. For ECIP it was possible to identify nine proteins as 
interactors in both samples and an additional 12 after CHIR 99021 treatment. In ICIP only one PPI 
was detected both in the untreated and the CHIR 99021-treated sample and five more after 
CHIR 99021 treatment. Furthermore, only already well-known interactors were seen during ICIP, 
while no novel ones were obtained. 
Overall higher CFs were detected after ICIP for the untreated sample in comparison to the same 
interacting proteins captured during ECIP. After CHIR 99021 treatment the capturing rates were 
lower for the addressed β-catenin variants after ICIP compared to the ones calculated for ECIP. But, 
the obtained interacting proteins during ICIP still showed a rise in the derived CFs in comparison with 
the same interacting proteins in ECIP. The obtained raw values revealed, similar or slightly higher AFI 
values being derived for the different antibodies against β-catenin or β-catenin interacting proteins in 
the input samples for all replicas after ICIP compared to the AFI values received after ECIP. 
 
4.4.5 Summary 
In conclusion an increase after CHIR 99021 treatment, for antibodies detecting β-catenin, was visible. 
Additionally, the same interesting result as in 4.3.2 for the anti-β-catenin (8E7), was seen. This 
antibody generates signal only in the CHIR 99021-treated bound sample (see Table 36).  
Surprisingly, much less interacting proteins were precipitated during ICIP with the intracellularly 
expressed BC1-chromobody in comparison to the earlier performed ECIP. Again, CHIR 99021 
treatment led to an increase in the amount of PPIs detected and also in the CF detected for  
α-catenin, which is the only protein measured as an interactor already in the untreated sample  
(see 4.4.2 and 4.4.3). In addition, all detected interacting proteins were well-known β-catenin 
interactors, with a strong or very strong interaction. Thus, no novel PPIs were identified. 
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5. Discussion 
5.1 Co-Immunoprecipitation and high throughput DigiWest 
For the detection and discovery of protein-protein interactions, the Co-Immunoprecipitation is a 
straightforward and widely used approach [95, 112]. The Co-IP is derived from the classical 
immunoprecipitation. The experimental procedure is performed identically, yet during the 
subsequent analysis, proteins are identified, which are precipitated together with the target protein 
[135]. Interactions are typically confirmed directly in gel or after blotting on membranes by 
immunological methods, which is a gold standard [94, 136]. Mass spectrometric approaches (MS) 
[232, 233] have become important in recent years. Antibody-based detection allows only a limited 
testing and is usually employed to verify known or highly predicted interacting partners, while MS-
based approaches allow wide ranging analyses, which are technically rather complex, but hold the 
advantage of being able to screen for unknown complex members or interacting proteins from the 
Co-IP products and to explicitly identify them. MS facilitates the unbiased analysis of samples and 
allows de novo identification of changes in the proteome. It thus has a massive impact on signaling 
research [234]. Hence, for identifying PPIs, Co-IP combined with MS became the method of choice 
lately [92-94], but is yet technically challenging. MS-based approaches show some major 
disadvantages: the limited throughput, the cost and complexity of the technique, the requirement of 
a higher amount of material and the difficulty of the reliable detection of differences in the 
phosphorylation states of signaling proteins. 
To address and overcome these disadvantages, a novel and recently described, digitalized, high 
output Western blotting approach, termed DigiWest [91] was applied. In this approach, the 
conventional Western blot [235] is adapted to a bead-based microarray platform and thus adds 
advantages, such as high throughput and low material consumption [91], to the highly reliable and 
well-established classical technique. This new method was shown to be capable of providing  
high-resolution data on protein phosphorylation and expression. Among the advantages of this 
approach are the ability to run focused proteomic studies to detect differences in the activation 
states of cellular signaling cascades and the capability of performing multiple assays in parallel [91]. 
By linking this bead-based immunoassay to a previously carried out, conventional Co-IP, a new 
screening approach was generated. This linkage results in a high throughput tool to screen for PPIs 
and henceforth it is possible to functionally analyze the signaling state of intracellular pathways, as a 
highly parallel analysis of protein expression and modification status is enabled [91]. 
An additional benefit of combining these two techniques, Co-IP and DigiWest, is the possibility to 
distinguish a variety of posttranslational modified protein fractions from each other in parallel. The 
interrogation of activation states of regulatory cascades by PTMs, helps to provide a better 
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understanding of cellular processes [91]. Combining Co-IP with a target-specific antibody and a novel 
readout system for immunoblots provides a versatile approach to study endogenous complexes and 
to identify dynamic PPIs, e.g. in cancer relevant signaling pathways. 
In this thesis, the focus is set on the detection of protein complexes comprising the central regulator 
of the canonical Wnt pathway, β-catenin, in various cell lines (55.1c, 70.4, HepG2, HB35 and 
HEK293T).  
Canonical Wnt signaling is one of the most relevant regulatory circuits of cell fate during the lifetime 
of any animal [36]. Besides its participation in many developmental processes and the indispensable 
role in tissue homeostasis, it is crucially linked to carcinogenesis [25-27]. The key effector of the 
canonical Wnt signaling, β-catenin, is responsible for signal transduction into the nucleus and 
inducing the transcription of specific Wnt target genes there. Thereby, these genes are responsible 
for modulating cell fate in various cells and tissues [36]. Aberrations or imbalances in the structure of 
β-catenin or the characteristics of the Wnt/β-catenin signaling often lead to the formation of 
diseases and deregulated growth properties linked to cancer or metastasis [36]. β-catenin, as the 
main molecule in the canonical Wnt pathway, cooperates with a great variety of interaction partners, 
which are either able to affect transcriptional output, permit its direct crosstalk with other 
transcription factors or provide a linkage to signaling cascades [36]. Thus, it is of high interest to gain 
a deeper insight into this altered signaling cascade and the spatially / temporally coordinated PPIs of 
β-catenin occurring in multiple cellular processes [112]. 
As an initial approach, a conventional Co-IP approach was performed, in the beginning by employing 
a β-catenin-specific antibody for precipitating protein complexes. As the system to study PPIs of  
β-catenin, differently mutated hepatoma cell lines were chosen. The Wnt/β-catenin signaling plays a 
major role in liver development and homeostasis, thus these cell lines depict a suitable model to 
study aberrant liver signaling and its influence on disease/cancer formation [236]. 
I aimed at gaining a higher resolution picture of the precipitated and isolated β-catenin complexes as 
well as the various interaction partners of the target protein (e.g. α-catenin and GSK3 β) via probing 
the precipitate with hundreds of antibodies. Thereby, differences in the expressed amount of  
β-catenin were seen and additionally unknown and unfamiliar interaction partners of β-catenin were 
detected.  
This workflow was further developed by changing the cell system from hepatoma cells to a  
well-established and good characterized cell line, the HEK293T cells. HEK293 is a human epithelial 
cell line, derived from embryonic kidney cells, which is suitable for transient transfection and protein 
expression. The cell line was transformed by the early region of adenovirus type 5 with an inserted 
gene for the temperature-sensitive SV40 T-antigen mutant tsA1609 [237, 238]. There are no known 
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mutations in proteins associated with the Wnt pathway and thus it should provide a relative 
undisturbed system for studying the mechanisms of this pathway [124]. 
In addition, the β-catenin-specific capturing antibody, directed towards a C-terminal epitope of the 
protein, was replaced by a nanobody, called BC1. This nanobody binds at the N-terminus of β-catenin 
with a high-affinity. By the usage of a nanobody, especially the limitations of antibodies used for  
Co-IP, which arise due to steric hindrances and large binding interfaces, can be overcome [112]. 
Another convincing characteristic of this binder is the ability of expressing it intracellularly, which 
enables the performance of intracellular Co-IPs [112]. The BC1 nanobody, used in this experimental 
setting, was recently designed and described in some detail. Additionally, its capability for Western 
blot was shown [112]. Among its characteristics are for example a detection level down to  
1 ng/ml and it is assumed, that the binder detects preferably an unphosphorylated  
three-dimensional epitope of β-catenin. This epitope is located close to the N-terminal SSTS-motif, 
which regulates the stability of the protein. The ability to bind and precipitate a high level of  
β-catenin especially after inhibiting GSK3 β might be based on the simplified accessibility of the 
epitope or on posttranslational changes of the epitope, which induce an increased affinity [112]. 
 
5.1.1 Utilization of a novel intracellular binding molecule 
To employ the BC1 nanobody, initially only used for conventional Co-IP, in intracellular IP, it was 
fused to the fluorescent protein tagGFP to detect endogenous β-catenin within living cells, resulting 
in the BC1-chromobody. A stable cell line, with a good expression of the BC1-chromobody, was 
generated [112]. After transfection and cellular expression of the chromobody, it becomes visible 
and can be used to trace the dynamic re-localization of β-catenin using fluorescence microscopy. 
Another interesting feature is the intracellular binding capacity and the possible use for ICIPs [112]. 
An advantage of an early intracellular binding might be the binding of protein complexes before 
encountering additional high affinity binding proteins during cell lysis, which are spatially separated 
in the original cellular structure. An exchange of low-affinity proteins to high-affinity proteins during 
lysis is still possible, but it was tried to be prevented this by using a very gentle lysis procedure during 
Co-IP. 
It was shown, that the chromobody does not hinder the functional activity of β-catenin and still binds 
preferably diffusible, non-phosphorylated β-catenin. Additionally, it is possible to visualize the 
enrichment of β-catenin and its relocation into the nucleus upon compound treatment [112].  
The combination of the conventional Co-IP approach linked to the earlier described DigiWest might 
provide a versatile approach to study endogenous complexes, to uncover dynamic PPIs and  
protein-protein modifications in general. This was exemplary shown for the cancer relevant Wnt 
signaling pathway, with its key player β-catenin in this work. 
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To establish the newly developed screening approach, consisting of Co-IP and DigiWest, four 
different hepatoma cell lines derived from two species were chosen. These cell lines seemed to be 
promising for the detection of a plethora of β-catenin interaction partners; three of them carrying a 
heterozygous activating mutation in the CTNNB1 gene, encoding for β-catenin (55.1c, HepG2, HB35), 
while one presenting the wild type (70.4) (see 1.3.2 – 1.3.4). As mentioned before: The cell system 
was changed and HEK293T cells were selected, in order to use a more general cell model during the 
further development of the experimental design and the BC1 nanobody as capturing molecule was 
introduced.  
For the establishment of a novel screening approach and showing its significant potential, the 
different Co-IP workflows (conventional Co-IP, ECIP and ICIP) were linked to the DigiWest. As the 
DigiWest provides a technique, which is able to visualize changes in the modification status of 
proteins and identifies dynamic variations in the PPIs, it is particularly suitable to detect differences 
upon compound treatment. 
 
5.1.2 Modulation of complex composition by drug treatment 
Two different inhibitors were chosen, which represent different cellular conditions: The first selected 
inhibitor, CHIR 99021, is a small organic molecule, which inhibits GSK3 α and GSK3 β by competing 
for their ATP-binding sites with a high specificity and potency [221, 222]. Inhibition of GSK3 plays an 
important role in the activation cascade of Wnt/β-catenin signaling. When Wnt signaling is active, 
GSK3 is inhibited [222]. After GSK3 loses its ability to phosphorylate β-catenin at the SSTS-motif, 
which marks it for ubiquitin-mediated degradation, unphosphorylated β-catenin is stabilized and 
accumulates in the cytosol. The accumulated β-catenin translocates to the nucleus and binds to 
transcription factors, mostly members of the TCF/LEF family. This leads to an active transcription of 
Wnt-regulated target genes [36]. During suppressed Wnt signaling, β-catenin is phosphorylated by 
GSK3 and targeted for ubiquitin-regulated degradation at the proteasome [44, 45]. Therefore, 
CHIR 99021 is an adequate tool to mimic the activated status of the canonical Wnt pathway [222]. As 
all used cell lines are either wild type according to their β-catenin expression or show a heterozygous 
deletion of the CTNNB1 exon 3 gene, they should be susceptible for a stimulation of Wnt signaling 
with CHIR 99021. In comparison to CHIR 99021, which leads to an enrichment especially of the free 
cytosolic [222], non-phosphorylated β-catenin (sometimes also called “active” β-catenin) in the cell, 
as it induces a decrease in β-catenin phosphorylation [239], a second inhibitor was applied, called 
MG132. MG132 is a potent, reversible and cell-permeable proteasome inhibitor. It has a rapid 
influence on the ubiquitin-proteasome pathway and blocks the proteasomal degradation of 
ubiquitinated proteins [223, 224]. β-catenin is one of the proteins, which is degraded by this 
degradation pathway [45]. Hence, not only the activated, non-phosphorylated form of β-catenin 
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should be present and enriched in the MG132-treated cells, but also phosphorylated and in addition, 
ubiquitinated forms of β-catenin and other proteins, which are degraded via the  
ubiquitin-proteasome pathway, should be available in a higher quantity. Subsequently a general 
enrichment of proteins degraded through the proteasome in the cell was expected. 
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5.2 Captured posttranslational modified forms of β-catenin 
Increasing evidence propose that PTMs, such as phosphorylation, ubiquitination, acetylation and 
others [36, 240], of key players of the Wnt/β-catenin pathway are crucial for its activation. PTMs play 
an essential role in a highly dynamic system, which does not require new protein synthesis, and 
facilitates a quick change of β-catenin’s properties, by covalently adding functional groups or 
presenting altered binding platforms [62, 241]. By that, they enable positive or negative  
crosstalk between each other, which depicts an important regulatory mechanism for signal 
transduction [241-243]. The different added PTMs result in changed complexation of β-catenin, as 
they determine its location and its diverse cellular roles [244].  
 
 
Figure 31: Structure of β-catenin and its phosphorylation sites. 
A schematic diagram of β-catenin (781 aa) represents its structure, divided into the NTD, the ARM domain, 
composed of 12 ARM sequences (each approximately 40 aa long), the Helix-C and the CTD. Additionally, the 
phosphorylation sites are shown: those in green/yellow promote its degradation, while those in purple 
enhance the signaling activity. The kinases, responsible for phosphorylating at the marked positions, can be 
obtained in Table 39 (Figure adapted from [36]). 
 
The operation mode of β-catenin can be regulated through phosphorylation by a large, yet defined 
set of different kinases (see Table 39) [36, 62]. Phosphorylations of β-catenin, especially at the  
C-terminal end, often result in the enhancement of signaling [36] and/or the stabilization of the 
protein as well as its nuclear accumulation [189, 245, 246]. On the contrary, phosphorylations at the  
N-terminal SSTS-motif introduced by kinases CK1 and GSK3 α/β, promote the degradation of  
β-catenin via β-TrCP-mediated proteolysis (see Figure 31) [43, 45, 62]. The weakening of the 
membrane-associated β-catenin complex, the catenin-cadherin interaction, and an impairment of 
the adhesive functions of β-catenin is also caused by phosphorylations [247-249]. Thus, β-catenin is 
guided towards an increased signaling and β-catenin driven transcription is induced [36, 250]. 
Phosphorylations of β-catenin towards the last ARM repeats enhance the possibility for additional 
interaction partners to bind. Causative is the development of a bond between the unphosphorylated, 
last ARM repeat and the partially flexible Helix-C, which prevents interacting proteins from binding 
[36]. The Helix-C is a specific conserved helix, which is located adjacent to the last ARM repeat, 
proximally to the CTD (see Figure 31) [36, 251]. As long as the CTD is folded and bound to the ARM 
repeats, interaction partners, such as transcriptional co-activators, cannot bind [251]. If the fold back 
of the C-terminal tail is prevented, the ARM region and the Helix-C are stabilized and stay open  
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[62, 250]. Hence, remain accessible for additional PTMs [250], which can lead to an increased 
recruitment of co-activators of β-catenin-mediated transcription [36, 58, 252]. 
 
Table 39: PTMs control the functional output of β-catenin.  
Antibodies against all of the listed PTMs of β-catenin, which are summarized with their functional impacts, 
were tested during the experimental setup (Table adapted from [36]). 
Modification Sites Enzyme Function Reference 
Serine/threonine 
phosphorylation 
S33, S37 GSK3 
degradation,  
provides sites for β-TrCP 
[253, 254] 
T41 GSK3 
degradation,  
phosphorylation relay sites 
[173] 
S45 CK1 degradation, priming for GSK3 [172] 
S552 Akt, PKA signaling [246] 
S675 PKA 
signaling,  
enhancement of CBP binding 
[246, 252] 
S675 PAK 
signaling,  
promoting stability and transcription 
[255] 
 
As mentioned earlier (see 4.2.1 and 4.2.3), different β-catenin pools were addressed by the use of 
specific antibodies during detection. On the one hand, this served as a control for the success of the 
Co-IP, on the other hand, it was hoped to gain a deeper insight into the role of different β-catenin 
PTMs. Besides the listed phosphorylation sites in Table 39, which were screened throughout the 
experiments, various additional serine/threonine, but also tyrosine residues of β-catenin can be 
posttranslational phosphorylated by different enzymes, but weren’t analyzed here, since no specific 
antibodies were available.  
Nine different β-catenin-specific antibodies were used for the experiments of this thesis. Two of 
them recognizing total β-catenin (BD and Millipore), differing in their binding region  
(N- and C-terminal), while seven antibodies addressed different PTMs of the target protein. 
The obtained differences in recognition of β-catenin by the BD and the Millipore antibody, might be 
explained by the polyclonality of the Millipore antibody. This antibody is intended to recognize not 
only one, but multiple epitopes on the β-catenin antigen, and can have a higher sensitivity than a 
monoclonal antibody, like the one purchased from BD Biosciences [256]. Both treatments, 
CHIR 99021 and MG132, usually lead to an increase of β-catenin, which is visible in the detected CFs. 
Although the raw data show a general decrease after treatment compared to the untreated samples 
(see Suppl. Table C – Suppl. Table H). This decrease can be caused by the cytotoxicity of MG132 [257] 
or by the enhanced proliferation after CHIR 99021 application and is seen for example in 70.4 or 
HB35 cells. The CFs for all different antibodies detecting β-catenin rise both after CHIR 99021 and 
MG132 application (fold changes of > 1.3 for 70.4 cells and > 1.8 for HB35 cells). However a distinct 
decrease in the raw data is obtainable for CHIR 99021 in HB35: The obtained raw input values are  
0.1 – 0.6 times of the raw values detected for the untreated input sample. For MG132 the decrease is 
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best observable in 70.4 cells: The obtained raw input values are 0.15 – 0.6 times of the raw values 
detected for the untreated input sample. For CHIR 99021 an activation of Wnt signaling without a 
concomitant toxicity was shown [258]. The enhanced proliferation, caused by an active canonical 
Wnt pathway, could result in the enrichment of the protein entity in the cell. This enrichment might 
lead to a shift in the amount of detected β-catenin coupled to the bead surface in comparison to the 
remaining proteins. 
As mentioned earlier, the anti-β-catenin (non-phospho Ser33/37/Thr41) antibody recognizes its 
target protein N-terminally and specifically detects the active β-catenin variant. β-catenin with an 
unphosphorylated SSTS-motif is not amendable to degradation, accumulates in the cytosol, is able to 
translocate into the nucleus and activates the transcription of Wnt/β-catenin target genes. The 
amount of β-catenin captured after CHIR 99021 treatment both for ECIP and ICIP on HEK293T cells is 
substantially higher than for the untreated cells: This indicates too the enrichment of  
non-phosphorylated β-catenin in the cytosol after GSK3 inhibition by CHIR 99021 treatment. 
Antibody 8E7 and the anti-β-catenin (non-phospho Ser33/Ser37/Thr41) antibody recognize both an 
active form of β-catenin. The similar pattern observed for both the DigiWest bar graphs and the 
conventional Western blots after CHIR 99021 treatment for these antibodies supports this 
characteristic. The very high capture rate of the antibody 8E7 found only after CHIR 99021 treatment, 
is due to the fact that specific signal in the DigiWest is only obtained after treatment. This might be 
due to a lower affinity of the 8E7 antibody and accordingly a lower signal detected during readout. In 
untreated cells, the available amount of unphosphorylated β-catenin in the cytoplasm is known to be 
low, since a permanent degradation takes place. The antibody 8E7 might have difficulties to detect 
these low β-catenin levels in the untreated samples. After CHIR 99021 treatment the 
unphosphorylated β-catenin accumulates, but is still not detected in the input sample by the 8E7 
antibody. This points to a low antibody affinity, which is supported by the much higher signals 
obtained for the non-phospho Ser33/Ser37/Thr41 antibody during ECIP and ICIP for all samples  
(see Suppl. Table G – Suppl. Table H). 
The anti-β-catenin pThr41/pSer45 antibody yielded very low signals. A similar outcome was observed 
for antibodies directed towards other phosphorylations (pSer33/Ser37/Thr41 and pSer45) of the 
SSTS-motif. That can be due to a low affinity of these antibodies. An absence of one allele of CTNNB1 
exon 3, which results in an N-terminally truncated protein, is a characteristic trait in most of the 
screened cell lines. This heterozygous truncation might additionally lead to lower detected signals for 
these antibodies. Deletion of exon 3 and the expression of N-terminally truncated  
β-catenin leads to activated Wnt signaling, since a part of the SSTS-motif is deleted and the β-catenin 
can not be flagged for degradation. A higher amount of active β-catenin is available in cells carrying 
these variants, due to the lack of these specific phosphorylation sites. 
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Contrary to degradation-promoting phosphorylations at the N-terminal SSTS-motif, phosphorylations 
of β-catenin, especially if located at the C-terminus, lead to enhanced signaling activity [36]. Among 
these phosphorylation sites are Ser552 and Ser675 at the C-terminus of β-catenin. These lead to a 
stabilization of the unfolded ARM region and Helix-C, and a general enhancement of signaling activity 
[189, 245, 246]. The phosphorylation of β-catenin at Ser552 indicates that the protein is able to 
dissociate from the membrane bound protein complex that mediates cell-cell contacts and can 
accumulate in the nucleus [246]. Phosphorylation at Ser675 leads to an increased recruitment of co-
activators of β-catenin-mediated transcription, such as CBP (CREB-binding protein) binding, and 
results in a promotion of transcription [36, 58, 255]. When Ser675 is phosphorylated, the β-catenin 
structure opens up, is stabilized and an increase in Wnt signaling by recruiting transcriptional 
activators, can be observed [252, 255]. It was shown for HEK293T cells that exposing the cells to a 
GSK3 inhibitor, such as CHIR 99021, results in the increased presence of β-catenin phosphorylated at 
Ser552 and Ser675. The level of β-catenin phosphorylated at these residues increases concomitantly 
with an increase of total β-catenin and free β-catenin [244]. It was postulated that the C-terminal 
phosphorylation of β-catenin is linked to canonical Wnt signaling, but still the regulatory functions of 
Ser552 and Ser675 phosphorylations are little characterized and need further investigation [244]. The 
increase of β-catenin phosphorylated C-terminally was observed after CHIR 99021 treatment 
accordingly. As MG132 also leads to a general rise in the cellular protein amount, an increase in the 
CF of precipitated β-catenin was expected and also observed here. 
The increasing need for the availability of improved techniques, which are able to detect PTMs was 
expressed recently [62]. Here, such an approach was developed and shows its ability to provide 
insights about differently phosphorylated forms of the target protein β-catenin. However, still little is 
known about the effective and combinatory interaction of PTMs both in ON and OFF state of the Wnt 
signaling [62]. It is important to identify specific Wnt pathways inhibitors, as an aberrant activation of 
this signaling cascade results in the development of various diseases, such as cancer [62, 259]. 
Modulating PTMs of components of the Wnt pathway, like its key player β-catenin, might be a 
promising alternative for drug development, as Wnt signaling itself is too complex and thus difficult 
to target specifically, while the direct inhibition of β-catenin can’t be undertaken without destroying 
its various functions within the cellular context [28, 62, 260].  
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5.3 Detection of known PPIs for β-catenin in different cell lines 
With the possibility to detect different β-catenin pools, a comprehensive search for proteins 
interacting with β-catenin was started. To obtain information about β-catenin protein complexes, a 
closer look at formerly published PPIs was taken. As MS-based approaches allow wide ranging 
analyses and result in large data sets, most of these PPIs were detected via MS. A common procedure 
is to list the detected interacting proteins in databases, such as BioGRID, UniProtKB and IntAct. For a 
broad characterization of the Wnt/β-catenin pathway and the complex partners of β-catenin, an 
extensive database and literature research was undertaken. The general description of the protein 
function was obtained at the UniProtKB database, which was used as a first reference. By that a 
plethora of antibodies (> 500) were identified and matched with more than 1000 available 
antibodies. This lead to a set of 344 particularly interesting protein antibodies, which covered the 
Wnt-/β-catenin pathway and allowed an additional glance at the spatial cellular surrounding, to 
display a possible crosstalk with other signaling cascades or novel protein interactions. 
While a large number of proteins, known to interact directly with β-catenin, were precipitated by  
Co-IP, only one protein was detected consistantly in all analyzed cell lines under all treatment 
conditions: α-catenin. In the cytosol, α-catenin exists as a monomer or a homodimer [148] with 
different binding properties. The monomeric α-catenin binds strongly to E-Cadherin-β-catenin, 
whereas the dimer preferentially binds Actin filaments. There is no simultaneously binding between 
the adhesion molecule E-Cadherin and the Actin cytoskeleton via α-catenin [149, 155]. Depending on 
β-catenin, it can accumulate in the nucleus and interact with β-catenin and TCF there [261]. The high 
amount of signal obtained for α-catenin in 55.1c in comparison to other cell lines, can be explained 
by a high amount of α-catenin present in this cell line. The detected amount of α-catenin is already 
higher compared to the other cell lines, according to the raw input values. 
Besides the presence of α-catenin in all analyzed samples, several other known complex partners of 
β-catenin were detected during the experiments in the different cell lines. Especially prominent are 
proteins, which are present in the membrane-associated β-catenin complex or participate in the  
β-catenin destruction complex (see Figure 2).  
E-Cadherin, as a central interacting protein, is part of the membranous complex linked to β-catenin. 
This transmembrane glycoprotein and endogenous adhesion molecule is one of the best 
characterized interaction partners of β-catenin. It associates with cytoplasmic proteins like α-catenin 
and β-catenin at its specific cytoplasmic domain [174, 262, 263]. The complexation of  
cadherin-catenin provides a dynamic link to the Actin cytoskeleton [149, 174, 175] and plays an 
important role maintaining the epithelial integrity [264]. The dissociation of the E-cadherin/β-catenin 
adhesion complex represents a key step in EMT and promotes metastasis [265] as well as the 
development of HCC [266]. Without Wnt signaling, most of the available β-catenin is either bound to 
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E-Cadherin or phosphorylated and marked for degradation by the destruction complex in the 
cytoplasm [36]. 
Also part of the membrane-associated β-catenin complex is β-Actin, which is ubiquitously expressed 
in all eukaryotic cells and is involved in various types of cell motility. It is one of the cytoplasmic 
Actins and is an extremely well conserved structural protein [153, 154]. Therefore, it is considered as 
housekeeping protein. β-Actin binds to α-catenin, which could provide a link to β-catenin [149, 155]. 
But α-catenin is not able to bind simultaneously to β-catenin and β-Actin. Still the function of  
α-catenin as a molecular switch [149, 155] might create an additional explanation for precipitating 
small amounts of β-Actin together with β-catenin besides the possibility of detecting a weak false 
positive interaction due to a small carry over into the bound sample, as it was seen for GAPDH. 
A second central regulatory complex associated with β-catenin is the β-catenin destruction complex. 
Seven proteins, which are part of this complex, occur repeatedly during the analysis of the different 
cell lines: APC, Axin1, Axin2, CK1 α, CK1 δ, GSK3 α and GSK3 β. 
The tumor suppressor protein APC, represents a scaffold protein in the β-catenin destruction 
complex [151]. Newly synthesized β-catenin or already existing β-catenin, which is released from the 
adherens junctions, is captured by APC or Axin. Both proteins establish a basis for allowing other 
proteins like GSK3 β or CK1 to posttranslationally modify β-catenin [36, 41, 151, 267]. APC plays a key 
role in the β-catenin turnover by participating in the destruction complex and also via its own direct 
binding to β-catenin. Various functions for APC have been suggested, e.g. increasing the binding 
affinity of β-catenin to the destruction complex, but its actual role remains still enigmatic [41, 152]. 
Axin1 and its homolog Axin2 are scaffolding proteins, that contain separate binding sites for APC,  
β-catenin, GSK3 β, CK1 and possibly other proteins [36, 151, 152]. They act as the core protein of the 
β-catenin destruction complex [268], which is required for regulating β-catenin levels through 
phosphorylation and ubiquitination as well as modulating Wnt signaling [168]. 
CK1 α (Caseinkinase 1 α) and CK1 δ (Caseinkinase 1 δ) are members of the CK1 family. Caseinkinases 
are responsible for phosphorylating serine/threonine residues of their target proteins [49]. CK1 α is 
one isoform of the priming CK1 kinases, which phosphorylates β-catenin at Ser45 [169] and is strictly 
required for subsequent phosphorylation of Thr41, Ser37 and Ser33 by GSK3 β. A depletion of CK1 α 
leads to an inhibition of β-catenin phosphorylation, which is a prerequisite for the degradation 
process. This results in an increase of β-catenin and in excessive Wnt/β-catenin  
signaling [36, 172]. CK1 δ is a key regulator of various cellular growth and survival processes, 
including Wnt signaling [269]. This kinase was, like CK1 α, identified for being in charge of the initial 
Ser45 phosphorylation of β-catenin [49, 169] and can therefore also contribute to Wnt-induced  
β-catenin stabilization [187].  
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The other two found proteins, belonging to the β-catenin destruction complex, are the two 
homologous forms of GSK3: GSK3 α (52 kDa) and GSK3 β (47 kDa) [170]. GSK3s are involved in many 
cellular processes, including the Wnt pathway. Both mammalian homologues seem to function 
identically in Wnt signaling, the difference in size is caused by an amino-terminal glycine-rich 
extension of unknown function [270]. GSK3 binds Axin at a central region and phosphorylates  
β-catenin at Thr41 [173], Ser37 and Ser33 [172] subsequent to the initial phosphorylation by CK1 
[169]. A tyrosine phosphorylation on the activation loop of GSK3, either at Tyr216 of GSK3 β or at 
Tyr279 of GSK3 α increases the enzyme’s activity [171, 271, 272]. 
It can be assumed that the developed screening approach works reliably, as it was possible to 
identify and verify well-known interacting proteins of the addressed target protein β-catenin. Thus, 
we concluded that other detected PPIs are true and classified these as authentic interactions. Not all 
of the found interacting proteins, assigned to one of the two described complexes, are seen in all 
screened cell lines. In addition and after comparison to the results obtained for the untreated cell 
lines, some of the PPIs show a higher CF or are detected only after treatment with CHIR 99021 or 
MG132. This rise in capturing or in the amount of detected interacting proteins can be explained by 
the influences through treatment which might vary for the different cell lines as all of them possess a 
different genotype. 
CHIR 99021 inhibits GSK3 and thereby prevents the phosphorylation of β-catenin. The binding of  
β-catenin to the remaining, now inactive destruction complex is not disabled. It can be assumed that 
after CHIR 99021 treatment, the existing destruction complexes get saturated with β-catenin. In the 
untreated cells a steady-state between binding of β-catenin to the destruction complex and its 
dissociation as well as its subsequent degradation is reached. Consequently, a proportionally higher 
amount of β-catenin can remain bound in the destruction complex after CHIR 99021 treatment as 
there are in total more available β-catenin molecules in the cytosol due to their  
CHIR 99021-dependent accumulation. Accordingly more proteins of the destruction complex are 
precipitated after CHIR 99021 treatment as β-catenin is still bound to them. The higher amount of 
cytololic, unphosphorylated β-catenin leads in addition to the distribution of β-catenin to other 
subcellular locations, as they for example its translocation into the nucleus. This simplifies the 
possibility for other proteins to form complexes and enhances the amount of precipitated interaction 
partners. MG132 on the other hand, as an inhibitor of the proteasome, causes a general enrichment 
of proteins, which use this degradation pathway. This presumably leads to an enrichment of  
β-catenin interactors, such as the membrane-associated complex partners or members of the 
destruction complex, which are degraded by the proteasome. 
Hence, dynamical, intracellular changes emerging through the application of different drug 
treatments become visible in this approach. This offers the possibility of directly analyzing the effects 
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of compound treatment on various proteins and proximate modulation of signaling cascades at once. 
Additionally, the usage of diverse samples, such as cell lines, but also lysed tissues, etc. is feasible and 
make the approach very versatile. 
  
  Discussion 
  125 
5.4 Wnt proteins detected after Co-IP in hepatoma cells 
19 Wnt proteins are encoded by the mammalian genome. It was suggested that Wnts can activate a 
variety of different signaling pathways, which again intersect with numerous other intracellular signal 
transduction pathways [150]. All mammalian Wnt proteins analyzed so far, can either activate or 
inhibit the canonical Wnt signaling pathway [38]. Wnts are grouped into so-called “canonical” Wnts 
and “noncanonical” Wnts, following the original assumption of being assigned either to “canonical” 
or “noncanonical” signaling pathways. Recent studies however showed, that the classification of 
Wnts into these two categories does not hold up to scrutiny. This is especially true, as Wnts 
themselves control and modulate multiple pathways [150]. All Wnt proteins are hydrophobic 
glycoproteins, which undergo heavy PTMs such as palmitoylation and glycosylation prior to transport 
and release into the extra-cellular milieu [35]. These lipid modifications are essential for their 
function [273]. Palmitoylation and glycosylation are needed to initiate the targeting of Wnt proteins 
to the plasma membrane to secret them, while palmitoylation also supports the binding of Wnts to 
their receptors [274]. After palmitoylation in the ER by the porcupine acyltransferase, Wnts are 
transported and packed in secretory vesicles, which is controlled by the multi-pass transmembrane 
protein Wntless/Evi. Wntless/Evi is present in the Golgi and/or the plasma membrane and was 
shown to interact with Wnts [273, 275, 276]. Once released into the extra-cellular milieu, they can 
pass signaling in an autocrine or paracrine manner (see Figure 32) [277]. 
Secreted Wnt proteins in the canonical Wnt signaling pathway initiate signaling by binding to their 
membrane receptors (FZDs) and their co-receptors (LRP5/6) [38]. This primary signaling leads to the 
phosphorylation of DVLs (DVL1, DVL2 and DVL3) [48, 49] and is further transduced to the 
multicomplex, consisting out of APC, GSK3, Axin and β-catenin. This complex dissociates as a result 
and β-catenin is stabilized [53]. As mentioned before, the stabilized β-catenin accumulates in the 
cytosol and translocates into the nucleus, where it is able to bind to transcription factors and activate 
transcription of Wnt/β-catenin pathway-specific target genes (see Figure 32) [36]. 
Wnt3a is the most prominent member of the “canonical” Wnts, which bind to the FZD receptor [53]. 
Yet, also Wnt7b, formerly classified as “noncanonical” Wnt, was shown to bind to two different FZD 
proteins: FZD1 (Frizzled1) and FZD10 (Frizzled10) [167]. Both were demonstrated to affect the 
canonical Wnt pathway in an activating manner [152, 167], but for Wnt3a a much higher activation 
was observed, than for Wnt7b in comparison [278]. Wnt11 is an example for a Wnt protein that 
holds dual signaling capabilities [150], on the one hand it was shown to inhibit the canonical  
β-catenin-dependent Wnt pathway [38], but it is also well-known for its ability to trigger 
noncanonical Wnt signaling [279]. All three mentioned Wnts were detected interactors of β-catenin 
in this work.  
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Figure 32: Wnt secretion and initiation of canonical Wnt signaling. 
Wnt proteins become palmitoylated in the ER (Endoplasmic Reticulum) by the porcupine acyltransferase after 
being produced. The multi-pass transmembrane protein Wntless/Evi controls the further transport and 
secretion of the Wnt proteins in secretory vesicles, such as exosomes. Wntless/Evi is present in the Golgi and 
the plasma membrane. It is also suggested, that they can travel by a second mechanism: lipoprotein particles.  
The association with ligands, like lipoprotein particle, might be promoted by a retromer complex to transport 
these Wnt forms in endosomal trafficking vesicles outside the cell. After release into the extracellular gap, 
signaling is passed in an autocrine or paracrine fashion. Upon binding to their membrane receptors (FZD) and 
co-receptors (LRP5/6), DVL is recruited to the complex. After forming a signalosome, which in turn recruits Axin 
to the plasma membrane, the destruction complex gets destabilized and dissociates. The degradation of  
β-catenin is now prohibited and the protein accumulates in the cytosol, before translocating into the nucleus. 
In the nucleus, β-catenin binds to transcription factors, such as members of the TCF/LEF family, and enables 
gene expression (Figure adapted from [34, 36, 50, 51, 273]).  
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Very little is known about how Wnts orchestrate the β-catenin signaling by inhibiting its 
phosphorylation. A combination of various processes, like Axin degradation, alteration of the 
destruction complex or inhibiting the kinase activities of GSK3 or CK1, is possible [151]. 
A direct interaction between Wnts and β-catenin or a cytosolic occurrence of Wnt proteins is not 
reported by the current literature; thus no indication for their presence in the cytosol, without being 
packed into secretory vesicles, was found. 
Hence the question arises, how Wnts can be co-immunoprecipitated with β-catenin and appear as 
interaction partners. Two explanations of the occurring phenomenon are likely: Co-IP of Wnts occurs 
via their link to the LRP5/6 and FZD receptor complex. This complex is able to bind via the DVL 
proteins to Axin, which is also part of the destruction complex, a place where β-catenin can be 
located [36]. Additionally, direct interaction for β-catenin with nuclear DVL was shown previously 
[219]. But no evidence for the relocation of members of this complex into the cytosol, where  
β-catenin would be able to bind directly, is available. Another possibility and a more likely 
explanation, is the generation of a protein complex after cell lysis. The occurrence of precipitated 
Wnts and members of the membranous Wnt signaling complex (LRP5/6 or FZD) as β-catenin 
interactors might be explained as result of the Co-IP procedure. 
ICIP holds the possible advantage of preventing these interaction partners by an earlier binding to  
β-catenin complexes. A signal occuring during ECIP but not ICIP would support the assumption of 
detecting an artificial interaction, which does not occur in vivo, but emerges after destroying the 
original cellular context. Therefore, antibodies against several Wnt proteins were tested on the ECIP 
duplicates and the ICIP triplicates, but no PPIs were detected. As HEK293T cells are known to exhibit 
normal Wnt signaling and were shown to be suitable for studying this signaling cascade many times 
before [112, 124], the occurring differences can’t be attributed to the change in cell system (liver to 
kidney). Thus, the detection of an interaction between β-catenin and Wnts has to be led back to the 
differences during the cell lysis and has to be evaluated as an interaction emerging from lysis and/or 
Co-IP. 
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5.5 β-catenin interaction with transcriptional regulators 
Several interactions of β-catenin with transcription factors or proteins, involved in the modulation of 
transcriptional activity, were tested and confirmed as such. Among these interacting proteins  
well-known interaction partners were detected, such as members of the TCF/Lef family [36, 54, 55], 
the proto-oncogenes Src [36, 185, 186, 252, 280, 281] and cJUN [36, 217-219]. In addition, 
interactions with other proteins, which can modulate the transcriptional activity, were identified. 
Below a discussion of some of these newly identified interactors (GLI1, FoxO3a, Smads and TAZ) is 
found and the result is put into a biological context. 
The zinc finger protein GLI1 is active in the Hedgehog signaling pathway. Like the Wnt/β-catenin 
pathway, the Hedgehog pathway plays a pivotal role in directing growth and patterning during 
embryonic development in the liver [138]. Wnt/β-catenin signaling and Hedgehog signaling show 
similarities, which might indicate a common ancestral evolutionary pathway [282]. Among the 
similarities is also the shared use of proteins, such as GSK3 or CK1 [283, 284], in both pathways. GLI1 
is an interactor of CK1 α/δ, that was found in this study [285, 286] and thus might provide a link to 
the β-catenin destruction complex. A physical interaction between GLI1 and stabilized  
β-catenin was shown recently by Co-IP and proximity ligation assay [156]. If the available amount of 
the stabilized form of β-catenin increases, for example through activated or mimicked Wnt/β-catenin 
signaling, the sequestration of GLI1 increases simultaneously and the transcriptional activity of GLI1 
is inhibited. It was even suggested, that the interaction with β-catenin leads to the degradation of 
GLI1 and the inhibition of Hedgehog signaling [156]. 
An interacting transcription factor is FoxO3a (Forkhead box O3). FoxO3a belongs to the forkhead 
transcription factor family (FoxOs), which critically controls fundamental cellular processes, like 
proliferation, apoptosis and survival [210]. It was shown for both FoxO4 and FoxO3a, that they are 
co-immunoprecipitated with β-catenin, which indicates the existence of a physical interaction in 
mammalian cells [211]. β-catenin serves as a co-factor for FoxOs and is known to be implicated as a 
pivotal protein in the oxidative stress defense [287]. Via the binding between β-catenin and FoxOs, 
their transcriptional activity is enhanced [211, 288]. Another crosstalk link between Wnt/β-catenin 
signaling and other signaling pathways is provided [289] by the competition of FoxOs with TCF for  
β-catenin [36]. This competition might influence various diseases, like diabetes [287], or 
developmental processes, such as bone development [290]. Besides the interaction of FoxOs with  
β-catenin, an interaction with many other transcription factors was shown for this protein family, like 
their complex formation with Smad3 and Smad4 [290] in a TGF-β-dependent manner [291].  
Several Smads are known interaction partners of β-catenin. They were detected as interactors 
throughout the analysis of the different cell lines. Smads are signal transducers, which facilitate 
signaling of the TGF-β (transformation growth factor-β) superfamily inside the cell [292]. Interactions 
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between TGF-β signaling and the Wnt/β-catenin pathway are central in many biological processes, 
while their alterations are associated with diseases, like cancer [293]. Smads can be divided into 
three groups: the receptor-regulated Smads (R-Smads, e.g. Smad 2, 3 and 5) [216], the common-
mediator Smad (only Smad 4) [180] and some inhibitory Smads, which act antagonistic to the former 
two Smad groups [294]. Smad 2 and Smad 3 are structurally highly similar and both mediate TGF-β 
signals. Smad 4 is distantly related to Smad 2 and 3 and can form a heteromeric complex with both of 
them [178, 179]. After phosphorylation upon ligand stimulation, Smads translocate from the cytosol 
to the nucleus. While R-Smads do not require the association with Smad 4 to be able to translocate 
into the nucleus, the nuclear accumulation of Smad 4 is driven by the heterodimerization with  
R-Smads [292]. The heteromeric complex, formed out of Smad 2/3 together with Smad 4 is able to 
associate with transcription factors in the nucleus after translocating [181]. Besides that 
complexation, Smad 2 is already able to associate with cytoplasmic β-catenin to mediate the 
increased activation of TGF-β target genes [177, 295]. It was shown by Co-IP, that Smad 3, Smad 4 
[296], TCF4 and GSK3 β are also present in this complex [297, 298]. While Smad 2 and 3 are active in 
TGF-β signaling, Smad 5 is part of the BMP (bone morphogenetic proteins) signaling. It also interacts 
with Smad 4 and accumulates in the nucleus to bind and regulate target gene expression there [182]. 
The last transcriptional regulator, described in this chapter, is TAZ (WW domain-containing 
transcription regulator protein 1). TAZ is a transcriptional co-activator of the Hippo pathway. One of 
the cytoplasmic functions of TAZ is constraining Wnt/β-catenin signaling by inhibiting  
CK1 δ/ɛ-mediated phosphorylation of DVL and thus promoting an interaction between TAZ and DVL. 
The phosphorylation of DVL precedes the stabilization and activation of β-catenin, which is now 
restrained [187]. Additionally it was shown, that TAZ can bind directly to β-catenin and by that retain 
it in the cytoplasm to suppress Wnt/β-catenin signaling [299, 300]. TAZ therefore provides a direct 
molecular link between Hippo and Wnt signaling pathways (see Figure 33) [187]. In the Hippo 
pathway, the tumor suppressor Mst1/2 is regulated by upstream molecules, which often transduce 
signals from the membrane. Mst1/2 activates LATS1/2 via phosphorylation [301, 302], before 
LATS1/2 in turn phosphorylates TAZ, which leads to the inhibition of its transcriptional co-activator 
activity and its cytoplasmic localization [301]. Therefore, many proteins participating in the Hippo 
signaling are identified as tumor suppressors [302]. 
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Figure 33: Schematic overview of the Hippo pathway-mediated inhibition of Wnt signaling. 
The cytoplasmic localization of TAZ is induced by the Hippo pathway, which leads to an enhanced interaction 
between TAZ and DVL. Interaction with TAZ inhibits the binding of DVL to CK1 δ/ɛ and prevents the 
transcriptional activity induced through activated Wnt signaling. Thus, Hippo is able to modulate Wnt signaling, 
by limited responses to Wnt signals (Figure adapted from [187]). 
 
β-catenin as a known transcriptional co-activator [152] is not only found in complexes with its major 
partners, but also associated with several other transcriptional co-activators, such as the FoxO 
proteins [211, 288] and the transcription factors from the TCF/LEF family [303, 304]. The detection of 
other transcriptional regulators showed, that the combinatory screening approach developed in this 
work is capable to detect new interactions of β-catenin with proteins, which are known to modulate 
transcription, but have not been brought into direct connection with β-catenin. Enabled by the 
identification of these PPIs, effects across different signaling cascades were detected and have to be 
interpreted in future. The possibility to add further, target-oriented screenings for specific proteins 
or to cover defined pathways completes the application spectrum of the developed screening 
approach. 
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5.6 β-catenin and MAPK signaling in hepatoma line 55.1c 
The analysis of the mouse hepatoma cell line 55.1c, showed several clearly interacting proteins, that 
were not seen consistently in the other screened cell lines. Interestingly these are frequently 
associated with the MAPK pathways.  
The MAPK pathways transduce signals from the cell membrane to the nucleus as a response to 
various stimuli. Thus, they participate in many intracellular signaling cascades [305]. They regulate 
many central processes, such as cell differentiation, proliferation, inflammation, cell growth and 
death [158, 306]. Hence, they also contribute to the pathology of various human diseases, like cancer 
or several neurodegenerative disorders [307]. The role of MAPKs in cancer is as pleiotropic as cancer 
itself [188, 308]. In total approximately 20 % of all human tumors show an activating mutation in a 
member of the RAS family (see Figure 34). Thus, both signaling cascades, Wnt/β-catenin and MAPK 
are subject to mutational activation in a large number of tumor types [29]. Gaining a deeper insight 
in the crosstalk between the two pathways, is of high interest. This crosstalk is rapidly emerging as 
more and more underlying, molecular details are unraveled [29]. 
The MAPK kinase family represents a group of four distinct subgroups, whereby the subsignaling 
cascades are named after their main MAP kinases: 1. MAPK/ERK pathway, 2. JNK/SAPK signaling,  
3. p38/MAPK pathway and 4. BMK1 signal cascade (see Figure 34) [306]. In the following, the 
interacting proteins belonging to the first three subgroups will be described exemplarily. The 
MAPK/ERK cascade is activated by mitogens and growth factors, while the JNK and p38 pathways are 
cytokine- and stress-response-dependent [157, 307, 309]. Each of the MAPK signaling axes comprises 
three or more components: MAPK kinase kinases (MAP3Ks), which phosphorylate and activate MAPK 
kinases (MAPK2Ks). These in turn phosphorylate and activate MAPKs. Subsequently activated MAPKs 
are enabled to phosphorylate various substrate proteins, including transcription factors and 
downstream effectors, such as Elk-1 or the DUSPs [158, 309]. Selected PPIs detected in 55.1c cells, 
belonging to the MAPK pathway, are illustrated below and are shown in Figure 34. 
A-Raf is a member of the Raf kinase family, which consists of three structurally similar kinases  
(A-Raf, B-Raf and C-Raf) and constitutes a family of Ser/Thr-protein kinases [196]. A-Raf mutations 
have not been found in human cancer [310], which can be explained by the fact that A-Raf requires 
two mutations for its oncogenic activation, while B-Raf, which is frequently mutated in cancer [311], 
only needs a single amino acid exchange [196]. Raf kinases are MAP3Ks and as such belong to the 
MAPK/ERK (extracellular signal-regulated kinase) pathway [197], but no direct physical interaction of 
A-Raf with β-catenin was shown so far. 
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Figure 34: MAPK signaling pathways. 
A: MAP4Ks or GTPases are stimulated via extracellular or intracellular stimuli and activate MAP3Ks. These 
mediate the phosphorylation and activation of MAP2Ks, which in turn phosphorylate and activate MAPKs. 
Activated MAPKs are able to phosphorylate various substrate proteins, including transcription factors. This 
results in the modulation of several cellular responses, such as cell proliferation, inflammatory responses, cell 
growth and death.  
B: Erk1/2, p38, JNK1/2/3 and BMK1 belong to the mammalian MAPKs and name the distinct subgroups of the 
MAPK family. The specific upstream kinases and stimuli, as well as the cellular responses for each pathway, are 
pictured (Figure adapted from [309, 312]). 
 
MKK7 belongs to the family of the Mitogen-activated protein kinase kinases (MAP2K) and is able to 
selectively activate only JNKs by phosphorylating preferably threonine but also tyrosine residues on 
the protein [190-194]. No direct physical interaction with β-catenin is known from literature so far, 
although it was identified as interactor here. 
JNK/SAPKs (cJUN N-terminal kinases and stress activated protein kinases, also called MAPK8) belong 
to the group of MAP kinases [190]. They are activated by cytokines or environmental stress [313]. 
Additionally, they participate in various cellular functions, like the regulation of cellular proliferation 
or the binding and phosphorylating of cJUN [313, 314]. Several isoforms exist, of which JNK1 and 
JNK2 proteins are ubiquitously expressed, while JNK3 is only found in brain [190]. Both, JNK1 and 
JNK2, can induce the nuclear translocation of β-catenin by directly phosphorylating the protein [189]. 
Furthermore JNK can be activated directly through dual phosphorylation by MKK7 [202, 313] or DVL 
[195, 315], while the JNK cascade can be activated via Axin [195, 316]. This provides a possibility, how 
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Wnt signaling can mediate JNK/SAPK signaling. It has been shown, that JNK activity can be induced by 
Wnts, but it is still unclear, how this mechanism works [317]. 
MAPKAPK5 (MAP kinase-activated protein kinase 5, also known as PRAK) also belongs to the Ser/Thr 
kinase family [318]. It acts as a tumor suppressor presumably by directly phosphorylating and 
thereby modulating p53 activity [198]. As part of the p38/MAPK pathway, it is activated in response 
to cellular stress and proinflammatory cytokines by phosphorylation at Thr182 [318]. It is also known 
to directly interact with FoxO3a and by phosphorylating this protein, it is promoting its nuclear 
localization [319]. 
For the transcription factor Elk-1, no direct interaction with β-catenin is described in literature, still it 
was detected as an interacting protein of β-catenin here. Elk-1 is activated in the cytoplasm via 
phosphorylation by three classes of MAPKs: JNK, p38/MAPK and Erk [157, 320]. Based on its 
phosphorylation by Erks [321], Elk-1 is enabled to translocate from the cytoplasm into the nucleus 
[29]. There it promotes chromatin remodeling via the acetylation and phosphorylation of histones 
and recruits transcriptional co-activators [157]. 
The dual-specificity phosphatases (DUSPs) have been established as important negative regulators of 
the MAPK pathway [322]. They are part of the auto-inhibitory feedback loop in the MAPK signaling, 
where they dephosphorylate Erk1/2 [312, 323]. Besides that, they represent important mediators of 
crosstalk between the two pathways, MAPK and Wnt/β-catenin [29], since the murine DUSP6 gene is 
a transcriptional target of the β-catenin pathway [158]. Hence, the activity of MAPK signaling can be 
negatively regulated by the β-catenin-dependent induction of DUSPs [29]. For DUSP1, DUSP4 and 
DUSP9 no direct or distant interaction with the Wnt/β-catenin pathway was found in literature. 
Besides the interaction between β-catenin and proteins of the MAPK pathways in 55.1c cells, also the 
other screened cell lines showed interacting proteins, which were assigned to the category 
“associated with MAPK pathway”. For example DUSP6 detected in untreated 70.4 cells, A-Raf found 
in CHIR 99021-treated 70.4 cells and JNK/STAT precipiated in HepG2 cells after MG132 treatment. 
It was shown that by usage of this combinatory screening approach, it is possible to perform a 
targeted screening, searching for specific interactions between the Wnt/β-catenin and the MAPK 
pathways. Beyond that, the used approach can easily be transferred to generally identify PPIs and 
thereby confirming links between two or more determined pathways.  
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5.7 Analysis of the human HCC cell line HB35 
The HB35 cell line is a recently established novel human hepatocellular carcinoma cell line. Its 
characterization was first published in 2012, with only little further investigations done so far. As the 
cell line is derived from a pediatric HCC, with no indication of viral hepatitis or cirrhosis, and since it 
shows a heterozygous deletion in the exon 3 of β-catenin [83], it serves as an interesting model to 
study Wnt/β-catenin signaling. During the analysis of the results obtained for the four  
different, screened liver cell lines, two proteins occurred as individual interaction partners of  
β-catenin only in HB35 cells. Furthermore, both proteins, histone deacetylase 6 (HDAC6) and Bcl9  
(B-cell CLL/lymphoma 9 protein), solely appear after MG132 treatment. 
HDAC6 belongs to the histone deacetylases, which catalyze the removal of acetyl groups from lysine 
residues in a variety of proteins and change the protein function in diverse ways [229]. 18 human 
histone deacetylases are known and sorted into three groups, according to their homology to the 
respective yeast proteins. HDAC6 has two catalytic sites and is member of the class II HDACs. As a 
protein belonging to class II, HDAC6 is able to shuttle between the cytoplasm and the nucleus [231]. 
In the cytoplasm, it can bind directly to β-catenin and deacetylates the Lys49 residue of β-catenin. 
This deacetylation has been shown to result in an inhibitory effect on the β-catenin phosphorylation 
at Ser45 [324]. HDAC6 also associates physically in a ternary complex with CD133 and β-catenin and 
stabilizes β-catenin via its deacetylase activity. If HDAC6 is down-regulated, β-catenin acetylation and 
degradation increases. Additionally, it was shown that HDAC6 is the deacetylase responsible for 
regulating the acetylation level of β-catenin [325], but it can also promote proliferation in cancer cell 
lines [326]. 
The Bcl9 protein, on the other side, is an important transcriptional co-activator of β-catenin [36]. It 
binds N-terminally to the first ARM repeats of β-catenin [327] and is able to shuttle, like other 
proteins, e.g. APC and TCF4, in and out of the nucleus. Additionally, it was suggested that both TCFs 
and Bcl9 might act as nuclear import factors, whereas APC and Axin may take part in actively 
exporting β-catenin into the cytoplasm [328]. Bcl9 could subsequently convey β-catenin from the 
cytoplasm to the TCF-target genes [64, 329] and is recruited by β-catenin to stimulate gene 
transcription [330, 331]. As Bcl9 is additionally able to directly interact with other transcriptional  
co-activators of β-catenin and strengthen their association with the TCF/β-catenin complex, it is 
implicated in signal transduction through the Wnt pathway [36, 228]. In addition, human tumor 
tissue expresses high levels of Bcl9 and the β-catenin/Bcl9 complex has become an interesting target 
for cancer therapy [332]. 
Hence, both identified interacting proteins, Bcl9 and HDAC6, are important partners of β-catenin. 
HDAC6 as well as Bcl9 can shuttle between the cytosol and the nucleus. Both are capable of binding 
β-catenin already in the cytosol, while for Bcl9 an interaction with β-catenin in the nucleus was 
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shown. It is striking, that most interacting partners were found in the untreated HB35 cells, while the 
amount of detected PPIs decreased after MG132 treatment and for CHIR 99021 only a low number of 
PPIs are obtained. Only three interactions remained detectable and four new ones were seen after 
CHIR 99021 treatment. For MG132 treatment seven novel interactions and five former ones recurred 
in comparison to the untreated sample. 
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5.8 Comparison of extracellular and intracellular IP 
In this thesis an interesting novel approach, that reaches beyond the classical Co-IP, was applied to a 
defined experimental system, HEK293T cells. The possibility to express the BC1 nanobody 
intracellularly holds the advantage to detect endogenous β-catenin complexes in vivo. By connecting 
this novel approach to a screening tool like the DigiWest the idea of performing a wide ranging 
comparison between the conventional Co-IPs and intracellular Co-IP is self-evident. This was possible 
for ECIP and ICIP on HEK293T cells, as monogenetic cells were used and the identical nanobody was 
employed for capturing during Co-IP. Differences in the precipitated protein complexes of varying cell 
lines (derived from various tissues (e.g. liver, kidney) or diverse species (e.g. human, mouse)) would 
lead to difficulties during interpretation of the results in order not to miss important insights and 
connections among intracellular signaling cascades. In addition, the use of different antibodies 
(conventional antibody in the beginning and high affinity nanobody in posterior experiments) for the 
Co-IP experiments in this thesis introduces an additional variability in the precipitated  
β-catenin complexes. This variability is difficult to evaluate, especially as the capturing antibodies 
were directed towards oppositional ends of β-catenin. The characteristics of the nanobody (small 
size; recognition of the target protein β-catenin at the regulatory domain, the N-terminal SSTS-motif) 
might prevent the loss of complexes due to steric hindrances, but they might also promote the loss 
of interaction partners by competing for N-terminally located binding sites. On the other side, it is 
known, that the C-terminus of β-catenin serves as a platform for the recruitment of transcriptional 
co-activators [36, 327]. Therefore, a binding of a nanobody on the opposite end of β-catenin, might 
facilitate the formation of complexes with transcriptionally regulating interactors. 
Introducing both a new cell line, HEK293T, and a new capturing molecule, led to the detection of four 
novel interacting proteins after ECIP, which were not obtained during the examination of the four 
different hepatoma cell lines. 
CDK2 (Cyclin-dependent kinase 2) is a Ser/Thr kinase, which is involved in the control of the cell cycle 
[333, 334]. It is known to directly interact and phosphorylate β-catenin specifically at the same 
phosphorylation sites as GSK3 β (Ser33, Ser37, Thr41 and Ser45), but also other serine or threonine 
residues, which are followed by a proline residue [335]. In contrast to GSK3 β, CDK2 needs no priming 
phosphorylation at Ser45 [169]. Also other proteins, like p53 [336] or Ezh2 [337, 338], are known to 
be phosphorylated by CDK2. 
MTA2 (Metastasis-associated protein) belongs to the metastasis tumor-associated family of 
transcriptional regulators. Together with other members of its family, it acts as core scaffold of the 
nucleosome remodeling and histone deacetylation (NuRD) complex [339]. So far no physical 
interaction between MTA2 and β-catenin is known from literature. It was shown, that a member of 
the MTA protein family, MTA3, is involved in controlling the E-Cadherin/β-catenin-complex and thus 
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maintaining the epithelial adhesion junctures and regulating EMT [340]. EMT being a process, which 
enables metastasizing of cancer cells [341]. 
Pontin52, also called RuvBL1 (RuvB-Like 1), is a protein, predominately localized in the nucleus. A 
direct, physical interaction with β-catenin was shown [342]. It may be involved in modulating the 
nuclear functions of β-catenin, independent of its interaction with LEF-1/TCF. In vivo a multiprotein 
complex composed of Pontin52, TCF and β-catenin exists, which suggests a stimulating role for 
Pontin52 in the activation of Wnt target genes [343, 344]. Reptin52, also called RuvBL2, as an 
interacting partner of Pontin52, is also known to bind β-catenin, but represses gene activation. This 
antagonistically mode of action on target gene activation constitutes a mechanism for controlling the 
Wnt/β-catenin pathway [344]. 
PP2A C is the abbreviation for the catalytic subunit of the Ser/Thr-protein phosphatase 2A. The PP2A 
family represent the most abundant Ser/Thr phosphatases in mammals and plays an important role 
in various biological processes [345, 346], like regulation of cell growth and division. PP2A has been 
shown to be part of the β-catenin destruction complex [36, 41]. In general, a suppressive effect of 
PP2A on the phosphorylation of Akt, which subsequently leads to the activation of GSK3 β and the 
phosphorylation, respectively degradation of β-catenin, has been described [347]. On the other 
hand, if N-terminally phosphorylated β-catenin is not associated with APC after leaving the 
destruction complex, PP2A dephosphorylates it immediately [348]. PP2A has been suggested to play 
both a positive and negative role in Wnt signaling. A regulatory role of PP2A, which promotes the 
phosphorylation and degradation of β-catenin, has been shown, as well as a direct interaction of the 
regulatory subunit PR55α of PP2A with β-catenin, which regulated the PP2A-mediated 
dephosphorylation of β-catenin [349]. Additionally, an interference with the destruction complex via 
Axin was shown [349]. This interference might provide an additional possibility of modulating Wnt 
signaling, if a loss of function for PP2A occurs [350]. Furthermore, PP2A C is a potent tumor 
suppressor, whose expression is decreased for example in prostate cancer and a correlation of the 
down-regulated expression with the tumor stage was shown [351]. 
As explained earlier (see 5.1) it is very interesting to be able to detect endogenous protein complexes 
directly and to discover dynamic PPIs related to Wnt/β-catenin signaling in a way that is as close to 
the natural cellular occurrence as possible. By the expression of a functional β-catenin-specific  
BC1-chromobody in living HEK293T cells, the investigation of already intracellularly existing β-catenin 
complexes via subsequent ICIP became possible. Hence, it was expected to precipitate low-affinity 
protein complexes, which are bound in the authentic cellular context, while additional binding 
proteins, with a higher affinity, but a spatial separation, can be largely avoided. Thus, it was assumed 
to obtain differences in the received interacting proteins after performance of the ICIP and at least a 
similar number of interaction partners as measured after ECIP. 
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The interaction of proteins was confirmed for several well-known interaction partners, such as GSK β, 
TCF1 and Axin. All three were detected both during ICIP and ECIP and were classified as strong or 
very strong interacting proteins. This can be seen as validation for the ICIP approach. Interestingly, 
less PPIs were detected via ICIP in the untreated and the CHIR 99021-treated HEK293T samples in 
general than in comparison to the interactors detected after ECIP. For ECIP in total 21 proteins were 
obtained, while for ICIP an entity of six proteins remained. Aside from that, only well-known 
interacting proteins arose after ICIP and the assumption of achieving novel, lower affinity complex 
partners could not be confirmed. A possible reason for that might be the difference in the performed 
duplicate or triplicate experiments. Both DigiWest and Co-IP have been shown to be reliable 
technical approaches before [89, 112], thus they can be excluded as cause for the obtained 
differences and the creation of artifacts in between multiple replicas. Biological replicas are known to 
show differences, thus it is the most probable remaining explanation for these artifacts is to trace 
their occurence back to cell culturing. 
Fundamental and stable complex partners were detected with both approaches (ECIP and ICIP), 
while for lower affinity or less abundant interactors differences among the replicas occurred. These 
weaker interaction partners can disappear, as they might not always be detected due to a broken 
binding or an overlay by other, stronger signals. This phenomenon looks similar to difficulties in 
creating reliable data replicas, but is de facto a side effect of generating biological replicas in cell 
culture and not necessarily a shortcoming of the Co-IP or the DigiWest approach. On the contrary the 
obtained variations between the biological replicas support the DigiWest approach, as it illustrates its 
high sensitivity by being able to detect, distinguish and visualize even minor differences between 
varying samples. Already among the hepatoma cell lines (70.4, 55.1c, HepG2 and HB35) high 
differences in the amount of captured proteins are visible. In addition, these cells are known to be 
tumor cells which hold the characteristics of uncontrolled cell growth and proliferation. Thus, a 
decrease in the precipitated interaction partners in HEK293T cells can be explained. The application 
of increasingly harsh elimination criteria (see 3.4.3.3) simoultaneous to the introduction of additional 
replicas led to a further natural decrease in the number of confirmed interaction partners during 
subsequent analysis, although the high number of interacting proteins for a single replica is not 
reduced. The raw data obtained for each replica and using the identical elimination criteria for a 
single replica (see 4.2.2), 13 additional interacting proteins are revealed for ECIP, while eight more 
interactors are identified for ICIP. This results in an equally high amount of PPIs detected for ECIP and 
a small decrease for ICIP in comparison to conventional Co-IP on the hepatoma cell lines. A higher 
amount of PPIs detected for ECIP in comparison to ICIP remains. This correlates with an observation 
of detecting more interacting proteins after ECIP than for ICIP in preliminary experiments (data not 
included in this thesis). A possible reason for a smaller amount of PPIs detected for ICIP might be, 
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that for capturing and precipitating protein complexes during ICIP, one additional interaction 
between the GFP and the capturing molecule, addressing GFP, is required. In ECIP, the β-catenin-
specific nanobody BC1 is directly coupled to the capturing beads used during Co-IP. Therefore, only 
two interaction points must endure a possible breakage during ECIP performance: the link between 
the nanobody and the target protein β-catenin as well as the bond between β-catenin and its 
interacting proteins (see Figure 35 A). For ICIP the possible breaking sites are increased by one, as 
one more physical connection has to be formed during Co-IP. Not only the interacting proteins have 
to remain linked to β-catenin and the bond between the intracellularly expressed BC1-chromobody 
and the target protein β-catenin has to stay together, but also the interaction between the  
GFP-Nanotrap® and the GFP, attached to the BC1-chromobody, needs to survive the washing steps 
during separation of input and bound sample after Co-IP (see Figure 35 B). 
 
 
Figure 35: Possible breaking points during ECIP and ICIP. 
The possible interaction points, which are built during ECIP (A) and ICIP (B) are represented. 
A: Two possible break points are shown, which have to endure ECIP procedure. The first between the 
interacting proteins and β-catenin, and the second between the BC1 nanobody coupled to the bead surface 
and the target protein.  
B: For ICIP in total three point have to remain after performing the Co-IP. First the link between β-catenin and 
the interacting proteins, second the intracellularly bond between β-catenin and the BC1-chromobody and third 
the binding between the GFP of the BC1-chromobody and the GFP-Trap®. 
 
While comparing ECIP and ICIP results, it was additionally striking, that the CFs for the  
β-catenin variants, detected by the same antibodies, were overall higher after ICIP than after 
performing ECIP, both on the untreated and CHIR 99021-treated samples. The same phenomenon 
occurred for interacting proteins. Here, the CFs were also higher in the ICIP results. After CHIR 99021 
treatment however, this result only recurred for the obtained PPIs, while for the differently 
addressed β-catenin pools the phenomenon was reversed. Thus, in comparison the CFs for ECIP were 
higher than the ones calculated for ICIP. 
The higher CFs and proportionally higher raw values for the bound samples after ICIP might be based 
on the earlier and maybe still better intracellular binding of the BC1-chromobody to the target 
protein β-catenin. The few interaction partners, which were confirmed for ICIP, can be evaluated as  
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more authentic, not only because they are well-known from literature, but also because the ICIP 
approach with the former intracellular binding of protein complexes by the BC1-chromobody reflects 
a system, which is closer to the in vivo conditions. In addition, PPIs, which occur after destruction of 
the spatial separation within the cell, can largely be prevented. 
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5.9 Conclusion and outlook 
The gained and presented results show that the combinatory approach of different Co-IP techniques 
and a novel readout system for immunoblots provides a versatile tool to examine protein complexes 
and their dynamic interactions. By employing target-specific antibodies and nanobodies towards  
β-catenin, the cancer relevant Wnt/β-catenin signaling was addressed and monitored in this thesis.  
Co-IP is considered to be a gold standard for the detection and investigation of endogenous PPIs [94]. 
Especially the intracellular expression of binding molecules, as a further development of the 
conventional Co-IP approach, might lead to knowledge about the in vivo interactions between 
proteins and their crosstalk. The DigiWest shows the advantages of the classical Western blot, such 
as a high reliability, combined with features, like high throughput and low material consumption. The 
combination of both techniques facilitates the run of focused proteomic studies and the facile 
detection of differences in the activation states of cellular signaling cascades.  
The ability of visualizing the modulation of available proteins by drug treatment in different cell 
lysates was shown. Differences occurring between screened cell lines and their individual response to 
treatment were illustrated (see 4.1) and classified the DigiWest as a valuable screening tool to 
uncover alterations in between various samples and upon drug treatment. In connection with the  
Co-IP approach, it was possible to precipitate β-catenin, the key player of the canonical Wnt 
signaling, and different posttranslational modified variants of the target protein. The modulation of 
these differently modified variants of β-catenin after drug treatment with CHIR 99021 and MG132 
was visible. Additionally, major differences in between the screened cell lines were seen according to 
the precipitated interaction partners of β-catenin (see 4.2). Besides the identification of proteins, 
participating in well-known β-catenin complexes, such as GSK3, E-Cadherin and α-catenin, also 
various other possible interacting proteins were classified.  
The application of a high-affinity nanobody against β-catenin and the exchange of the cell system, led 
to changes in the detected interaction partners. Besides newly identified PPIs, many of the well-
known interactors, like TCF4, GSK3 β and Axin, were seen by using ECIP (see 4.3). By employing a 
nanobody as capturing molecule, it was moreover possible to use it as an intracellularly expressed 
captor to perform ICIPs. It was shown, that the combination of ICIP with the DigiWest constitutes an 
useful screening tool, which precipitated and detected highly affine proteins (see 4.4). In addition, 
the effects of CHIR 99021 treatment were visible both for ECIP and ICIP and resulted in general in an 
increase of the precipitated proteins. 
By classifying a large variety of interacting proteins during performance of the different combinatory 
screening approaches, the possibility of covering the Wnt signaling cascade and its spatial cellular 
surrounding with specific antibodies was enabled. This provides an opportunity to both reveal links 
to other important signaling cascades, such as the MAPK pathway, as well as to identify entirely 
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unknown crosstalks in between pathways. It was possible to show the suitability of employing this 
novel screening approach to illustrate differences between samples and upon treatment. 
Additionally, the opportunity to screen for a multitude of potential PPIs of β-catenin and for specific 
PTMs of the analyzed proteins, facilitates new insights into cellular networks. These will allow a to 
gain a deeper understanding of the cellular signaling crosstalk in the long run. 
Still, several validation experiments (e.g. generating replicas of the hepatoma cell lines) have to be 
performed. A confirmation of the results using different experimental approaches would be possible, 
such as targeted MS analyses, immunohistochemistry (IHC) or mRNA expression analyses. It also 
seems possible, to expand the gained knowledge about HCCs and HBs by comparing the generated 
results to identical performed experiments on primary hepatocytes. Primary hepatocytes are closest 
to the real system and might provide a better reflection of the actual signaling in the liver, thus 
occurring changes due to cell culturing might be prevented. Since the nanobody for capturing  
β-catenin in ECIP and ICIP used in this thesis can be stably expressed inside the living cell, additional 
cell lines could be transfected and compared in order to complete the so far gained knowledge. In 
addition, many of the obtained results have to be put into biological context, which includes further 
target-oriented screenings to round off the gained information. 
The combinatory high throughput screening approach of Co-IP and DigiWest offers several promising 
ways of application, such as the observation of dynamic changes of PPIs dependent on time point, 
drug treatment or the examined sample tissue. The importance of achieving a deeper understanding 
of the PPIs and the crosstalk between two pathways, e.g. between Wnt/β-catenin and MAPK 
signaling (see 5.6), becomes clear, as many diseases such as cancer result from disturbed or unusual 
forms of inter- and intracellular communication. These disturbances are caused by mutational 
changes or the deregulation of cellular pathways [352]. A way of deciphering these aberrant cellular 
communications needs to be learned in order to target and modulate the altered signaling cascades 
[308]. Thereby is the identification of proteins, which modulate the activation state of various 
pathways as well as the understanding of their mode of action, of high relevance, as it provides a 
possibility for identifying biomarkers. Biomarkers in turn may not only help to diagnose diseases, but 
also to design effective drugs for therapy [352]. 
In this thesis, a possible way of achieving deeper insights into the cellular network was shown for 
addressing β-catenin, as one of the main molecules in the canonical Wnt signaling, and precipitating 
its complex partners. Proteins, which caught attention in research recently, such as TAZ (the 
transcriptional co-activator of the Hippo pathway) [187, 299, 300], E-cadherin (playing an important 
role in cell adhesion and preventing tumor metastasis) [265, 266, 353] or HDAC6 (a deacetylase 
modifying β-catenin and regulating its acetylation, active at various subcellular locations) [324-326] 
were detected as interaction partners in this work. All of them link β-catenin to different pathways or 
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complexes and thereby create the basis for its influence on a variety of signaling cascades and 
disease progression [62, 259, 354, 355]. An understanding of the physical interaction between  
β-catenin and other proteins or pathways might point to central connections which might help to 
identify specific Wnt pathways inhibitors. These inhibitors are important, as an aberrant activation of 
this signaling cascade results in the development of various diseases, such as cancer [62, 259]. 
Additionally, the modulation of PTMs of Wnt pathway components might depict a promising 
alternative in drug development, as these modifications have a high impact on the signaling state. 
Taken together, this combinatory screening approach was developed, verified and applied in this 
thesis. Beyond that, PPIs published in research recently were detected and provided an additional 
confirmation of the approach. Furthermore, the approach is not limited to the canonical Wnt 
signaling or β-catenin as the addressed Co-IP molecule, but can easily be transferred and applied to 
other signaling cascades and their key proteins. By usage of this combinatory screening approach, it 
is possible to perform a targeted screening, searching for specific interactions between two or more 
determined pathways. Thereby it provides a versatile high throughput tool for the analysis of protein 
networks and signaling cascade interactions in general. The obtained results may be seen as a first 
impression, although validation and explanation of the biological mechanisms behind the generated 
knowledge remain challenging and will need further experimental studies. 
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7. Appendix 
7.1 Supplementary tables 
Suppl. Table A: List of all used primary antibodies. 
All antibodies tested within this thesis are listed with their individual properties. If they belong to the defined 
antibody set, tested on the Co-IP samples derived from the different liver cell lines (see 0), they are marked 
with “*”. If they were screened on the ECIP captured with the BC1 binder (see 4.3) or the ICIP samples  
(see 4.4), the antibodies are marked with “**”. 
Antigen Mod. Spec. Reactivity Distributor 
Product 
number 
NMI  
number 
*/** 
14-3-3 ε  rb hu, ms, rt Cell Signaling 9635 # 1554 * 
14-3-3 ζ δ  rb hu, ms, rt Cell Signaling 9639 TK # 009 * 
4E-BP1 pSer65 rb hu, ms Epitomics 2206-1 # 0428  
4E-BP1  rb hu, ms, rt Epitomics 1557-1 # 0446  
ABL2  rb hu, ms, rt abcam ab134134 # 1343  
Akt  rb hu, ms, rt Cell Signaling 9272 # 0548  
AML1   rb hu, ms, rt Cell Signaling 8229 # 1540  
Androgen receptor   rb hu Cell Signaling 3202 # 1161  
Apaf-1  rb hu, ms, rt Cell Signaling 8723 # 1544 * 
APC  rb hu, ms, rt Cell Signaling 2504 TK # 025 */** 
A-Raf  rb hu, ms, rt Cell Signaling 4432 # 1145 * 
ATF3  rb hu Sigma HPA001562 # 1353  
ATF4  gt hu ms, rt Acris 
AP15940PU-
N 
# 0725 * 
ATF6 α  rb hu Acris 
AP17892PU-
N 
# 0726  
Axin1  rb hu, ms, rt Cell Signaling 3323 # 0690 */** 
Axin2   rb hu Cell Signaling 2151 # 1724 * 
Axin2  rb hu Cell Signaling 5863 # 0956 */** 
Bax  rb hu, ms, rt Cell Signaling 2772 # 1173 * 
Bcl2  rb hu, ms, rt Cell Signaling 2870 # 0682 * 
Bcl9  ms  ABNOVA  # 1743 * 
Bcl9l  rb hu, ms, rt Thermo Scientific PA5-21111   
Bcl-xL  rb hu, ms, rt Cell Signaling 2764 # 0435 * 
Biotin  gt all spec.s Cell Signaling 7075 # 0303  
BMP4  rb hu Epitomics 5163-1 # 0936 * 
b-Raf  rb hu, rt, ms Upstate 07-453 # 1692 * 
BRCA1  rb hu Cell Signaling 9010 # 1003  
BRCA1  pSer1524 rb hu Cell Signaling 9009 # 1018  
Caveolin-1  rb hu, ms, rt Cell Signaling 3238 # 1188  
CBP  rb hu, ms, rt Cell Signaling 7389 # 1095  
CD133  rb hu Cell Signaling 3663 # 0460 * 
CD36  rb ms, rt, hu abcam ab133625 # 1400  
CD44  rb hu, ms, rt abcam ab51037 # 1413 * 
CD45  rb hu Epitomics 1577-1 # 0444  
CD45  ms  BD Biosciences 610266 # 0500  
CD51   ms hu, rt, ms BD Biosciences 611012 # 0501  
CDK2  rb hu, ms, rt Cell Signaling 2546 # 1479 */** 
CDK4  ms hu, ms Cell Signaling 2906 # 1272  
CDK5  rb hu, ms, rt Cell Signaling 2506 # 1478  
CDK6  ms hu, ms, rt Cell Signaling 3136 # 1305  
CDK6 pTyr24 rb hu, ms biorbyt orb15014 # 1340  
CDK6 pTyr13 rb hu, ms biorbyt orb15013 # 1341  
CDKN2B  rb hu, ms, rt Cell Signaling 4822 # 0412  
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Antigen Mod. Spec. Reactivity Distributor 
Product 
number 
NMI  
number 
*/** 
c-Fos  rb hu, ms, rt Cell Signaling 4384 TK # 011  
CHD3  rb hu, ms Cell Signaling 4241  ** 
CHD4  rb hu, ms, rb Cell Signaling 11912  ** 
CITED2  rb hu, ms, rt Epitomics 3297-1 # 0934  
cJUN  pSer63 rb hu, ms, rt Cell Signaling 2361S # 1744 * 
cJUN pSer63 rb hu, ms, rt Cell Signaling 2361 # 1162 */** 
cJUN  rb hu, ms, rt Cell Signaling 9165 # 1187/HD */** 
CK 1 α  rb hu, ms, rt  Cell Signaling 2655 TK # 035 * 
CK 1 δ  ms hu, ms, rt abcam ab85320 # 0719 * 
CK 1 ε  rb hu, ms, rt Invitrogen 487600 # 0340 * 
CK 2 α  rb hu, ms Cell Signaling 2656 TK # 034 * 
c-Met  ms hu, ms, rt Cell Signaling 3127 # 0434 * 
c-myc  rb hu, ms, rt Cell Signaling 9402 TK # 023  
c-Raf  rb hu, ms, rt Cell Signaling 9422 TK # 029 * 
CREB  rb hu, ms, rt Cell Signaling 9197 BG # 005  
CREB  pSer133 rb hu, ms, rt Cell Signaling 9198 # 1043  
Cytokeratin Pan  ms hu, ms, rb Dako M0821 # 0261 * 
Cytokeratin Pan  ms hu, rt Cell Signaling 4545 # 0474 * 
Cytokeratin Pan  ms hu Ventana 760-2135 # 0588 * 
DKK1  rb hu, ms, rt Biorbyt orb27676 # 1593 * 
DKK1  rb hu, ms, rt Biorbyt orb13376 # 1594 * 
DKK2  rb hu Cell Signaling 4683 # 1522 * 
DNMT1  rb hu, ms, rt Cell Signaling 5032 # 1066 * 
DUSP1  rb hu, ms Millipore 07-535 TK # 081 * 
DUSP10   rb hu, ms, rt Cell Signaling 3483 # 0406 * 
DUSP14  gt hu, ms Santa Cruz sc-48039 # 0487 * 
DUSP16   rb hu, ms abcam ab65151 # 0391 * 
DUSP2   gt ms, rt Santa Cruz sc-1622 # 0394 * 
DUSP4   rb hu, ms, rt abcam ab72593 # 1568 * 
DUSP5  rb hu, ms Sigma D8819 # 0417 * 
DUSP6   rb hu, ms ProteinTech Group 10433-1-AP # 0335 * 
DUSP7  gt hu, ms, rt Santa Cruz sc-47667 # 0497 * 
DUSP9  rb hu, ms ProteinTech Group 14484-1-AP # 0337 * 
DVL1  ms ms, rt, hu Santa Cruz sc-8025 # 1729 * 
DVL2  rb hu, ms, rt Cell Signaling 3224 # 0687 * 
DVL2  rb hu, ms, rt Cell Signaling 3224S # 1739 * 
DVL3  rb hu, ms, rt Cell Signaling 3218 # 1182 * 
DVL3  ms ms, rt, hu Santa Cruz sc-8027 # 1731 * 
E-Cadherin 
pSer838/ 
pSer840 
rb hu, ms, rt Epitomics 2239-1 # 0203  
E-Cadherin  gt ms R&D AF748 # 0742  
E-Cadherin  rb hu, ms Cell Signaling 3195 # 1180 */** 
EGFR  rb hu, ms, rt Cell Signaling 2232 BG # 034  
EGR1  rb hu, ms, rt Cell Signaling 4153 # 1226  
eIF2 α  rb hu, ms, rt Cell Signaling 9722 # 1691 * 
eIF2 α  pSer51 rb hu, ms, rt Cell Signaling 3398 # 1204 * 
eIF4E  pSer209 rb hu, ms, rt Cell Signaling 9741 # 1221  
eIF4E  rb  Cell Signaling 2067 # 0441 * 
Elk-1  rb hu, ms, rt Cell Signaling 9182 TK # 021 * 
Erk1/2  rb hu, ms, rt Cell Signaling 4695 # 1071 * 
Erk3  rb hu, ms, rt Epitomics 2030-1 # 0248 * 
ER β  gt  Santa Cruz sc-6820 # 0845  
Evi   rb  Protein Tech  # 1740 * 
Ezh2  gt hu, ms R&D AF4767 # 0743  
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Antigen Mod. Spec. Reactivity Distributor 
Product 
number 
NMI  
number 
*/** 
Ezh2  rb hu, ms, rt Cell Signaling 5246 # 1454 */** 
FAK  rb hu, ms, rt Cell Signaling 3285 # 1451 * 
FAK1  rb hu, ms, rt Epitomics 2146-1 # 0223  
FAS  ms hu Calbiochem AM01 # 0314 * 
FoxM1  rb hu Cell Signaling 5436 # 1196  
FoxM1  rb hu, ms Cell Signaling 3948 # 0949 * 
FoxO1/ 
O3a/O4 
pThr24/ 
pThr32/ 
pThr28 
rb hu, ms Cell Signaling 2599 # 1483 * 
FoxO3a  pSer413 rb hu Cell Signaling 8174 # 1539 * 
Frizzled1  rb hu abcam ab71342 # 1417 * 
Frizzled4  rb ms, hu, rt abcam AB83042 # 1733 * 
Frizzled7  rb ms, rt, hu abcam AB64636 # 1734 * 
Fyn  rb hu, ms Cell Signaling 4023 # 1326  
GAPDH  rb hu, ms, rt abcam ab9485 # 1648 */** 
GATA4  gt ms, rt, hu Santa Cruz sc-1237 # 1725 * 
GCN5L2  rb hu, ms, rt Cell Signaling 3305 # 1022  
GFP (3H9)  rt  ChromoTek    
GLI1  rb hu, ms, rt Cell Signaling 2534 # 1434 * 
Gpr49  rb hu, ms, rt Epitomics 2495-1 # 0200  
Gpr49 P2 T1  rb ms NMI P2 T1 TK # 125  
GSK3 α/β 
pTyr279/ 
pTyr216 
rb hu, ms, rt Epitomics 2309-1 # 1714 */** 
GSK3 β  rb hu, ms, rt Cell Signaling 9315 # 1627 */** 
GSK3 β pSer9 rb hu, ms, rt Cell Signaling 9336 # 1665 */** 
Ha-ras  rb hu, ms, rt Upstate 05-775 TK # 002 * 
HDAC1  ms hu, ms, rb Cell Signaling 5356 # 1629  
HDAC1  rb hu, ms, rt Cell Signaling 2062 # 1165 */** 
HDAC2  rb hu, ms Cell Signaling 2545 # 1637 * 
HDAC2  rb hu, ms, rt Epitomics 1603-1 # 1680 ** 
HDAC3  rb hu, ms, rt Epitomics 1580-1 # 0734 */** 
HDAC6  rb hu, ms Upstate 07-732 # 1666  
HDAC6  rb hu, ms Millipore 07-732 # 0739 */** 
HELLS  rb hu, ms Cell Signaling 7998 # 1070 */** 
Her2  rb hu Cell Signaling 2242 # 1276  
Her3  rb hu Santa Cruz sc-285 # 1076  
HIF1 α  rb hu Cell Signaling 3716 # 0694 * 
Histone H3 me3Lys4 ms hu Millipore 05-1339 # 1040  
Histone H3 acLys27 rb hu Millipore 07-360 # 1041  
HMGCS1  rb hu, ms biorbyt orb36826 # 1127  
HNF-1   rb hu, rt, ms Santa Cruz sc-8986   
HNF1A  rb hu, ms, rt abcam ab96777 # 1563 * 
HNF-1 α   ms ms, rt, hu Santa Cruz sc-135939   
HNF-1 α   gt ms, rt, hu Santa Cruz sc-6548   
HNF-4 α  gt  Santa Cruz sc-6556 # 0889  
HSP 90  ms hu, ms, rt abcam ab1429-50 # 0266  
IKK α  rb hu, ms, rt Cell Signaling 2682 # 0670  
IKK α/β  pSer176/pSer180 rb hu, ms, rt Cell Signaling 2697 # 1267  
IKK β  rb hu, ms, rt Cell Signaling 2370 # 0671  
ILK1 pSer259 rb hu, ms, rt biorbyt orb6215 # 1300  
ILK1  rb hu, ms, rt Cell Signaling 3862 TK # 112 */** 
IMP  ms hu, ms, rt Santa Cruz sc-166012 # 0396 * 
Integrin α1 subunit  rb hu, ms, rt  Chemicon AB1934 BG # 126  
Integrin α5  ms hu BD Biosciences 610634 # 0515  
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Antigen Mod. Spec. Reactivity Distributor 
Product 
number 
NMI  
number 
*/** 
Integrin β1  ms hu BD Biosciences 610468 # 0516  
Integrin β3  ms hu BD Biosciences 611141 # 0517  
JNK/SAPK  rb hu, ms, rt Cell Signaling 9252 # 1319 * 
JNK/SAPK 1/2/3 
pTyr185/ 
pTyr223 
rb hu, ms, rt Epitomics 2155-1 # 0215  
JNK1  ms hu, ms, rt Cell Signaling 3708 # 1686 * 
JNK3  rb hu, ms, rt Cell Signaling 2305 # 1690 * 
KLF4  rb ms, hu Millipore 09-821 # 0928  
KLF4  rb hu Cell Signaling 12173S # 1283  
KLF5  rb hu Sigma HPA040398 # 1700 * 
LATS1 pSer909 rb hu, ms, rt Cell Signaling 9157 # 1547 * 
LATS1 pThr1079 rb hu, ms, rt Cell Signaling 8654 # 1250 */** 
LATS1  rb hu, ms Cell Signaling 3477 # 1251 */** 
LATS2  rb hu Cell Signaling 5888 # 1306 * 
LEF1  rb hu, ms Cell Signaling 2286 # 0426  
LEF1  rb hu, ms, rt Cell Signaling 2230 # 1470  
LGR5  gt hu, ms Santa Cruz sc-68580 # 1696 * 
LRP6  rb hu, ms, rt Cell Signaling 3395 # 0691 * 
LRP6 pSer1490 rb hu, ms Cell Signaling 2568 # 1567 * 
LRP6  pSer1490 rb hu, ms Cell Signaling 2568S # 1750 * 
LRP6   rb hu, rt Cell Signaling 2560 HD * 
LSD1  rb hu, ms, rt Cell Signaling 2184 # 1640 */** 
MAPKAPK-2  rb hu, ms, rt Cell Signaling 12155 # 1685 * 
MAPKAPK-3  rb hu, ms, rt Cell Signaling 7421 # 1693 * 
MAPKAPK-5  rb hu, rt Cell Signaling 7419 # 1694 * 
MBD2  rb hu, ms bethyl laboratories A301-633A  ** 
MBD3  rb hu, ms, rt Cell Signaling 3896 # 1632  
MBD3  rb hu abcam ab91458 # 1639 ** 
MDM2  pSer166 rb hu, ms, rt Cell Signaling 3521 TK # 015  
MDM2  ms ms, rt, hu Santa Cruz sc-965 # 1083 * 
MEK1  rb hu, ms, rt Cell Signaling 9124 TK # 005 * 
MEK2  rb hu, ms, rt Cell Signaling 9125 TK # 004 * 
MEKK3  ms hu, rt, ms BD Biosciences 611102 # 0502 * 
MKK4   rb hu, ms, rt Epitomics 1658-1 # 0241 * 
MKK6  rb hu, ms, rt Epitomics 1821-1 # 0247 * 
MKK7  rb hu, ms, rt Cell Signaling 4172 # 1225 * 
Mnk1  rb hu, ms Cell Signaling 2195 # 0422 * 
MOB1 pThr35 rb hu, ms, rt Cell Signaling 8699 # 1252 */** 
MOB1  rb hu, ms, rt Cell Signaling 3863 # 1253 */** 
MSK1 pThr589 rb hu, ms Cell signaling 9595P # 1752 * 
Mst1  rb hu, ms, rt Cell Signaling 3682 # 1254 */** 
Mst2  rb hu, ms, rt Cell Signaling 3952 # 1255 */** 
MTA1  rb hu, ms, rt Cell Signaling 5646 # 1633 ** 
MTA2  rb hu, ms, rt Sigma HPA006214 # 1631 */** 
MUC1  ms hu Cell Signaling 4538 # 0445  
N-Cadherin  ms rt BD Biosciences 610920 # 0762  
N-Cadherin  rb hu, ms, rt Cell Signaling 4061 # 1227 * 
NDRG1 pThr346 rb hu, ms, rt Cell Signaling 3217 # 1181  
NF-κB p100/p52  rb hu, ms, rt Cell Signaling 4882 # 0667  
NF-κB p50   rb hu, ms, rt Santa Cruz sc-7178   
NF-κB p65  rb hu Epitomics 2229-1 # 0205  
NF-κB p65  pSer468 rb hu, ms, rt Cell Signaling 3039 # 0465  
NF-κB p65   rb hu, ms, rt Santa Cruz sc-372   
NIK   rb hu, ms, rt Cell Signaling 4994 # 0668  
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Antigen Mod. Spec. Reactivity Distributor 
Product 
number 
NMI  
number 
*/** 
NR5A2  rb hu, ms, rt Epitomics 5450-1 # 1110  
Oct-4  ms hu, ms Cell Signaling 4286 # 0696  
p15  rb hu, ms, rt Santa Cruz sc-67279 # 1622 ** 
p21  rb hu Cell Signaling 2947 # 1102 * 
p300 pSer89 rb hu biorbyt orb34489 # 1285  
p300 pSer1834 rb hu, ms, rt biorbyt orb6262 # 1299  
p38/MAPK  rb hu, ms, rt Cell Signaling 9212 # 0350 * 
p38/MAPK α  rb hu, ms, rt Cell Signaling 9218 # 1684 * 
p38/MAPK β  rb hu Cell Signaling 2339 # 1688 * 
p38/MAPK γ  rb hu, ms, rt Cell Signaling 2307 # 1695 * 
p38/MAPK δ  rb hu, rt Cell Signaling 2308 # 1689 * 
p53  rb hu, rt Cell Signaling 9282 # 1121  
p53 acLys305 rb hu, ms, rt abcam ab109396  # 1274  
p53 pSer46 rb hu Cell Signaling 2521 BG # 101  
p53  acLys382 rb hu Cell Signaling 2525 # 1269  
p53  pSer392 rb hu, ms Cell Signaling 9281 # 1549  
p53  pSer6 rb hu, ms Cell Signaling 9285 BG # 103  
p53  pSer9 rb hu Cell Signaling 9288 BG # 105  
p53  pSer37 rb hu Cell Signaling 9289 BG # 106  
p53 pSer15 rb hu, ms, rt Cell Signaling 9284 # 1164 * 
p53  pSer20 rb hu, ms Cell Signaling 9287 # 1213 * 
p53   gt hu, ms, rt R&D af1355 TK # 001 * 
PARP cleAsp214 rb hu Cell Signaling 9541 # 1044  
PARP  rb hu, ms, rt Cell Signaling 9542 # 1358 * 
PARP  rb hu, ms, rt Cell Signaling 9532 # 0708 ** 
PARP1  ms hu, ms, rt BD Biosciences 611038   
PCAF  rb hu,ms,rt Cell Signaling 3378 # 1052  
PCNA  rt hu, ms, rt Kremmer  # 0256 */** 
PI3-kinase p110 α  rb hu, ms, rt Cell Signaling 4255 # 1160  
PI3-kinase p110 β  rb hu Millipore 04-400 # 1049  
PI3-kinase p85 α  rb hu, rt Epitomics 1675-1 # 0240  
PI3-kinase γ  ms hu, ms Jena Bioscience ABD-026S # 1051  
PI3-kinase δ  rb  Santa Cruz sc-7176 # 0533  
Pontin52  rb hu, ms, rt Cell Signaling 12300 # 1634 */** 
PP2A C pTyr307 rb hu, ms, rt R&D AF3989 TK # 105 ** 
PP2A C    rb hu, ms, rt Cell Signaling 2259 TK # 093 */** 
PRMT1  rb hu, ms, rt Cell Signaling 2449 # 1093  
PRMT4  rb hu, ms, rt Cell Signaling 3379 # 1094 * 
PTCH1  rb hu Cell Signaling 2468 # 1437 * 
PTCH2  rb hu Cell Signaling 2470 # 1436 * 
PTEN  rb hu, ms, rt Cell Signaling 9552 TK # 031  
PTEN  pSer380 rb hu, ms, rt Cell Signaling 9551 # 1045  
PTPN7  rb hu, ms ProteinTech Group 15286-1-AP # 0336  
PTP-PEST  ms hu, ms, rt Cell Signaling 4864 # 0407  
Rac1 pSer71 rb hu, ms, rt Cell Signaling 2461 # 1476  
Rac1  rb hu, ms, rt Cell Signaling 4651 # 1521  
RACK1  ms hu, ms, rt BD Biosciences 610177 # 1590  
Ras  rb hu, ms, rt Cell Signaling 8955 # 1545 * 
Rb  
pSer807/ 
pSer811 
rb hu, ms, rt Cell Signaling 8516 # 1270  
Rb  pSer608 rb hu Cell Signaling 8147 # 1271  
Rb  ms hu Cell Signaling 9309 BG # 046 * 
RelB  rb hu, ms, rt Cell Signaling 4954 # 0672  
RelB pSer552 rb hu, ms, rt Cell Signaling 5025 # 1280  
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Antigen Mod. Spec. Reactivity Distributor 
Product 
number 
NMI  
number 
*/** 
RPTP β  ms hu, ms, rt BD Biosciences 610179 # 0526  
Sav1  rb hu, rt Cell Signaling 3507 # 1256 */** 
SFRP2  rb ms, rt, hu abcam ab111874 # 1404 * 
SFRP2  rb hu, ms, rt abcam ab92667 # 1414 * 
SHP-2 pTyr582 rb hu Epitomics 2165-1 # 0214  
SHP-2  rb hu, ms, rt Epitomics 1609-1 # 0239  
SHP-2 pTyr542 rb  Cell Signaling 3751 BG # 112  
Slug   rb hu, ms Cell Signaling 9585 # 1355  
Smad1  rb hu, ms,  Cell Signaling 6944 # 0955 */** 
Smad2  
pSer245/ 
pSer250/ 
pSer255 
rb hu, ms, rt Cell Signaling 3104 # 0880 */** 
Smad2/3  rb hu, ms, rt Cell Signaling 3102 # 0879 */** 
Smad3 
pSer423/ 
pSer425 
rb hu, ms, rt Cell Signaling 9520 # 0953 */** 
Smad3  rb hu, ms, rt abcam ab40854 # 1237 */** 
Smad4  rb hu, ms, rt Cell Signaling 9515 # 1552 * 
Smad5  rb hu, rt Cell Signaling 9517 # 0954 * 
Smad9  gt hu R&D AF2309 # 0916  
Snai1  rb hu, ms, rt Santa Cruz sc-28199   
Snail  rb hu, ms, rt Cell Signaling 3879 # 1375 */** 
SOX17  ms  Sigma  # 1741 * 
Sox2  rb hu Cell Signaling 3579 # 0946  
Sox9  rb hu, ms, rt Millipore AB5535 # 0919  
SP1  rb hu Cell Signaling 9389 # 1550  
SPRY2  rb hu, rt, ms Millipore 07-524 # 0342 * 
Src pTyr527 rb hu, ms, rt Cell Signaling 2105 # 1189 */** 
Src pTyr416 rb hu, ms, rt Cell Signaling 6943 # 1262 */** 
Src  rb hu, ms, rt Cell Signaling 2108 # 1359 */** 
SRC-3  rb hu, ms, rt Cell Signaling 2126 # 1097  
SRC-3  pThr24 rb hu Cell Signaling 2979 # 1096  
STAT1  rb hu Cell Signaling 9175 # 1186  
STAT1  rb hu, ms, rt Cell Signaling 9172 TK # 038  
STAT3  rb hu, ms, rt Cell Signaling 9132 # 0358  
STAT3  rb  Cell Signaling  # 1736 * 
STAT3 pTyr705 ms hu, ms, rt Cell signaling 9138S # 1745 * 
STAT3 pTyr705 rb hu, ms, rt Cell Signaling 9145 # 1192 */** 
STAT3  rb hu, ms, rt Cell Signaling 4904 TK # 054 */** 
STAT3  pSer727 rb hu, ms, rt Cell Signaling 9134 # 1606 */** 
STAT4  ms hu Cell signaling 5097S # 1735 * 
STAT4  pTyr693 rb hu, ms, rt Cell signaling 4134S # 1749 * 
STEP  rb ms, rt, hu Cell Signaling 4817 # 0405  
Tag(CGY)FP  rb  evrogen AB122 # 1565 ** 
TAK1  pSer412 rb hu, ms, rt Cell Signaling 9339 TK # 089  
TAK1  pThr187 rb hu, ms, rt Cell Signaling 4536 TK # 091  
TAK1  rb hu, ms, rt Cell Signaling 4505 TK # 090 * 
TAZ  ms hu, ms BD Biosciences 560235 # 1626 * 
TAZ  rb  Novus  # 1737 * 
TAZ  rb hu Cell Signaling 2149 # 1184 ** 
TBP  rb hu, ms, rt Cell Signaling 8515 # 1104  
TCF1  ms  Upstate  # 1746 * 
TCF1  rb hu, ms, rt Cell Signaling 2206 # 1673 */** 
TCF4  rb hu Epitomics 2114-1 # 0226  
TCF4  rb hu, ms, rt Cell Signaling 2565 # 0939  
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Antigen Mod. Spec. Reactivity Distributor 
Product 
number 
NMI  
number 
*/** 
TCF4  rb hu Sigma AV100775 # 1148  
TCF4   ms  Upstate  # 1753 * 
TCF4   rb hu Santa Cruz sc-13027 # 1727 * 
TCF4  rb hu, ms Cell Signaling 2569 # 1481 */** 
TCF7L2  ms hu Abgent AT4192a # 1730 * 
Topo 2 α  rb  Santa Cruz sc-13058 # 0892  
Vimentin  rb hu, ms, rt Cell Signaling 5741 # 1376 */** 
Wnt1  gt ms, rt, hu Santa Cruz sc-6266 # 1728 */** 
Wnt11  rb hu, rt abcam ab31962 HD * 
Wnt16  rb hu, ms GeneTex GTX128468 # 1751 */** 
Wnt2  rb ms, rt, hu Santa Cruz sc-50361 # 1726 */** 
Wnt3A  rb hu, ms, rt Millipore 09-162 # 0741 */** 
Wnt5a  rb ms, rt, hu Santa Cruz sc-30224 # 1732 */** 
Wnt7a  rb hu, ms abcam ab100792 # 1738 */** 
Wnt7b  rb  GeneTex GTX11488 # 1742 */** 
YAP  ms hu, ms, rt Santa Cruz sc-271134 # 1625  
YAP pSer127 rb  Cell Signaling  # 1747 * 
YAP   rb  Cell Signaling  # 1748 * 
YAP pSer127 rb hu, ms, rt Cell Signaling 4911 # 1260 */** 
YAP  rb hu, ms, rt Cell Signaling 4912 # 1605 */** 
YAP/TAZ  rb hu, ms Cell Signaling 8418 # 1258 */** 
Yes  rb hu Cell Signaling 3201 # 1261 */** 
ZO-1  rb hu Cell Signaling 8193 # 1383  
α-catenin  ms hu, ms, rt USBiological C2069-44H # 1678 */** 
α-Tubulin  ms hu, ms, rt Synaptic Systems 302211 # 1086  
β-Actin  ms  Sigma A1978 # 1284 */** 
β-catenin  rb hu, ms Biosource AHO0462 # 0802  
β-catenin  rb hu, ms Invitrogen AHO0462 # 1361  
β-catenin  rb hu, ms, rt Santa Cruz sc-7199 H102  
β-catenin   ms hu, ms, rt Santa Cruz sc-65484 7A7  
β-catenin pSer45 rb hu, ms, rt Cell Signaling 9564 # 0952 * 
β-catenin acLys49 rb hu, ms, rt Cell Signaling 9534 # 0982 * 
β-catenin 
pSer33/ 
pSer37/ 
pThr41 
rb hu, ms, rt Cell Signaling 9561  * 
β-catenin   ms hu, ms, rt Upstate 05-665 8E7 ** 
β-catenin pThr41/pSer45 rb hu, ms  Cell Signaling 9565 # 0763 */** 
β-catenin  rb hu, ms, rb Millipore 06-734 # 0917 */** 
β-catenin  ms hu BD Biosciences 610154 BD */** 
β-catenin  pSer675 rb hu, rt, ms Cell Signaling 9567 # 0950 */** 
β-catenin  pSer552 rb hu, ms, rt Cell Signaling 9566 # 1001 */** 
β-catenin  
non-p Ser33/ 
pSer37/ 
pThr41 
rb hu, ms, rt Cell Signaling 8814 # 1356 */** 
γ-catenin  rb hu, ms, rt Cell Signaling 2309 # 1472  
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Suppl. Table B: Antibodies, detecting isoforms of the same protein or several ones. 
All antibodies detecting different isoforms and cleaved versions of one protein or binding to more than one 
protein are listed and separated into their different peaks assigned to different MWs. 
Antigen Modification NMI number MW Protein/Isoform 
Axin2  # 0956 
95 isoform 
98 isoform 
cJUN  # 1187 
43 isoform 
48 isoform 
Cytokeratin Pan  # 0474 
ca. 46 Krt-13 or -18 
ca. 55 Krt-4, -8 or -10 
Erk1/2  # 1071 
42 Erk2 
44 Erk1 
Evi  # 1740 
50 isoform 
60 isoform 
FoxO1/O3a/O4 
pThr24/pThr32/ 
pThr28 
# 1483 
65 FoxO4 
95 FoxO3a 
GSK3 α/β pTyr279/pTyr216 # 1714 
47 GSK3 β 
51 GSK3 α 
JNK1  # 1686 
46 isoform 
54 isoform 
JNK/SAPK  # 1319 
46 isoform 
54 isoform 
LRP6 pSer1490 # 1567 
180 isoform 
210 isoform 
LRP6 pSer1490 # 1750 
180 isoform 
210 isoform 
MDM2  # 1083 
90 isoform 
60 isoform 
MSK1 pThr589 # 1752 
61 isoform 
85 isoform 
PARP  # 1358 
24 isoform 
116 isoform 
Smad2/3  # 0879 
52 Smad3 
60 Smad2 
SOX17  # 1741 
30 isoform 
44 isoform 
STAT3 pTyr705 # 1192 
79 isoform 
86 isoform 
STAT3  TK # 054 
79 isoform 
86 isoform 
STAT3  # 1736 
79 isoform 
86 isoform 
TCF4  # 1481 
60 isoform 
70 isoform 
TCF4  # 1753 
60 isoform 
50 isoform 
TCF4  # 1727 
60 isoform 
50 isoform 
TCF7L2  # 1730 
30 isoform 
50 isoform 
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Suppl. Table C: Co-immunoprecipitated proteins with β-catenin in 70.4 cells. 
All different β-catenin variants and proteins precipitated with β-catenin, after eliminating unspecific signals, are 
illustrated and sorted alphabetically. The respective raw data values for input and bound in the differently 
treated samples, as well as the calculated CFs, can be obtained. Proteins which only occur as a signal in the 
bound sample, thus represent complex partners of β-catenin, which are enriched during Co-IP, are marked with 
a “+”. The corresponding raw values for other treatments of these proteins are included in the table, albeit the 
calculation of a CF. If these signals were eliminated by earlier cutoff limits, the cell “-” was inserted into the cell. 
 
 
 
  
Analyte Modification input bound CF  + input bound CF  + input bound CF  +
α-catenin 120 175 7.29 21 107 25.48 68 205 15.07
APC 17 89 26.18 11 11  - 11 11  -
A-Raf 73 11  - 11 48 21.82  + 43 21  -
β-Actin 60390 57646 4.77 34895 3304 0.47 39159 81 0.01
β-catenin
non-p Ser33/ 
Ser37/Thr41
354 4706 66.47 44 2201 250.11 52 2408 231.54
β-catenin pSer552 353 2916 41.30 181 2022 55.86 96 1715 89.32
β-catenin pSer675 572 4726 41.31 163 2209 67.76 86 1446 84.07
β-catenin pThr41/pSer45 20 55 13.75 11 22  - 11 27  -
β-catenin (BD) 2596 9349 18.01 1239 7437 30.01 1519 13598 44.76
β-catenin (Millipore) 2434 11812 24.26 846 6459 38.17 1076 8672 40.30
CK1 δ 856 26  - 336 72 1.07 615 198 1.61
cJUN (# 1744) pSer63 11 16  - 11 12  - 56 86 7.68
cJUN (HD) 11 11  - 11 16  - 84 137 8.15
Cytokeratin Pan           
(~46 kDa, # 474)
11 84  - 44 60 6.82 1055 11  -
Cytokeratin Pan           
(~55 kDa, # 474)
2762 121  - 11 58  - 73 614 42.05
Cytokeratin Pan              
(~60 kDa, # 588) 
1301 840  - 567 5626  - 2665 36739 68.93
DUSP6 160 82 2.56 116 11  - 41 11  -
DVL1 11 11  - 11 88 40.00  + 11 11  -
DVL2 (# 1739) 11 32  - 11 33  - 11 305 138.64  +
Elk-1 107 191 8.93 54 28  - 116 11  -
Evi (50 kDa isoform) 75 25  - 193 29  - 175 52 1.49
GLI1 32 48 7.50 11 11  - 16 17  -
GSK3 β 2315 13  - 397 11  - 694 60 0.43
LRP6 (210 kDa isoform,   
# 1567) pSer1490 11 11
 -
11 11
 -
11 47
21.36  +
STAT3                                 
(79 kDa isoform, # 1736) 71 151
 -
31 346
 -
11 5489
2495.00  +
STAT3                                 
(86 kDa isoform, # 1736) 81 11
 -
110 54
2.45
206 19497
473.23
STAT4 11 63 28.64  + 11 78 35.45  + 11 53 24.09  +
Vimentin 343 465 6.78 871 153 0.88 2688 20  -
Wnt11 11 45 20.45  + 11 11  - 11 11  -
Wnt7b 11 11  - 11 123  - 11 69 31.36  +
untreated CHIR 99021 MG132
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Suppl. Table D: Co-immunoprecipitated proteins with β-catenin in 55.1c cells. 
All different β-catenin variants and proteins precipitated with β-catenin, after eliminating unspecific signals, are 
illustrated. The respective raw data values for input and bound in the differently treated samples, as well as the 
calculated CFs, can be obtained. Data representation was done analog to Suppl. Table C. 
 
 
  
Analyte Modification input bound CF  + input bound CF  + input bound CF  +
α-catenin 888 2878 16.20 968 1504 7.77 732 2764 18.88
APC 23 54 11.74 11 11  - 22 11  -
A-Raf 240 141 2.94 505 42  - 344 11  -
ATF4 742 370  - 11 839 381.36  + 226 628  -
Axin1 50 758 75.80 14 11  - 38 307 40.39
Axin2 (# 1724) 11 90 40.91  + 11 11  - 11 11  -
β-Actin 167362 535130  - 176674 467673 13.24 138494 335905 12.13
β-catenin pSer552 2497 23560 47.18 1114 6343 28.47 2206 18517 41.97
β-catenin pSer675 2491 30807 61.84 810 6157 38.01 1317 14049 53.34
β-catenin 
non-p Ser33/ 
Ser37/Thr41
48 1088 113.33 255 5570 109.22 82 2555 155.79
β-catenin (BD) 14047 63725 22.68 15515 37887 12.21 20615 74652 18.11
β-catenin (Millipore) 969 5525 28.51 2955 12880 21.79 1320 8773 33.23
CK1 α 480 223 2.32 360 94 1.31 206 57  -
Cytokeratin Pan           
(~46 kDa, # 474)
92 1202 65.33 8223 1257 0.76 10909 682 0.31
Cytokeratin Pan           
(~55 kDa, # 474)
51241 628  - 9941 2089  - 403 1882 23.35
Cytokeratin Pan             
(~60 kDa, # 588) 
28948 7650  - 24510 24522 5.00 30185 22750  -
DUSP1 1324 9861  - 1236 6724 27.20 926 4686 25.30
DUSP4 5500 3468  - 7361 5433  - 4590 5930 6.46
DUSP6 831 1876 11.29 349 39  - 270 20  -
DUSP9 226 8781  - 11 2662 1210.00  + 143 326  -
E-Cadherin 781 3328 21.31 1191 1493 6.27 1102 2511 11.39
eIF4E 8820 189 0.11 5043 118  - 2534 11  -
Elk-1 1155 6119  - 742 2740 18.46 428 1604 18.74
Evi (50 kDa isoform) 147 165  - 209 789 18.88 323 556  -
Evi (60 kDa isoform) 503 452 4.49 193 417 10.80 254 618 12.17
Ezh2 1435 109 0.38 598 41  - 657 47  -
Frizzled4 1085 1219  - 8081 12505  - 4960 10430 10.51
GSK3 β pTyr216 696 2100 15.09 233 281  - 493 534 5.42
GSK3 α pTyr279 436 746 8.56 22 89 20.23 312 211 3.38
GSK3 β 3653 8018 10.97 2442 2795 5.72 2856 2767 4.84
HDAC2 49 83 8.47 15 72  - 41 12  -
HNF1A 1211 391 1.61 228 122 2.68 726 880 6.06
JNK/SAPK                         
(54 kDa isoform)
256 78 1.52 638 133  - 779 45  -
LRP6 (180 kDa isoform,   
# 1750) pSer1490
58 67 5.78 65 25  - 64 16  -
MAPKAPK-5 64 57 4.45 263 53  - 165 48  -
MDM2 (60 kDa isoform) 43 90 10.47 44 45  - 49 20  -
MKK7 166 81 2.44 174 29  - 141 34  -
Smad3 618 189 1.53 2394 119 0.25 522 71  -
Smad4 387 72 0.93 572 22  - 988 28  -
Smad5 355 94 1.32 902 181 1.00 549 84  -
Src 9241 3738 2.02 4022 1085 1.35 4374 501  -
Src pTyr416 144 11  - 17 135 39.71 25 51 10.20
Src pTyr527 5370 3097  - 2982 968 1.62 4024 550 0.68
STAT3 (79 kDa isoform,            
TK # 054)
862 73 0.42 761 47 0.31 362 11  -
TAZ 3726 10502 14.09 38 27  - 58 295 25.43
TCF4                                    
(60 kDa isoform, # 1727)
11 294 133.64  + 234 388 8.29 227 531 11.70
TCF4                                    
(70 kDa isoform, # 1481)
30 77 12.83 11 21  - 12 12  -
Vimentin 7346 24060 16.38 2818 14117 25.05 2763 9111 16.49
Wnt3a 11 105 47.73  + 11 11  - 78 11  -
Wnt7b 70 537 38.36 135 4904 181.63 11 84 38.18  +
MG132CHIR 99021untreated
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Suppl. Table E: Co-immunoprecipitated proteins with β-catenin in HepG2 cells. 
All different β-catenin variants and proteins precipitated with β-catenin, after eliminating unspecific signals, are 
illustrated. The respective raw data values for input and bound in the differently treated samples, as well as the 
calculated CFs, can be obtained. Data representation was done analog to Suppl. Table C. 
 
 
  
Analyte Modification input bound CF  + input bound CF  + input bound CF  +
α-catenin 1200 133 0.55 229 304 6.64 576 768 6.67
ATF4 11 92 41.82  + 11 11  - 11 11  -
Axin1 24 25  - 11 23  - 11 116 52.73  +
Axin2                                  
(95 kDa isoform, # 956)
18 17  - 14 22  - 40 67 8.38
Axin2                                   
(98 kDa isoform, # 956)
11 11  - 12 48 20.00 14 11  -
β-Actin 131914 606  - 129705 442  - 144040 4539 0.16
β-catenin 
non-p Ser33/ 
Ser37/Thr41
24 17  - 108 4150 192.13 81 2313 142.78
β-catenin pSer552 2775 2384 4.30 303 2593 42.79 422 8789 104.14
β-catenin pSer675 2161 1994 4.61 159 1193 37.52 245 3703 75.57
β-catenin (BD) 8037 4464 2.78 8021 25290 15.76 16848 92633 27.49
β-catenin (Millipore) 410 232 2.83 1752 8796 25.10 1271 7972 31.36
CK1 δ 867 46 0.27 1298 40  - 2290 73  -
Cytokeratin Pan             
(~60 kDa, # 588) 
189398 572  - 116755 9825  - 196115 58514 1.49
E-Cadherin 679 223 1.64 533 500 4.69 1235 3683 14.91
eIF4E 1930 54 0.14 1608 20  - 3580 11  -
Evi (60 kDa isoform) 922 39  - 124 81 3.27 288 364 6.32
FoxO3a pSer413 11 54 24.55  + 11 11  - 12 11  -
GAPDH 138556 386 0.01 172504 11  - 157497 2896  -
GSK3 β pTyr216 278 64 1.15 61 58 4.75 239 932 19.50
GSK3 α pTyr279 397 36  - 11 11  - 181 303 8.37
GSK3 β 2085 244 0.59 1072 632 2.95 1873 4515 12.05
HNF1A 293 60 1.02 816 375 2.30 924 316 1.71
JNK/SAPK                          
(46 kDa isoform)
317 22  - 231 25  - 309 116 1.88
LRP6 (180 kDa isoform,   
# 1567) pSer1490 11 53
24.09
 + 27 25
 -
65 43
 -
LSD1 1160 15  - 881 116 0.66 1758 170 0.48
Snail 11 117 53.18  + 38 11  - 11 141  -
STAT3                                 
(79 kDa isoform, # 1736) 2249 168
 -
1778 1303
3.66
2318 12015
25.92
STAT4 11 52 23.64  + 46 11  - 11 34  -
TCF1 32 24  - 26 28  - 11 283 128.64  +
TCF4                                    
(60 kDa isoform, # 1481)
56 14  - 43 141 16.40 52 626 60.19
TCF4                                    
(70 kDa isoform, # 1481)
17 14  - 16 12  - 53 158 14.91
Vimentin 39 13  - 13 11  - 20 56 14.00
Wnt7b 11 71 32.27  + 11 11  - 313 64  -
MG132CHIR 99021untreated
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Suppl. Table F: Co-immunoprecipitated proteins with β-catenin in HB35 cells. 
All different β-catenin variants and proteins precipitated with β-catenin, after eliminating unspecific signals, are 
illustrated. The respective raw data values for input and bound in the differently treated samples, as well as the 
calculated CFs, can be obtained. Data representation was done analog to Suppl. Table C. 
 
 
  
Analyte Modification input bound CF  + input bound CF  + input bound CF  +
α-catenin 350 80 1.14 112 191 8.53 1198 1819 7.59
Axin1 48 230 23.96 11 13  - 11 19  -
β-Actin 140755 1250 0.04 78367 32  - 124953 76  -
Bcl9 11 11  - 11 11  - 11 72 32.73  +
β-catenin
non-p Ser33/ 
Ser37/Thr41
40 78 9.75 27 294 54.44 59 1257 106.53
β-catenin pSer552 2102 6121 14.56 212 1264 29.81 1166 6061 25.99
β-catenin pSer675 1179 3107 13.18 147 1069 36.36 497 3222 32.41
β-catenin (BD) 12678 13472 5.31 2710 8423 15.54 12872 34538 13.42
β-catenin (Millipore) 680 764 5.62 401 1394 17.38 1098 4313 19.64
cJUN                                   
(43 kDa isoform, # 1187)
301 77 1.28 29 16  - 477 118  -
cJUN (# 1162) pSer63 22 14  - 20 14  - 135 52 1.93
Cytokeratin Pan           
(~55 kDa, # 474)
140930 277 0.01 2884 11  - 48554 154  -
DVL1 11 38  - 11 47 21.36  + 11 62 28.18  +
E-Cadherin 1246 1077 4.32 78 187 11.99 328 641 9.77
eIF4E 6969 74 0.05 100 17  - 585 23  -
Evi (60 kDa isoform) 55 11  - 29 54 9.31 11 11  -
GAPDH 178263 848 0.02 27760 11  - 121293 232 0.01
GSK3 β pTyr216 204 847 20.76 33 16  - 154 22  -
GSK3 α pTyr279 295 197 3.34 11 15  - 141 66  -
GSK3 β 1868 4036 10.80 397 61 0.77 1113 208 0.93
HDAC6 3675 57  - 112 11  - 194 47 1.21
HNF1A 1348 11  - 90 81 4.50 45 140 15.56
LRP6 (180 kDa isoform,   
# 1567)
pSer1490 11 11  - 12 24  - 20 57 14.25
LSD1 3015 97 0.16 70 11  - 374 35  -
Smad2 598 93 0.78 11 11  - 154 11  -
Smad5 11 11  - 33 22  - 45 45 5.00
Snail 11 185 84.09  + 42 11  - 11 190  -
Src pTyr527 9362 188 0.10 1205 13  - 3692 27  -
STAT3                                 
(79 kDa isoform, # 1736)
1465 212  - 685 583 4.26 1279 9210  -
STAT3 (79 kDa isoform,            
TK # 054)
2679 92 0.17 269 11  - 870 70 0.40
STAT3                                 
(86 kDa isoform, # 1736)
475 58 0.61 536 11  - 1990 11  -
TAZ (HD) 27 82 15.19 41 96  - 61 39  -
TCF1 29 62 10.69 11 22  - 17 55  -
untreated CHIR 99021 MG132
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Suppl. Table G: Proteins precipitated in HEK293T cells during ECIP. 
All different β-catenin variants and proteins precipitated with β-catenin, after eliminating unspecific signals, are 
illustrated. The respective raw data values for inputs and bounds of the two replicas in the differently treated 
samples, as well as the calculated CFs and their mean, can be obtained. Data representation was done analog 
to Suppl. Table C. 
 
 
  
Analyte Modification  +  +
1. Repl. 2. Repl. 1. Repl. 2. Repl. 1. Repl. 2. Repl. AM 1. Repl. 2. Repl. 1. Repl. 2. Repl. 1. Repl. 2. Repl. AM
α-catenin 1077 701 585 315 2.72 2.25 2.48 1553 898 3003 1599 9.67 8.90 9.29
Axin1 51 15 28 30  -  -  - 58 37 171 51 14.74 6.89 10.82
Axin2                                  
(95 kDa isoform, # 0956)
16 27 17 19  -  -  - 33 46 323 210 48.94 22.83 35.88
β-catenin
non-p Ser33/ 
Ser37/Thr41
161 270 379 311 11.77 5.76 8.76 2281 1471 57383 54784 125.78 186.21 156.00
β-catenin pSer552 178 94 343 62 9.63 3.30 6.47 1109 582 18188 11656 82.00 100.14 91.07
β-catenin pSer675 488 400 465 256 4.76 3.20 3.98 1039 800 3728 2665 17.94 16.66 17.30
β-catenin (8E7) 11 11 11 11  -  -  - 11 11 8850 7871 4022.73 3577.73 3800.23  +
β-catenin (BD) 3641 3193 4666 3008 6.41 4.71 5.56 20850 16206 82797 75472 19.86 23.29 21.57
β-catenin (Millipore) 2519 2975 4247 4029 8.43 6.77 7.60 14506 11152 90439 92357 31.17 41.41 36.29
CDK2 2244 1838 112 72 0.25 0.20 0.22 2029 1700 117 178 0.29 0.52 0.41
GSK3 β pTyr216 836 742 21 52  -  -  - 133 210 59 69 2.22 1.64 1.93
GSK3 α pTyr279 1437 1176 11 28  -  -  - 52 58 115 61 11.06 5.26 8.16
GSK3 β 6286 6365 196 368 0.16 0.29 0.22 4523 4881 1739 1992 1.92 2.04 1.98
HDAC2 (# 0238) 5627 5069 104 117  -  -  - 5450 5104 147 296 0.13 0.29 0.21
HDAC3 665 533 53 29  -  -  - 425 392 76 115 0.89 1.47 1.18
HELLS 3741 2532 164 11  -  -  - 3792 3172 381 324 0.50 0.51 0.51
LSD1 3592 2221 259 196 0.36 0.44 0.40 4282 2984 189 191 0.22 0.32 0.27
MTA2 6807 6735 240 538 0.18 0.40 0.29 9085 7528 438 400 0.24 0.27 0.25
PCNA 53848 51143 288 142 0.03 0.01 0.02 57406 50808 235 107 0.02 0.01 0.02
Pontin52 4040 5100 146 339  -  -  - 2858 3715 439 859 0.77 1.16 0.96
PP2A C 7425 6676 169 135 0.11 0.10 0.11 7373 7407 174 243 0.12 0.16 0.14
Smad1 1434 1127 48 78  -  -  - 1266 1313 138 132 0.55 0.50 0.52
Smad2 
pSer245/pSer250/
pSer255
287 359 18 38  -  -  - 185 134 50 73 1.35 2.72 2.04
Src pTyr527 7121 5551 424 231 0.30 0.21 0.25 6703 5994 230 536 0.17 0.45 0.31
Src 7594 7983 1042 970 0.69 0.61 0.65 6224 6404 880 2223 0.71 1.74 1.22
TCF1 517 382 43 53  -  -  - 1543 1510 703 1200 2.28 3.97 3.13
TCF4                                    
(60 kDa isoform, # 1481)
88 56 11 19  -  -  - 117 114 65 89 2.78 3.90 3.34
CF
untreated
input bound CF
CHIR 99021
input bound
Appendix   
178 
Suppl. Table H: Proteins precipitated with β-catenin in HEK293T cells during ICIP. 
All different β-catenin variants and proteins precipitated with β-catenin, after eliminating unspecific signals, are 
illustrated. The respective raw data values for inputs and bounds of the two replicas in the differently treated 
samples, as well as the calculated CFs and their mean, can be obtained. Data representation was done analog 
to Suppl. Table C. 
 
 
  
Analyte Modification  +
1. Repl. 2. Repl. 3. Repl. 1. Repl. 2. Repl. 3. Repl. 1. Repl. 2. Repl. 3. Repl. AM
α-catenin 2047 1672 775 1529 1979 541 3.73 5.92 3.49 4.38
Axin1 82 58 11 42 43 18  -  -  -  -
Axin2                                  
(95 kDa isoform, # 0956)
13 11 12 59 28 11  -  -  -  -
β-catenin
non-p Ser33/ 
Ser37/Thr41
25 62 62 286 311 151 57.20 25.08 12.18 31.49
β-catenin pSer552 183 232 329 426 679 364 11.64 14.63 5.53 10.60
β-catenin pSer675 391 396 210 516 665 231 6.60 8.40 5.50 6.83
β-catenin (8E7) 11 11 11 11 11 11  -  -  -  -
β-catenin (BD) 2728 3179 1532 5997 6948 2162 10.99 10.93 7.06 9.66
β-catenin (Millipore) 1065 1328 935 2430 3383 1694 11.41 12.74 9.06 11.07
GSK3 β pTyr216 1054 1066 775 213 20 117  -  -  -  -
GSK3 β 7462 6418 4880 1510 1057 907  -  -  -  -
TCF1 296 312 109 65 51 70  -  -  -  -
Analyte Modification  +
1. Repl. 2. Repl. 3. Repl. 1. Repl. 2. Repl. 3. Repl. 1. Repl. 2. Repl. 3. Repl. AM
α-catenin 2084 1909 907 3490 6510 1317 8.37 17.05 7.26 10.89
Axin1 106 52 17 454 831 170 21.42 79.90 50.00 50.44
Axin2                                  
(95 kDa isoform, # 0956)
126 32 16 629 1567 229 24.96 244.84 71.56 113.79
β-catenin
non-p Ser33/ 
Ser37/Thr41
1225 611 414 15607 29052 9027 63.70 237.74 109.02 136.82
β-catenin pSer552 1500 1203 987 9880 19991 8260 32.93 83.09 41.84 52.62
β-catenin pSer675 1240 972 528 2041 4435 1174 8.23 22.81 11.12 14.05
β-catenin (8E7) 11 11 11 1430 2347 697 650.00 1066.82 316.82 677.88 +
β-catenin (BD) 22554 14505 7706 43443 74633 29463 9.63 25.73 19.12 18.16
β-catenin (Millipore) 8973 5822 4298 34660 57757 24092 19.31 49.60 28.03 32.31
GSK3 β pTyr216 390 90 216 155 87 130 1.99 4.83 3.01 3.28
GSK3 β 6612 5792 4527 2433 4485 1945 1.84 3.87 2.15 2.62
TCF1 1088 809 534 527 757 255 2.42 4.68 2.39 3.16
untreated
CHIR 99021
CF
CFboundinput
boundinput
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